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ABSTRACT 
 
Purpose: The purpose of this project was to look at the costs of individuals with Alzheimer’s 
disease and related dementias (ADRD), ALS, and MS in long stay home care in Ontario, 
Canada. The specific goals were to produce estimates of costs for these individuals, as well as 
identify clinical and personal characteristics associated with these costs. This project also tested 
the effectiveness of the Resource Utilization Group for home care case-mix system for use in 
these special populations. 
Methods: This project was conducted using a secondary analysis of assessment data from the 
Canadian Staff Time Resource Intensity Verification Project, a 13-week study of home care costs 
(N=435 141). The project was guided by the Andersen and Newman (1973) framework for 
healthcare resource utilization. Descriptive characteristics and mean costs were produced using 
bivariate frequency and means procedures for each of three conditions. Predictors of costs were 
identified for each of the three neurological conditions through multivariate regression analysis 
conducted separately for each condition. In total 41 independent variables were included into the 
bivariate and multivariate analyses. The dependent variable was the total weekly formal and 
informal home care costs across all multivariate analyses. 
Results: In total, ADRD, ALS, or MS diagnoses were present in 16% of the assessments. The 
mean costs for the three conditions combined were $594.81. The mean costs for ADRD, ALS, 
and MS were $593.32, $898.41, and $574.92, respectively. Characteristics that were predictive 
of cost across all conditions included the Resource Utilization Group for home care case-mix 
system, ADL functionality, IADL functionality, cognitive performance, unsteady gait, stair use, 
difficulty swallowing, respiratory challenges, and bowel incontinence. The Resource Utilization 
   iv 
Group for home care case-mix system had the highest level of explained variance of any single 
item tested in this project across all conditions. However, other clinical characteristics also 
contributed substantial levels of explained variance to the models for each of the three 
conditions. 
Conclusions: The findings from this project suggest that although diagnosis of ADRD, ALS, 
and/or MS can describe cost, clinical characteristics are the most important predictors of costs 
for individuals with these conditions. In addition, the Resource Utilization Group for home care 
case-mix system can adequately predict costs of individuals with these conditions. The addition 
of some clinical characteristics would likely improve the predictive abilities of the Resource 
Utilization Group for home care case-mix system. 
   v 
ACKNOWLEDGEMENTS 
 
I would like to extend my appreciation to my supervisor, Dr. John Hirdes for being an excellent 
mentor, and a source of continuous support throughout the writing of this thesis, and this degree. 
I would also like to thank my committee members, Drs. Jeff Poss and George Heckman for their 
guidance and support. Dr. Jeff Poss, thank you for sharing your valuable insight on study design 
and statistical modeling, as well as your CAN-STRIVE expertise with me. Dr. George Heckman, 
you are responsible for my understanding of the neurological conditions I chose to study, and I 
am grateful for your patience in assisting me throughout this thesis.  
 
I am also grateful to Julie Koreck, and Jonathan Chen. Julie, without your organization, this 
thesis would not have been possible. Jonathan, thank you for teaching me all you know about 
SAS, and providing me with my output at all hours. 
 
Finally, I wish to acknowledge the Public Health Agency of Canada and the Neurological Health 
Charities Canada for their funding and support of the Innovations in Data, Evidence and 
Applications for Persons with Neurological Conditions project.
   vi 
TABLE OF CONTENTS 
DECLARATION ......................................................................................................................................................... II 
ABSTRACT .............................................................................................................................................................. III 
ACKNOWLEDGEMENTS ........................................................................................................................................ V 
LIST OF FIGURES ............................................................................................................................................... VIII 
LIST OF TABLES .................................................................................................................................................... IX 
1.0  INTRODUCTION ........................................................................................................................................... 1 
2.0 BACKGROUND ............................................................................................................................................... 4 
2.1 THE NEUROLOGICAL CONDITIONS ................................................................................................................................ 4 
Alzheimer’s Disease and Related Dementias .............................................................................................................. 4 
Amyotrophic Lateral Sclerosis ........................................................................................................................................... 6 
Multiple Sclerosis ..................................................................................................................................................................... 7 
2.2 HOME CARE .................................................................................................................................................................... 12 
Home Care in Ontario ......................................................................................................................................................... 12 
2.3 INTERRAI ....................................................................................................................................................................... 16 
Resident Assessment Instrument for Home Care ................................................................................................... 17 
2.4 METHODS FOR ESTIMATING THE COSTS OF NEUROLOGICAL CONDITIONS ......................................................... 18 
Cost of Illness .......................................................................................................................................................................... 18 
Estimation Procedure ......................................................................................................................................................... 19 
Other Considerations .......................................................................................................................................................... 21 
Limitations ............................................................................................................................................................................... 23 
Case-Mix Systems .................................................................................................................................................................. 24 
2.5 CONCEPTUAL FRAMEWORK ......................................................................................................................................... 27 
3.0 EXISTING COST LITERATURE FOR THE NEUROLOGICAL CONDITIONS .................................... 29 
3.1 STUDY DESIGNS .............................................................................................................................................................. 30 
STUDY FINDINGS ................................................................................................................................................................... 31 
3.2 STUDY STRENGTHS AND LIMITATIONS ...................................................................................................................... 32 
4.0 STUDY RATIONALE ..................................................................................................................................... 34 
4.1 PURPOSE, OBJECTIVES, AND GOALS ............................................................................................................................ 35 
4.2 RESEARCH QUESTIONS ................................................................................................................................................. 35 
4.3 RELEVANCE OF RESEARCH ........................................................................................................................................... 36 
5.0 METHODS ....................................................................................................................................................... 37 
5.1 BASIC DESIGN ................................................................................................................................................................. 37 
5.2 ETHICS ............................................................................................................................................................................. 37 
5.3 STUDY SAMPLE AND SETTING...................................................................................................................................... 37 
5.4 MEASUREMENTS ............................................................................................................................................................ 38 
Cost Measurement ................................................................................................................................................................ 39 
Exposure Measurement ..................................................................................................................................................... 40 
Independent (Predictor) Variables............................................................................................................................... 40 
5.5 STATISTICAL ANALYSIS ................................................................................................................................................. 50 
Bivariate Analysis ................................................................................................................................................................. 50 
Multivariate Regression Analysis .................................................................................................................................. 51 
Model Diagnostics ................................................................................................................................................................ 52 
   vii 
Missing Values ........................................................................................................................................................................ 53 
Sensitivity Analysis ............................................................................................................................................................... 53 
6.0 RESULTS .......................................................................................................................................................... 54 
6.1 SAMPLE CHARACTERISTICS .......................................................................................................................................... 54 
6.2 BIVARIATE REGRESSION MODELS............................................................................................................................... 66 
6.3 MULTIVARIATE REGRESSION MODELS....................................................................................................................... 67 
7.0 DISCUSSION.................................................................................................................................................... 89 
7.1 DESCRIPTIVE CHARACTERISTICS ................................................................................................................................. 89 
Distribution of Populations Across Characteristics .............................................................................................. 89 
Mean Costs and Resource Use ......................................................................................................................................... 92 
7.2 REGRESSION MODELS ................................................................................................................................................... 93 
Predisposing Factors ........................................................................................................................................................... 94 
Enabling Factors ................................................................................................................................................................... 95 
Illness Factors ......................................................................................................................................................................... 97 
7.3 ANDERSEN AND NEWMAN FRAMEWORK ............................................................................................................... 110 
7.4 LIMITATIONS ............................................................................................................................................................... 112 
7.5 STRENGTHS .................................................................................................................................................................. 113 
7.6 IMPLICATIONS.............................................................................................................................................................. 115 
7.7 FUTURE DIRECTIONS .................................................................................................................................................. 117 
7.8 CONCLUSIONS .............................................................................................................................................................. 118 
REFERENCES ....................................................................................................................................................... 120 
APPENDICES ....................................................................................................................................................... 136 
APPENDIX A: CCAC/LHIN MAP .................................................................................................................................... 137 
APPENDIX B: MEDLINE PUBMED SEARCH STRATEGY ............................................................................................. 138 
APPENDIX C: SUMMARY OF EXISTING COST LITERATURE .......................................................................................... 139 
APPENDIX D: UNIVERSITY OF WATERLOO OFFICE OF RESEARCH ETHICS, ETHICS CLEARANCE ......................... 141 
APPENDIX E: STANDARDIZED SERVICE WAGE RATES IN ONTARIO HOME CARE (2007-8) ............................... 142 
APPENDIX F: SCORING RULES FOR THE RAI ADL SELF-PERFORMANCE HIERARCHY .......................................... 143 
APPENDIX G: HSI MULTIPLICATIVE FUNCTION AND MAPPING ................................................................................. 144 
APPENDIX H: RUGIII/HC GROUPING CRITERIA ......................................................................................................... 146 
APPENDIX I: RUGIII/HC CASE-MIX INDEX VALUES ................................................................................................... 147 
 
 
 
 
   viii 
LIST OF FIGURES 
 
Figure 1: Andersen and Newman, 1973 Characteristics Determining Resource Utilization in 
Healthcare ............................................................................................................................. 28 
Figure 2: Distribution of Population across RUGIII/HC CMI Groups......................................... 63 
 
   ix 
LIST OF TABLES 
 
Table 1: Relevant Clinical Variables, by Condition ..................................................................... 10 
Table 2: Distribution of Predisposing Factors by Condition by Percent (number) ...................... 57 
Table 3: Distribution of Enabling Factors by Condition by percent (number) ............................. 57 
Table 4: Distribution of Need Variables by Condition by percent (number) ............................... 58 
Table 5: Distribution of Population across RUGIII/HC CMI Groups by percent (number) ........ 62 
Table 6: Mean costs (in dollars) by Formal and Informal RUGIII/HC Case-Mix Groups ........... 65 
Table 7: Untransformed multivariate regression model for ADRD ............................................. 68 
Table 8: Untransformed Multivariate Regression Model for ALS ............................................... 71 
Table 9: Alternate Untransformed Multivariate Regression Model for ALS ............................... 72 
Table 10: Untransformed Multivariate Regression Model for MS ............................................... 74 
Table 11: Log-transformed multivariate regression model for ADRD ........................................ 77 
Table 12: Log-transformed Multivariate Regression Model for ALS .......................................... 80 
Table 13: Alternate Log-transformed Multivariate Regression Model for ALS .......................... 81 
Table 14: Log-transformed Multivariate Regression Model for MS ............................................ 83 
Table 15: Summary Table of the Effects of Independent Variables ............................................. 85 
Table 16: Explained Variances (R2) by Model and Condition ..................................................... 88 
Table 17: Incremental Effect of Independent Variables on Explained Variances by Model and 
Condition............................................................................................................................... 88 
 
PREDICTORS OF COSTS FOR ADRD, ALS, AND MS  
 
  1 
1.0  INTRODUCTION 
 
Neurological conditions are disorders of the central and peripheral nervous systems. In 
general, few of these conditions are curable, many are both chronic and progressive, and most 
are clinically complex (Canadian Institute for Health Information [CIHI], 2007; Grima et al., 
2000; LePen et al., 1999). A large number of neurological conditions exist, and while conditions 
such as strokes, migraines, Parkinson’s disease and Alzheimer’s disease are common, the 
majority of neurological disorders are quite rare (MacDonald et al., 2000). Overall, the lifetime 
prevalence of the neurological conditions has been estimated at 625 per 100 000 (MacDonald et 
al., 2000), but result in substantially greater disease and financial burden because of associated 
impairments and disabilities (Gustavsson et al., 2011a). According to the World Health 
Organization (2006), neurological conditions account for six percent of the global burden of 
disease, and 11 percent in developed countries. In Canada, CIHI estimates that one million 
Canadians live with some type of neurological disorder, costing roughly $9 billion a year, or 6.7 
percent of direct medical expenditures on hospital care, physician care, and drug expenditures 
alone (CIHI, 2007).  
Although estimates of cost for the neurological conditions are typically for hospital and 
acute-care settings, a substantial amount of care for individuals with these conditions occurs in 
non-acute care settings. Depending on the region(s) affected, symptoms can include cognitive 
problems, gait ataxia, muscle spasticity or rigidity, dyspnea, or involuntary movements, resulting 
in functional limitations. In the past, many of these conditions, their symptoms, and eventual 
limitations were addressed through hospitalization followed by institutionalization (Lacey, 
1999). A combination of health policy shifts and changes in the care for individuals with these 
conditions has resulted in greater home care use (Coyte, 2000; Lacey, 1999). Due to functional 
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limitations, services required by these individuals include personal support, occupational 
therapy, speech language pathology, physiotherapy, nursing, and social work services, all of 
which are available in home care settings. Overall, these services have been found to be equally 
effective as services provided within hospitals and long-term care facilities for individuals with 
neurological conditions (Barnes and Radermacher, 2001). In addition, those with neurological 
conditions typically prefer to remain in their homes (Barnes and Radermacher, 2001). Finally, 
the prevalence of neurological conditions is expected to rise (WHO, 2006). Altogether, the 
demand for home care services by individuals with neurological conditions is expected to grow 
in coming years. 
Despite the importance of home care for individuals with neurological conditions, very 
little is known about the costs of these conditions, and service needs for individuals within this 
care setting. With a rising prevalence in the neurological conditions coupled with an increasing 
reliance on home care services, a better understanding of the resource utilization patterns of these 
individuals is required in order to adequately plan for the expected rise in home care use by 
individuals with these conditions. While a small number of studies have attempted to estimate 
and identify predictors of costs associated with various neurological conditions, constraints in the 
availability of data have limited the number and types of studies that can be carried out in this 
research area. In addition, no previous research has attempted to estimate the costs and identify 
predictors of these costs within the home care setting. With the availability of data from the 
Resident Assessment Instrument for Home Care, which collect person-level data on over 200 
clinical variables, and corresponding cost estimates from the Canadian Staff Time Resource 
Intensity Verification Project, the aim of this project ws to produce reliable estimates of cost for 
three common neurological conditions, as well as determine clinical predictors of costs for these 
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conditions. The three neurological conditions considered include Alzheimer’s disease and related 
dementias (ADRD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS).
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2.0 BACKGROUND 
2.1 The Neurological Conditions 
 
Neurological conditions are disorders of the central and peripheral nervous system, which 
include the brain, cranial and peripheral nerves, nerve roots, autonomic nervous system, 
neuromuscular junction, and muscles (WHO, 2007). Depending on the condition, these 
neurological disorders can be common, can affect various age groups, and can be costly. The 
three clinical conditions chosen for this project represent these aspects. ADRD was chosen for 
this project because of its high prevalence in elderly populations, MS due to its substantial 
burden on younger populations, and ALS because it is amongst the most costly of neurological 
conditions. Symptoms associated with each of the three neurological conditions can be found in 
Table 1. More detailed clinical descriptions for each of the three conditions included in this 
project can be found below.  
Alzheimer’s Disease and Related Dementias 
 
ADRD is a progressive and fatal condition primarily afflicting individuals after the age of 
60. It is estimated that 24 million individuals worldwide currently have dementia, of which the 
majority are believed to have Alzheimer’s disease (Ballard et al., 2011). Alzheimer’s disease is 
the result of amyloid plaques and neurofibrillary tangles causing cognitive decline and ultimately 
death (Ballard et al., 2011). Other types of dementia, such as vascular dementia, Pick’s disease, 
frontal lobe dementia, Creutzfeldt-Jacob disease are the result of cerebrovascular disease, nerve 
cell death, or infectious agents such as prions (Geldmacher and Whitehouse, 1996). Many 
dementias, including Alzheimer’s disease can only be diagnosed definitively post mortem, 
though probable diagnosis is possible with individuals’ detailed history of symptoms in order to 
PREDICTORS OF COSTS FOR ADRD, ALS, AND MS  
 
  5 
assess the presence of cognitive impairment (Ballard et al., 2011). Accurate diagnosis of ADRD 
is important in order to manage potentially treatable disorders that contribute to cognitive 
impairment in individuals with ADRD, including depression, vitamin deficiencies, and 
hypothyroidism (Ballard et al., 2011). In addition, due to the degenerative nature of ADRD, 
diagnosis is useful in allowing affected individuals and their families to plan for future life and 
finances while cognitive functions are still intact (Ballard et al., 2011).  
In the mild stage of Alzheimer’s disease, symptoms include short-term memory 
impairment, depression, and anxiety (Gauthier, 2002). During this stage, individuals with 
Alzheimer’s disease are still generally able to live independently (Tyas and Gutmanis, 2008). 
Recommended care for individuals during this stage includes the management of comorbidities, 
and consultation with geriatricians and/or neurologists (Hogan et al., 2007). The management of 
behavioral problems can be achieved through simple environmental modification, task 
simplification, and redirection at this stage (Tyas and Gutmanis, 2008). As Alzheimer’s disease 
progresses, symptoms include hallucinations and false beliefs, reversal of sleep patterns, motor 
rigidity and very prominent cognitive decline (Gauthier, 2002). In addition, adverse events 
including sedation, Parkinsonism, and increased risk of stroke can occur due to the use of 
pharmacological treatments such as anti-psychotics in controlling symptoms of Alzheimer’s 
disease (Ballard et al., 2011). Individuals with Alzheimer’s disease are often institutionalized 
during the moderate and severe stages of the condition. According to Yaffe et al. (2002), being 
80 and above, living alone, and having difficult behaviors such as having psychotic symptoms, 
being dangerous, and waking up the caregiver were all significantly associated with nursing 
home admission. The progression for other dementias vary, ranging from rapid decline for 
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Creutzfeldt-Jacob disease, to a fluctuating course dependent on underlying cerebrovascular 
disease for vascular dementias (Geldmacher and Whitehouse, 1996). 
Amyotrophic Lateral Sclerosis 
 
 ALS is one of the major neurodegenerative diseases, causing rapid degeneration of the 
motor system at all levels due to the death of motor neurons in the anterior horn of the spinal 
cord (Mitchell and Borasio, 2007). Little is known about the epidemiology of the condition, 
although estimates have placed the incidence at 3 per 100 000 person years for males, and 2.4 
per 100 000 person years for females (Kiernan et al., 2011). The condition is primarily sporadic, 
but is inherited in about five to 10 percent of cases (Kiernan et al., 2011; Rowland and Shneider, 
2001). At this time, the cause of ALS is unclear. Onset typically occurs after the age of 45, but 
rarely after 80 (Kiernan et al., 2011). Approximately half of all individuals with ALS die within 
30 months of symptom onset, although the survival can range from one to 20 years (Kiernan et 
al., 2011; Ropper and Samuels, 2009; Rowland and Shneider; 2001).  
Initial symptoms of ALS vary depending on the ALS type, but are marked by the 
presence of upper and lower motor neuron features that involve the brainstem and areas of 
innervation along the spinal cord (Kiernan et al., 2011). The progression of ALS is contingent on 
the disease type and whether it is familial or sporadic, and also has implications on appropriate 
therapies (Kiernan et al., 2011). For individuals with bulbar-onset ALS, initial symptoms include 
dysarthria and/or dysphagia (Mitchell and Borasio, 2007). This type of onset can be caused by 
upper or lower motor neuron dysfunction (Rowland and Shneider, 2001). Similarly, cervical-
onset ALS can be indicative of upper or lower motor neuron damage; however, early symptoms 
for cervical-onset ALS include proximal and distal weakness of the arms (Mitchell and Borasio, 
2007). Finally, lumbar-onset ALS presents proximal weakness in the legs (Mitchell and Borasio, 
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2007).  Roughly a quarter of individuals present with bulbar-onset, 70 percent present with 
cervical or lumbar onset, and five percent present with both bulbar and limb-onset (Kiernan et 
al., 2011). Regardless of initial onset, fasciculations, weakness, and degeneration of muscle 
eventually spread to other regions (Kiernan et al., 2011). Additionally, fatigue, dysphagia, and 
respiratory challenges are present across all ALS types (Kiernan et al., 2011). For some 
individuals with ALS, associated frontotemporal dementia is also present (Mitchell and Borasio, 
2007).  
Together, these symptoms lead to the need for assistance with ADLs, as well as therapies 
and treatments for weight loss and malnutrition, shortness of breath, and depression associated 
with initial diagnosis of ALS (Kiernan et al., 2011). Almost all individuals with ALS prefer to 
remain in their homes, with care from a spouse (Krivickas et al., 1997). Home care services are 
generally required as the condition progresses, and the caregiver can no longer provide care 
alone (Krivickas et al., 1997). For individuals without caregivers, institutionalization is usually 
required (Krivickas et al., 1997). Although still not used by all individuals with ALS, palliative 
care near the end of life provides individuals with ALS and their families with comfort (Borasio 
and Voltz, 1997). Death for individuals with ALS is typically the result of respiratory problems, 
in many cases leading to pneumonia (Kiernan et al., 2011). 
Multiple Sclerosis 
 
 MS is a central nervous system disorder that is characterized by inflammatory 
demyelination and axonal loss, followed by some remyelination (Compston and Coles, 2002). 
Ultimately, this process results in lesions in the brain, the optic nerve, brainstem or spinal cord 
(Compston and Coles, 2002). The condition is caused by a combination of genetic susceptibility 
and environmental factors that are currently unknown (Compston and Coles, 2002). The typical 
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age of onset is in the third or fourth decades of life (Compston and Coles, 2002). The worldwide 
incidence is about seven cases per 100 000 person years, but primarily affects northern 
Europeans (Compston and Coles, 2002). The incidence of MS is higher in females than in males 
at a ratio of roughly 2 to 1 (Ropper and Samuels, 2009).  
The progression and symptoms of MS are dependent on the type of MS, the severity of 
the condition, as well as the location of the lesions. Individuals with relapsing-remitting MS 
accumulate disability over time as relapses cause gradual damage (Compston and Coles, 2002). 
Approximately 80 percent of individuals have this type of MS (Compston and Coles, 2002). On 
the other hand, primary progressive MS does not remit, and presents in about 20 percent of 
individuals (Compston and Coles, 2002). Primary progressive MS generally affects the spinal 
cord, but can also affect the optic nerve, cerebrum, or cerebellum, though less frequently 
(Compston and Coles, 2002). Lesions in the cerebrum can lead to loss of sensation on one side of 
the body, movement impairments, depression, and cognitive impairments (Compston and Coles, 
2002). In early stages, cognitive impairment results in attention, reasoning, and executive 
function deficits (Compston and Coles, 2002). Late stage cognitive impairment results in 
dementia (Compston and Coles, 2002). In rare cases, lesions in the cerebrum can also cause in 
epilepsy, or even focal cortical deficits (Compston and Coles, 2002). In contrast, lesions to the 
cerebellum and cerebellar pathways lead to postural, action, and/or speech tremors, clumsiness, 
and poor balance (Compston and Coles, 2002). Lesions to the optic nerve lead to painful visual 
impairments that include scotoma, reduced visual acuity, loss of colour, temporary blindness, 
and loss of vision in one side (Compston and Coles, 2002). The brainstem can also be affected 
by lesions, which results in diplopia and oscillopsia, dizziness, impaired speech and swallowing 
functions, and a sudden intensification of symptoms (Compston and Coles, 2002). Spinal cord 
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lesions cause upper motor neuron signs such as muscle weakness and stiffness, as well as painful 
spasms (Compston and Coles, 2002). Spinal cord lesions also result in bladder dysfunction, 
constipation, and erectile dysfunction (Compston and Coles, 2002). Finally, lesions in other areas 
can result in pain, fatigue, temperature sensitivity, and intolerance of exercise (Compston and 
Coles, 2002).  
On average, the life expectancy for individuals with MS is a minimum of 25 years; 
however, differences in symptoms lead to variations in prognosis (Compston and Coles, 2002). 
Roughly 25 percent of all individuals with MS never experience ADL limitations, while severe 
disability occurs over a very short period of time in about 15 percent of individuals (Compston 
and Coles, 2002). Those who primarily have sensory symptoms tend to have a good prognosis, 
while prognosis is generally poor when symptoms involve disturbed coordination and balance 
(Compston and Coles, 2002). Due to the relapsing-remitting pattern of MS seen for the majority 
of individuals, treatment primarily consists of reducing the proximity between relapses 
(Compston and Coles, 2002). Treatments are also provided to prevent permanent disability, 
manage symptoms of fixed lesions, and treat symptoms caused by established progression 
(Compston and Coles, 2002). Individuals with MS generally remain in their homes and are cared 
for by spouses (Aronson et al., 1996). Only a fifth to a quarter of individuals with MS eventually 
admitted to nursing home (Stolp-Smith et al., 1998). Death for individuals with MS is typically 
unrelated to scleroses, but can be the result of dyspnea in some individuals (Gosselink et al., 
1999). 
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Table 1: Relevant Clinical Variables, by Condition 
Condition Clinical Symptom Resulting Effect 
ADRD 
Cognitive Decline 
Memory impairment  
Acalculia 
Goal setting/planning 
Behavioral Symptoms 
Aggression/Hostility 
Delusions/Hallucinations 
Agitation 
Depression/Anxiety 
Social Interaction 
Movement (Rigidity, Apaxia) 
Gait Disturbance 
Fine motor movement 
Urinary Incontinence 
Falls 
Walking 
Stair use 
Comorbidity 
Stroke 
Parkinsonism 
ALS 
MS 
Other 
Pain 
Respiratory Difficulty 
ALS 
Muscle Weakness and Rigidity 
 
ADL Difficulties 
Unsteady Gait/Falls 
Stairs 
Dysphagia/Dysarthria/Dyspnoea 
Swallowing 
Malnutrition 
Weight Loss 
Shortness of breath 
Respirator use 
Other Respiratory Treatment 
Tracheostomy 
Indirect Symptoms 
Depression/Anxiety 
Sleep Problems 
Constipation 
Drooling 
Pain 
Fatigue 
Comorbidities Frontotemporal Lobe Dementia 
MS 
Unilateral Optic Neuritis, diplopia 
 
Vision 
Gait Ataxia, limb weakness, 
clumsiness, chorea, rigidity, tremor, 
poor coordination 
Falls 
Walking 
Stairs 
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 ADL Function 
Neurogenic Bladder/Bowel 
Bladder Incontinence 
Bowel Incontinence 
Constipation 
Sexual Dysfunction Erectile Dysfunction 
Cognitive Impairment 
Dementia (rare) 
Emotional Lability 
Dysarthria/ Dysphagia 
Speech 
Swallowing 
Vertigo Dizziness 
Pain Pain 
Fatigue Fatigue 
Depression Depression 
Other 
Dementia (rare) 
Respiratory Problems 
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2.2 Home Care 
 
 Home care (HC) was first established in Canada as a publicly funded service in Ontario 
in 1970, and by 1988, had been established in all Canadian provinces and territories (Canadian 
Healthcare Association, 2009). Despite the presence of HC programs across Canada, HC 
services are not federally mandated, and as a result no national definition or standards on HC 
exist. Nevertheless, HC is understood to provide health and social services to help individuals 
with health conditions or functional limitations remain in their homes (MacAdam, 2004). Unlike 
other types of healthcare, HC is focused on prevention and maintenance, and can sometimes be a 
substitute for post-acute care, and long-term care (MacAdam, 2004; Canadian Healthcare 
Association, 2009). Even without federal mandate, HC programs are amongst the fastest growing 
components of the Canadian healthcare system. HC expenditures increased substantially in the 
1990s, and at least some shift in expenditures from other post-acute and non-acute care settings 
to HC programs have been seen (Canadian Healthcare Association, 2009; Coyte, 2000; 
MacAdam, 2004). This trend is the result of a number of factors including the cost-effectiveness 
of HC programs relative to hospital and nursing home care, the use of HC to respond to the aging 
Canadian population, as well as the desire for Canadians to remain in their homes (Coyte, 2000; 
Ontario Home Care Assocation, 2010). Thus, despite the lack of federal involvement, HC is 
expected to be an increasingly healthcare service for Canadians with health conditions or 
functional limitations.  
Home Care in Ontario 
 
In Ontario, HC falls under the jurisdiction of the Ontario Ministry of Health and Long-
Term Care, is funded by Local Health Integration Networks (LHINs), and is administered by 
Community Care Access Centers (CCACs). The CCACs act as the single-point entry for all HC 
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services in Ontario so that all individuals wishing to receive HC services must contact their 
CCAC, as defined by their geographical location. In total, there are 14 CCACs, which have the 
same geographic boundaries as the LHINs. The 14 CCACs are as follows: Erie St. Clair (ESC), 
South West (SW), Waterloo Wellington (WW), Hamilton Niagara Haldiman Brant (HNHB), 
Central West (CW), Mississauga Halton (MH), Toronto Central (TC), Central, Central East 
(CE), South East (SE), Champlain, North Simcoe Muskoka (NSM), North East (NE), and North 
West (NW). A map of the CCACs can be found in Appendix A.  
Service Provision 
 
 While CCACs administer HC services, they do not provide direct services. The provision 
of services is instead contracted to individual service provider agencies that provide professional 
services. These services include nursing services, physiotherapy, occupational therapy, speech-
language therapy, social work services, and nutritionist/dietitian services, as well as non-
professional personal support services. In general, nursing services in HC include the promotion 
of health and the treatment of conditions (CCAC, 2006). These tasks encompass post-acute 
services such as wound care, and IV therapy. Dietetics services help to treat and prevent 
nutrition-related disorders, while speech language pathology services help with oral motor and 
communication functions (CCAC, 2006). Occupational therapists address adaptive behaviors to 
develop, maintain, or rehabilitate function for self-care, leisure, and productivity (CCAC, 2006). 
Physiotherapists treat physical dysfunction, injury, or pain, and help to develop, maintain, 
rehabilitate, or augment physical function, as well as relieve pain (CCAC, 2006). Social work 
services help individuals and their families with skills that optimize functioning within the home. 
Specific treatments can include assisting in adjustment to altered health state, behavioral 
problems, as well as providing support to informal caregivers (CCAC, 2006). Finally, personal 
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support workers provide homemaking services to individuals with functional limitations, which 
can include assistance with ADLs and IADLs, and account for the greatest proportion of HC 
service provision.  
Eligibility  
 
 Eligibility for HC services is determined by case managers at CCACs based on the 
following criteria: individuals must require one of the professional services provided by HC, 
excluding social workers and dietitians; must require these services in order to remain in their 
homes; are unable to access these services at community based settings; live where services can 
be provided safely and effectively; and services provided are expected to lead to reasonable 
levels of rehabilitation (CCAC, 2006). In addition, the professional service required by 
individuals must be available in the CCAC in order to qualify for HC services. Finally, 
individuals must be insured under the Ontario Health Insurance Plan.   
Clinical Assessment and Care Planning 
 
 Clinical assessments of HC users are conducted for all long-stay individuals requiring HC 
services for greater than 60 days. These assessments are performed using the RAI-HC 
instrument, which was first introduced to Ontario HC in 2004. HC services are not age restricted, 
but assessments are only required for individuals ages 18 and over. In addition, the RAI-HC is 
not used for those receiving palliative, acute, or rehabilitation services. For HC service users 
requiring clinical assessments, CCAC case managers perform assessments every 6 months, or 
more frequently if deemed necessary by the case manager. The purpose of these assessments is 
to provide clinicians with a comprehensive view of the strengths and needs of HC service users 
(Morris et al., 1997). Specifically, these assessments help case managers develop plans of service 
for HC service users based on these clinical assessments (CCAC, 2006). These plans of service 
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determine the amount of each service to be provided to HC service users, as well as the 
coordination of these services (CCAC, 2006). RAI-HC reassessments are also used to evaluate 
and revise plans of service as the clinical needs and preferences of service users change (CCAC, 
2006).  
Service Users 
 
Formal HC service use is uncommon in the general population in Ontario (Hall and 
Coyte, 2001). For individuals with functional disabilities, however, HC is much more common 
as restriction in ADLs and IADLs are significantly and independently predictive of HC (Hall and 
Coyte, 2001). Other characteristics predictive of HC use include having a diagnosed health 
problem, being disabled, having poor self-reported health status, and older age (Hall and Coyte, 
2001). In other jurisdictions, cognitive status has also been identified as a predictor of HC use 
(Hall and Coyte, 2001). Overall, individuals using HC services are likely to have greater levels 
of disability and functional impairments.  
 Due to the functional impairments and disability associated with ADRD, ALS, and MS, 
individuals with these neurological conditions are more likely to be HC service users. For 
example, Vazirinejad et al. (2008) have found that the proportion of individuals with MS seeking 
HC services such as home help, occupational therapy, speech language pathology, 
physiotherapy, nursing, and social work services all increased with disease severity. In contrast, 
general practitioner and specialist services remained consistent throughout the course of the 
condition (Vazirinejad et al., 2008). Similar patterns of resource use exist for individuals with 
ADRD (Kraft et al., 2010), and it is likely that patterns of resource use for persons with ALS are 
similar given the clinical similarities between the three conditions. Overall, HC services are also 
likely to command a great deal more resource utilization than primary care for individuals with 
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neurological conditions. Kraft et al. (2010) found that in Switzerland, visits to general 
practitioners accounted for 0.4 percent of the annual cost of dementia, while community care 
accounted for 4.8 percent of total annual costs. Based on HC service utilization literature 
available for ADRD and MS, it is likely that HC service use is a crucial part of the care plan for 
individuals with ADRD, ALS, and MS.  
2.3 interRAI  
The interRAI family of assessment instruments was designed for use on various 
vulnerable populations (Hirdes et al., 2008). The first of these instruments was the Resident 
Assessment Instrument for nursing home, which was developed to address the need for a 
national resident assessment system in nursing homes identified by the Omnibus Budget 
Reconciliation Act (OBRA) of 1987 (Morris et al., 1990). This instrument was developed by a 
consortium of researchers and clinicians that has since become the interRAI network. The goals 
of the interRAI nursing home instrument were to replace previous nonuniform assessment 
instruments, to encourage the integration of resident assessment and care planning information, 
to improve quality of life through better care planning and provision, and finally, to set a 
standard methodology for resident assessment that could be updated and adapted to suit future 
needs (Morris et al., 1990). Unlike previous resident assessment tools, the interRAI nursing 
home instrument was designed to measure physical and psychological well being, functional and 
cognitive status, quality of life, and resource need using a case-mix system approach (Morris et 
al., 1990). The interRAI consortium has since developed a number of other assessment 
instruments, all of which are guided by the same goals and methodology of the interRAI nursing 
home instrument (Hirdes et al., 2008). These instruments include assessments for use in mental 
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health, acute care, post-acute care, palliative care, and home care settings. Today, the interRAI 
collaborative network and its instruments are in use in over 30 countries worldwide. 
The interRAI instruments were introduced to Canada on July 1, 1996 in Ontario complex 
continuing care (CCC) facilities (Hirdes et al., 2003). The interRAI nursing home instrument was 
implemented in CCC to improve the role of CCC in the Ontario healthcare system. The absence 
of CCC user data meant that there was little evidence to base funding and resident admissions 
criteria. The need for data to inform funding decisions for CCC responsibilities eventually led 
the Ontario Joint Policy and Planning Committee to establish the use of the interRAI nursing 
home instrument for patient level data collection. Although other assessment tools had also been 
considered, the interRAI tool was chosen because of its rigorous scientific testing, its sensitivity 
to clinical complexity, its use in international settings, and the inclusion of a clinical component 
that would be beneficial to patient need (Hirdes et al., 2003). Today, interRAI tools are used 
across different care settings in Canada. Some of these settings are nursing home, inpatient and 
community mental health, palliative care, as well as HC. 
Resident Assessment Instrument for Home Care 
The Resident Assessment Instrument for Home Care (RAI-HC) was designed to provide 
comprehensive assessment for the needs of individuals in HC using the same methods and 
principles as the interRAI nursing home instrument (Morris et al., 1997; Morris et al., 2000). 
Unlike most other community care assessment instruments, the RAI-HC is a multidimensional 
system that included measures of functional, social, disease, and environmental status (Morris et 
al., 1997). Where possible, the RAI-HC adopted assessment items that were compatible with 
measures in the nursing home instrument (Morris et al., 2000). Overall, 47 percent of the 223 
items found in the RAI-HC were derived directly from the nursing home assessment instrument, 
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and included items in the cognition, communication, vision, mood, behavior, ADL, and 
continence areas (Morris et al., 1997). Items found in the RAI-HC that are not found in the 
nursing home assessment instrument include informal support, IADL self-performance, alcohol 
abuse, and environmental conditions (Morris et al., 1997). Like the interRAI nursing home 
instrument, the RAI-HC tool designed for use by trained professionals performing assessments to 
observe individuals in the nursing home environment, review available health documents, in 
addition to directly questioning the nursing home residents and his or her informal caregiver(s). 
Finally, the RAI-HC provides a substantial improvement on previous community care 
assessment tools as both the validity and reliability of this instrument has been confirmed in 
various studies (Morris et al., 1997; Kwan et al., 2000; Landi et al., 2000).  
2.4 Methods for Estimating the Costs of Neurological Conditions 
 
 Accurate estimates of costs for neurological conditions are required in order to better 
allocate scarce health care resources. In some cases, estimates help to justify the costs of 
expensive new pharmacological treatments. In HC, cost estimates are typically required for 
policy planning uses such as estimating future service and resource needs. Indeed, understanding 
clinical characteristics that affect costs for the neurological conditions is important given 
evidence suggesting that for at least some neurological conditions, the cost of care is costlier care 
for those without this these conditions (Kang et al., 2006). It is important to note, however, that 
while the costs for individuals with neurological conditions can be estimated, it is not possible to 
estimate the costs caused by neurological conditions (Jönssen et al., 2006).  
Cost of Illness 
 
 The most common method for estimating the cost of neurological conditions relies on the 
cost of illness (COI) methodology. COI research was the first economic evaluation technique 
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used in the health field that standardized the methodology for estimating the cost of illness and 
injury (Tarricone, 2006). Although studies estimating the economic impact of disease on society 
had been conducted for many years using average costs for all illnesses, Rice (1967) argued that 
estimating the costs of specific illnesses was favorable since it provided more accurate 
reflections of costs. Accurate estimates of cost could then be used to estimate the total economic 
burden of specific illnesses to society, as well as to help further programs of research, to control 
or justify program expenditures, and to compare the costs of different illnesses (Rice, 1967; 
Cooper and Rice, 1976; Byford et al., 2000). Since Rice’s seminal paper, COI studies have 
shifted from measuring global disease costs, to measuring the combined social and financial 
costs of specific illnesses. 
Estimation Procedure 
 
 COI is estimated by identifying components where costs are incurred, and then 
attributing a monetary value to those components (Tarricone, 2006). The components are 
measured by the individual services and resources consumed through the course of care, such as 
meals, medications, lab procedures, or surgeries. Opportunity costs, which are the values placed 
on the lost opportunity to select the next best options, are used to measure the monetary value in 
COI estimates so that the full economic cost can be estimated as best as possible (Hodgson and 
Meiners, 1982). The application of these opportunity costs is placed on components of care that 
include the utilization of specific services, as well as losses in productivity. Specific components 
of associated costs are described in greater detail below. 
Direct Costs: 
 
 Direct costs can include both healthcare and non-healthcare related costs, and are 
invariably included in cost estimates for the neurological conditions. Healthcare related direct 
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costs refer to the services or goods consumed in the process of prevention, detection, treatment, 
rehabilitation, research, training, and capital investment in medical facilities of a given condition 
(Rice, 1967). Expenditure data for these health related activities are generally available through 
government bodies such as the United States National Health Accounts, or CIHI in Canada. Data 
are available for the majority of healthcare related activities, particularly, physician, hospital and 
drug costs. However, components such as research, training, and capital investment are difficult 
to allocate to specific illnesses since these activities are not necessarily carried out at the same 
time that other expenditures for care are made (Hodgson and Meiners, 1982). Non-healthcare 
related activities considered in direct costs include transportation related to health provider visits, 
relocation due to illness, and informal care (Tarricone, 2006). Costs incurred by family providing 
care to the ill are also considered as non-medical direct costs (Hodgson and Meiners, 1982). 
Although expenditures related to these non-healthcare related activities form an important 
component of the total direct costs, these expenditure data are not often systematically collected. 
As a result, non-medical direct costs generally rely on self-reported data collected for COI 
research purposes. 
Indirect Costs: 
 
 Direct costs alone do not measure the full economic costs resulting from illness and 
injury; therefore, total COI estimates must also include indirect costs. Unlike direct costs, 
indirect costs are not measured by expenditures. Instead, these costs are measured by losses in 
output or productivity caused by illness, as in a human capital approach. Losses of output to the 
economy because of illness, disability, or premature death can be estimated by applying mean 
earnings to work-loss data for a given illness or condition to the time taken away from 
employment for both the ill and their informal caregivers (Rice, 1967). The basic premise behind 
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indirect cost estimates has been challenged for a number of reasons, however. One of the 
primary arguments challenges the assumption that illness is the cause for losses in productivity, 
and that had death or illness not interfered, all individuals of the same age and sex would have 
had the same employment experiences (Rice, 1967). Similarly, measuring indirect costs through 
losses in productivity have been critiqued for systemically favoring diseases that traditionally 
afflict higher income groups (Hodgson and Meiners, 1982). This bias is problematic as losses 
caused by these illnesses necessarily have greater valuations based on indirect cost calculations 
rooted in earnings data. Nevertheless, indirect costs continue to be included in the majority of 
COI studies. 
Intangible Costs: 
 
 Although COI studies attempt to estimate the total burden of disease, certain aspects of 
disease cannot be valued using this approach. Specifically, these aspects include psychosocial 
costs associated with pain and suffering (Cooper and Rice, 1976). Common examples of these 
intangible costs include family conflict caused by disease, changes in personality, reduced self-
esteem, and physical pain (Hodgson and Meiners, 1982). Intangible costs that are not captured 
by indirect costs also include loss of ability to engage in leisure activities, economic dependence, 
unwanted employment changes, as well as loss of opportunities for promotions or higher 
education (Hodgson and Meiners, 1982). Finally, grief due to death for family and friends cannot 
be quantified and included in COI estimates.  
Other Considerations 
 
 Although the basic COI estimation procedure has been described above, a number of 
other methodological considerations must be made. These considerations pertain to the type of 
data that are used to estimate incidence or prevalence, individual or group level data, and finally 
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prospective as opposed to retrospective data. The corresponding advantages and disadvantages of 
each of these data types are discussed below. 
Prevalence and Incidence: 
 
 As in epidemiological studies, disease temporality must be considered. Prevalence based 
COI studies estimate the direct and indirect costs associated with all cases of the given illness 
that occur over a specified period of time (Byford et al., 2000). On the other hand, incidence 
based studies include the direct and indirect costs of cases of illness beginning in the year in 
which an illness first begins (Byford et al., 2000). In general, prevalence based approaches to 
COI produce larger estimates of cost. This observation is particularly true of conditions with 
long sequelae, although the estimates from both approaches will be similar for illnesses with 
short durations (Tarricone, 2006). Nevertheless, both incidence and prevalence-based estimates 
are of value. Prevalence based studies are preferred for planning cost containment policies since 
they are better able to comprehensively show the costliest components of care (Tarricone, 2006). 
Meanwhile, incidence based studies are preferred when considering preventive measures, short-
term illnesses or analyzing the cost of disease from onset until death (Tarricone, 2006).  
Top down and Bottom up: 
 
 The top down and bottom up consideration in COI estimates describes whether 
population, or individual level data will be used. A bottom up approach requires the quantity of 
health services consumed to first be estimated, followed by an estimation of the service costs for 
each of the different services consumed. The consumed services are then multiplied by the 
service costs, and the costs of all the different consumed services are then summed (Tarricone, 
2006). Finally, the number of individuals within a given sample or population is multiplied by 
the summed value in order to produce a gross estimate of health service expenditures (Olesen et 
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al., 2012). In top down studies, total expenditures for a given illness are used so that service use 
and service cost data are not required.  The advantage of the top down approach is that the 
estimates of expenditures cannot be larger than the known total expenditure (Tarricone, 2006). 
However, the bottom up approach is considered the ‘gold standard’ of COI estimation due to its 
ability to accurately attribute costs to specific components of illness, and is preferred where 
reliable data of service utilization and cost are available (Akobundu et al., 2006).  
Prospective and Retrospective: 
 
 Like incidence and prevalence, the prospective and retrospective approaches in COI 
estimates are derived from epidemiological concepts. Retrospective studies, which were 
described by both Rice (1967), and Cooper and Rice (1976), are most common, and involve data 
that have already been collected from relevant events. On the other hand, follow up data are used 
for prospective COI studies, and involve events that have not yet occurred (Tarricone, 2006). 
Due to the high costs associated with follow up studies, prevalence based studies are typically 
preferred where relevant data are available.  
Limitations 
 
 Although COI estimates have become extremely popular since Rice (1967) first 
attempted to standardize burden of disease studies, some methodological problems limit the 
applicability of these studies for policy and planning purposes. According to Currie and 
colleagues (2000), COI studies cannot be used for priority setting purposes. As COI studies only 
involve the costs of an associated activity and not the benefits, true opportunity costs cannot be 
determined, and thus the activities that would best maximize health cannot be determined (Currie 
et al., 2000). In addition, COI estimates cannot be used to predict future COI, as drivers of cost 
are not generally included in these studies.  
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Case-Mix Systems 
 
Although the COI methodology is effective in identifying components of cost, it is 
inadequate at identifying predictors of costs based on clinical and personal characteristics. Case-
mix systems, on the other hand, are able to identify predictors of cost since they were initially 
designed for prospective payment systems. Unlike COI, which essentially estimates opportunity 
cost, case-mix systems view costs in terms of service utilization. The notion of cost in case-mix 
systems is based on the concept that healthcare resource use is driven by personal and clinical 
characteristics (Fetter, 1991). As a result, case-mix systems were designed to classify individuals 
into resource homogenous groups based on their personal characteristics, followed by the 
attachment of a ratio level value to describe group resource intensity (Fetter, 1999). 
While case-mix systems are not strictly used for cost estimation purposes, case-mix does 
involve an element of cost measurement through its use as a reimbursement tool in hospitals and 
nursing homes (Fetter, 1999). In addition, case-mix systems were designed for use as predictors 
of resource utilization. Unlike the COI approach, which requires a number of considerations such 
as prevalence and incidence, top-down and bottom-up, and direct and indirect measures, case-
mix estimates of cost are simple in that they are invariably prevalence-based, bottom-up, direct 
estimates of cost. Case-mix based estimates of cost only require data on service utilization and 
costs, in addition to clinical information. Depending on care setting, clinical information can 
come from ICD codes representing an individual’s primary diagnosis, or from assessment 
instruments such as the RAl-HC described previously. It is generally accepted that measurements 
of service utilization only include services related directly to the medical treatment of a condition 
in hospitals, or to symptom management in non-acute settings (Fetter et al., 1991). As a result, 
only these services are included as part of resource intensity and cost estimates using the case-
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mix approach (Fetter et al., 1991). Resource utilization information is typically obtained from 
administrative records. Based on the defined services, unit costs representative of the wages for 
each of the different services are applied to the services provided in order to produce the total 
cost of treatment or care for an individual. A mean cost of care can then be calculated to describe 
the mean cost of care across the entire population. This mean is used as the reference value, and 
the resource use for all case-mix groups are then compared to this value. Case-mix groups are 
identified based on a set of clinical characteristics that have been identified to drive resource 
utilization. Mean costs are then produced for each of the different clinically homogenous groups. 
These mean costs are then used to determine the resource intensity weights for each of the 
resource homogenous groups, as compared to the mean cost of the total population. Based on the 
cost measurement component of case-mix systems, individual- and group-level estimates of costs 
can be derived. Ratio measures of resource intensity are also available using the case-mix 
approach. Some level of variability is expected between the individual- and group-level cost 
estimates using these ratio measures; however, variability should be limited as much as possible. 
Effective case-mix systems are expected to have low levels of variation between an individual’s 
group-level cost, and their individual-level cost (Fetter, 1991).  
Though simple in comparison to the COI approach, the grouping of a case-mix system is 
paramount to the effectiveness of a given system at estimating resource use, and must be 
considered. Overall, case-mix systems must meet statistical, clinical, and incentive criteria 
(Fetter, 1999; Fries et al., 1994). As briefly mentioned above, the clinical criterion requires that 
individuals within a group are clinically homogenous and have similar expected resource 
utilization (Fries et al., 1994; Fetter et al., 1980). However, groupings must also be based on a 
number of different clinical variables in order to ensure that all individuals are identified by the 
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system, even if they are rare (Fries et al., 1994). For example, grouping based solely on illness is 
problematic since descriptive labels and treatments for the same illnesses can differ, and not all 
diseases are equally well understood (Fetter, 1991). The statistical criterion is also crucial in 
case-mix systems, and requires that variability within case-mix groups can be predicted (Fetter, 
1991). Finally, as case-mix systems are primarily used for prospective payment systems, the 
incentive criterion is also important in ensuring that estimates of cost are reflective of actual 
needs-based costs, rather than desired costs (Fries et al., 1994; Botz, 1992).  
Overall, the case-mix systems approach provides a reasonable alternative to the more 
traditional COI approach. Even though case-mix measurement can only be used to estimate costs 
in defined care settings, this approach is likely to produce more reliable estimates of cost within 
these settings because of incentive criteria, and use for funding purposes. As Fetter (1991) 
argues, clinical variables primarily lead to differences in costs. While individual clinical 
characteristics result in only small variations to the equipment and supply needs that make up the 
bulk of COI component variables, they result in substantial differences in service needs in care 
programs and facilities (Fetter, 1991). As a result, the case-mix approach is likely preferable 
when the purpose is to identify predictors of cost, rather than components of cost. Perhaps the 
only potential problem associated with the case-mix measurement system is its exclusion of 
services not directly related to care or treatment. In hospitals, non-acute care settings, and 
community care programs, this exclusion is likely to underestimate costs associated with 
administrative tasks required to ensure the provision of treatments and care. Assuming that these 
administrative tasks are in proportion with the resource intensity weights for the different 
resource homogenous groups, however, this exclusion of administrative services is not likely to 
greatly impact the resource utilization ratios generated using this system.    
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2.5 Conceptual Framework 
 Andersen and Newman proposed a framework for predicting the utilization of healthcare 
services. The framework includes both societal and individual determinants of service utilization. 
Societal determinants affect healthcare utilization through changes in treatment and technology, 
as well as the financing of healthcare (Andersen and Newman, 1973). Individual determinants, 
on the other hand, affect healthcare service utilization through individuals’ predisposition to use 
services, the ability for individuals to access these services, and individuals’ medical needs based 
on their conditions (Andersen and Newman, 1973). The predisposing determinants describe the 
likelihood for individuals use healthcare services irrespective of illness (Andersen and Newman, 
1973). Enabling determinants are described as family and/or community resources that may 
affect resource utilization (Andersen and Newman, 1973). These include family attributes such 
as availability of caregiver, income, or insurance coverage (Andersen and Newman, 1973). 
Finally, according to Andersen and Newman (1973), illness is the most important determinant of 
healthcare service utilization, and is affected by the severity of the illness. The full list of 
predisposing, enabling, and illness components proposed by Andersen and Newman (1973) can 
be found in Figure 1. Across care settings, illness levels have the greatest relative importance for 
predicting resource utilization (Andersen and Newman, 1973). The relative importance of other 
characteristics depends on care setting. In HC, enabling factors have been found to have medium 
relative importance, while predisposing factors have low relative importance in predicting HC 
service utilization (Kempen et al., 1991).   
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Figure 1: Andersen and Newman, 1973 Characteristics Determining Resource Utilization 
in Healthcare 
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3.0 EXISTING COST LITERATURE FOR THE NEUROLOGICAL CONDITIONS 
 
Existing research on the cost of neurological conditions such as ADRD, ALS, and MS 
have largely focused on identifying the annual costs associated with care for these conditions 
using COI methods. Indeed, the findings suggest substantial economic burden associated with 
each of the neurological conditions discussed in this project. According to the Canadian 
Alzhiemer Society (2010), for example, the total economic burden of ADRD was $15 billion in 
2008. The lifetime cost per individual with MS, meanwhile, was estimated at $1.6 million (The 
Canadian Burden of Illness Study Group, 1998), and over $1 billion per year in Canada (MS 
Society of Canada, 2007). For MS, the most substantial component of cost has been attributed to 
lost productivity rather than costs incurred from health and social services (The Canadian Burden 
of Illness Study Group, 1998). For ADRD, the largest component of cost was due to informal 
care (Canadian Alzheimer Society, 2010). As very little cost research has been conducted for 
ALS, no estimates of economic burden could be found for Canadians with ALS. According to a 
Spanish estimate, the annual cost of ALS was €36 194 for 2004 ($58 065 CAD based on the 
November 30, 2004 exchange rate) (Lopez-Bastida et al., 2009).  
 While estimates of economic burden are helpful in identifying the components of costs, 
these traditional estimates of costs provide little insight into factors that drive healthcare resource 
use and funding needs for individuals with ADRD, ALS, and MS. In fact, very little research has 
specifically addressed the need for such information. Therefore, little is known about the 
mechanisms surrounding the high costs of care for ADRD, ALS, and MS. A review of existing 
literature was conducted through a MEDLINE search to identify previous studies that had 
attempted to identify predictors of costs for the three neurological conditions. In total, ten articles 
were identified that could be retrieved. These articles primarily looked at the relationships 
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between disease severity, and cost for individuals with ADRD, ALS, and MS. Of the ten articles 
that were identified, eight articles were dementia related. Only one study looked at MS, and one 
article looked at ALS. The full search strategy used to identify these articles can be found in 
Appendix B. Although non-scholarly literature was also searched for possible findings, no such 
reports could found. 
3.1 Study Designs 
  Of the ten articles identified, six were cross-sectional (Reese et al., 2011; Leicht et al., 
2011; Gustavsson et al., 2011b; McCrone et al., 2008; Grima et al., 2000; Kang et al., 2006; 
López-Bastida et al., 2009), three were prospective cohort studies (Andersen et al., 2003; 
Jönsson et al., 2006), and one had a case-control design (Rojas et al., 2011). The sample sizes for 
all studies were large by statistical standards, ranging from a sample size of 42 (Grima et al., 
2000), to 3346 (Andersen et al., 2003). Study participants were recruited from disease registries 
(López-Bastida et al., 2009; McCrone et al., 2008), population registries (Andersen et al., 2003; 
Kang et al., 2006), and outpatient hospital, clinic and office visits for neurologists and general 
practitioners (Reese et al., 2011; Leicht et al., 2011; Grima et al., 2000; Jönsson et al., 2006; 
Gustavsson et al., 2011b).  
 Cost and clinical data were collected through interviews (Andersen et al., 2003; 
Gustavsson et al., 2011b; Kang et al., 2006; Reese et al., 2011; Rojas et al., 2011) by self-
reported survey data (Jönsson et al., 2006; Leicht et al., 2011; McCrone et al., 2008; López-
Bastida et al., 2009), and clinical assessment (Grima et al., 2000). Clinical data were measured 
exclusively through disease severity scales including the Mini Mental State Examination 
(Gustavsson et al., 2011b; Jönsson et al., 2006; Rojas et al., 2011), Disability Assessment for 
Dementia scale (Gustavsson et al., 2011; Reese et al., 2007), Expanded Disability Status Scale 
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(Grima et al., 2000), Neuropsychiatry Inventory (Gustavsson et al., 2011b; Reese et al., 2007; 
Jönsson et al., 2006) and ADL Functionality Scale (Kang et al., 2007; Reese et al., 2011; 
Andersen et al., 2003). The measurement of severity used was undefined in the López-Bastida et 
al. (2009) and Leicht et al. (2011) studies. In addition, some studies looked at quality of life 
using the Euro Quality of Life (EQ-5D) (López-Bastida et al., 2009; McCrone et al., 2008) and 
the Health Utility Index 2 (Grima et al., 2000), as well as time since onset. Only one study 
looked at depression using the Geriatric Depression Scale (Reese et al., 2007). Cost data were 
self-reported (López-Bastida et al., 2009; Andersen et al., 2003; Grima et al., 2000), identified 
using the Resource Utilization in Demential Lite questionnaire (Gustavsson et al., 2011b; 
Jönsson et al., 2006), administrative records (Kang et al., 2007; Reese et al., 2011; Leicht et al., 
2011), or were estimated based on total population costs (Rojas et al., 2011; McCrone et al., 
2008).  
A variety of statistical analyses were also found across the ten studies. These included the 
use of t-tests, Fisher’s exact tests, and chi-square tests to detect differences across groups (Reese 
et al., 2011; Leicht et al., 2011). Multivariate linear regression models were also common across 
the ten studies (Reese et al., 2011; Gustavsson et al., 2011b; McCrone et al., 2008; Andersen et 
al., 2003; Rojas et al., 2011). ANOVA methods were used by Jönsson et al., (2006) as well as 
Rojas et al., (2011). No details were provided on the statistical analyses for Grima et al. (2000), 
and López-Bastida et al. (2009).   
Study Findings 
 
The findings across the ten studies suggested that disease progression and severity were 
positively associated with cost. For individuals with ADRD, Jönsson et al. (2006), Andersen et 
al. (2003), Rojas et al. (2011), Leicht et al. (2011), and Gustavsson et al. (2011b) all found that 
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ADRD progression and corresponding severity, as well as level of cognitive impairment were all 
significantly associated with increasing cost. In addition, Gustavsson et al. (2011b) and Kang et 
al. (2006) reported that ADL function was the most important predictor of care costs in 
community dwelling individuals with ADRD. One study also found that costs and predictors of 
costs varied depending on the type of dementia (Rojas et al., 2011). Comparatively fewer studies 
looked at ALS or MS; however, MS type (primary or secondary progressive), years with MS, 
quality of life, and disability were all significantly associated with care cost for this condition 
(McCrone et al., 2008; Grima et al., 2000). Finally, Lopez-Bastida et al. (2009) found that 
disease severity was positively significantly associated with care costs for ALS. More 
information of study findings can be found in Appendix C.  
3.2 Study Strengths and Limitations 
 
The ten studies identified were generally of high quality. The sampling methodology 
used across the studies appeared to produce samples that were representative of the community-
dwelling sample. The measurement of disease progression or severity, and cost were somewhat 
questionable for the studies using self-reported questionnaires (Jönsson et al., 2006; Leicht et al., 
2011; McCrone et al., 2008; López-Bastida et al., 2009) due to possible misreporting biases. In 
addition, recall bias is also likely to result from studies of individuals with reduced cognitive 
performance. As no details were provided outlining the statistical analyses in the studies by Kang 
et al. (2006), Grima et al., (2000) and López-Bastida et al. (2009), the significance of their 
findings could not be assessed.  
Although these studies do provide valuable insight into the clinical characteristics that are 
predictive of cost for the neurological conditions, it is clear that research in this area is still in its 
early stages. Primarily, research in this area has been constrained by the absence of high-quality 
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data. In many cases, the studies relied on self-reported questionnaire data for measurements of 
both disease progression and severity, and cost (Jönsson et al., 2006; Leicht et al., 2011; 
McCrone et al., 2008). In addition, the absence of high quality indicators of personal and clinical 
characteristics limited the numbers and types of variables that could be tested as potential 
predictors of cost. Finally, even though these studies were based almost exclusively on 
community-dwelling samples, only the studies by Grima et al. (2000), Gustavsson et al. (2011), 
and McCrone et al. (2008) included a range of community care services commonly used by 
individuals with ADRD, ALS, and MS. The majority of studies included only home care nursing 
and homemaking services, but excluded services by physiotherapists, occupational therapists, 
dietitians, social workers, and speech language pathologists (Andersen et al., 2003; Gustavsson 
et al., 2011; Jönsson et al., 2006; Kang et al., 2006; Leicht et al., 2011; Reese et al., 2011; Rojas 
et al., 2011). 
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4.0 STUDY RATIONALE 
Individuals with ADRD, ALS, and MS form three distinct groups with neurological 
conditions within the HC population. Those with ADRD are the largest and oldest neurological 
groups within the HC setting. In contrast to individuals with ADRD, persons with MS form one 
of the youngest diagnostic groups within the HC population. They experience substantial 
functional loss over time but less cognitive loss. Finally, individuals with ALS have the greatest 
clinical complexity and disability levels within the HC population, and tend to fall between the 
ADRD and MS age groups. Although the populations of each of these conditions are quite 
different, formal and informal services are an important part of the care plan for individuals with 
each of these three conditions in HC (Yaffe et al., 2002; Krivicaks et al., 1997; Aronson et al., 
1996). Individuals with these conditions overwhelmingly prefer community care to 
institutionalization where possible (Yaffe et al., 2002; Krivicaks et al., 1997; Aronson et al., 
1996). In order to ensure individuals with these conditions are able to remain in their homes, it is 
necessary to understand their service needs and costs to ensure that appropriate levels of service 
provision are available. As a result, it is necessary to identify the factors affecting costs of care 
for individuals with these conditions.  
As outlined in the background section, methodological and data limitations have affected 
the number and quality of studies examining the costs of these conditions. In particular, no 
research has looked specifically at the costs of ADRD, ALS, and/or MS in a HC setting. Existing 
studies were able to identify predictors of costs for these conditions; however, they were general 
measures of condition severity such as ADL functionality, cognitive performance, or scales 
related to disability. More specific clinical and personal characteristics that contribute to overall 
severity of these conditions were not examined in any of the previous studies identified. Finally, 
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only one of the ten studies identified dealt with Canadian samples (Grima et al., 2000). Therefore 
further research identifying the relationships between costs and the characteristics of persons 
with ADRD, ALS, and MS was warranted.  
4.1 Purpose, Objectives, and Goals 
 
 Given the scarcity of cost research for the neurological conditions, the purpose of this 
proposed research study was to contribute to the current cost literature for the neurological 
conditions. More specifically, the objectives were to provide estimates of costs for individuals 
with ADRD, ALS, and MS in HC settings, and to determine whether specific predisposing, 
enabling, and illness factors could be used to predict HC care costs for individuals with ADRD, 
ALS, and MS. The specific goals of this project were to identify reliable weekly estimates of 
costs for individuals with ADRD, ALS, and MS in the Ontario HC program, as well as clinical 
and personal characteristics associated with the cost of care for individuals with these conditions.  
4.2 Research Questions 
The overarching questions being addressed in this project are as follows: 
1. How do costs differ for individuals with ADRD, ALS, and MS? 
2. What characteristics associated with ADRD, ALS, and MS affect HC care costs? 
3. Is the existing RUGIII/HC categorization effective for predicting resource utilization for 
individuals with neurological conditions? 
4. What factors identified by Andersen and Newman (1973) are most important in 
predicting the costs of care for individuals with ADRD, ALS, and MS after controlling 
for RUGIII-HC? 
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4.3 Relevance of Research 
 The need for an increased understanding of cost for the neurological conditions is 
undeniable. According to the WHO (2006, p.1), “a large body of evidence shows that policy-
makers and health-care providers may be unprepared to cope with the predicted rise in the 
prevalence of neurological and other chronic disorders and the disability resulting from the 
extension of life expectancy and ageing of populations globally.” In Canada, the research needed 
to cope with the expected rise in the prevalence of neurological conditions has been outlined by 
CIHI in their 2007 Burden of Neurological Diseases, Disorders and Injuries in Canada report. 
This report specifically called for research that can “examine how factors such as severity of 
illness, comorbidities and quality of care influence the patterns of healthcare utilization by 
patients with neurological conditions” (CIHI, 2007, p.16). The findings from this project will 
contribute to the research undertaken through the Innovations in Data, Evidence, and 
Applications for Persons with Neurological Conditions (ideas PNC) project. The ideas PNC 
project is aimed at identifying factors affecting individuals with neurological conditions such as 
changes to quality of life and resource utilization. This study will respond to the need for direct 
cost data beyond the current scope of hospital, physician, and drug expenditures. The addition of 
expenditure information for HC programs will improve the availability of information, and 
enhance understanding on the direct cost of healthcare for Canadians with neurological 
conditions. 
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5.0 METHODS 
5.1 Basic Design 
 
  A secondary analysis of assessment data and costs from a 13-week study of home care 
was used in order to estimate, and determine the predictors of costs for ADRD, ALS and MS in 
the community. Assessment data were collected at a single point in time, while billed cost data 
were collected in the 13 weeks following initial assessment. Although secondary data analyses 
have many limitations, the availability of high quality data, the long duration of neurological 
conditions, and the low costs associated with this proposed study warrant the use of this 
approach. Indeed, one of the main advantages of this proposed project was the availability of 
comprehensive assessment and cost data from the Canadian Staff Time Resource Intensity 
Verification (CAN-STRIVE) project, which includes the entire population of individuals 
receiving long-stay HC in Ontario.  
5.2 Ethics 
 
 This project was cleared for ethics by the Office of Research Ethics at the University of 
Waterloo on 10 December 2012 (Appendix D).  
5.3 Study Sample and Setting 
 
 The sample for this project was drawn from the sub-study of CAN-STRIVE project 
dealing specifically with HC (Hirdes et al., 2010). This research project was based on a parallel 
US Staff Time and Resource Intensity Verification Project that was also intended to examine the 
RUG-III system. In both Canada and the United States, the aim was to validate the use of the 
RUG-III for the funding of institutionalized care, but only the Canadian study extended to 
research to HC. The CAN-STRIVE project was funded by Ontario Ministry of Health and Long 
PREDICTORS OF COSTS FOR ADRD, ALS, AND MS  
 
  38 
Term Care, and the Canadian Institute for Health Information (CIHI).  Data for the CAN-
STRIVE study were collected in Ontario, Canada for CCAC clients receiving long-stay services 
between April 2005 and June 2008. While long-stay individuals included those on service for 60 
days or greater, individuals receiving palliative, acute, or rehabilitation home care services do not 
receive a RAI-HC assessment, and were therefore not included into this dataset. Since those 
requiring palliative services are likely to have more advanced illness, the population of HC users 
with ADRD, ALS, and MS in this study are likely to represent less severe cases. In addition, 
those requiring palliative care will probably require greater levels of service. In contrast, acute 
and rehabilitation clients may be more likely to have short-term needs for intense services but 
may have less advanced illness meaning less long-term need for services compared with long-
stay HC users in this study. The data were provided by the Ontario Association of Community 
Care Access Centers (OACCAC), which collects RAI-HC assessment, admission and discharge 
records, and service billing/payment records from contracted agencies from the 14 individual 
CCACs that can be linked by encrypted health card number. The entire population of individuals 
using HC services was included into the HC portion of the CAN-STRIVE project, which 
included a total of 435,141 client assessments.  
5.4 Measurements 
 
 Data for exposure, outcome, and other variables were also gathered in the CAN-STRIVE 
project. The exposure of interest in this research project was identified as having ADRD, ALS, 
or MS, while the outcome of interest were the total HC costs. Other variables required for this 
proposed study included personal and clinical characteristic items that were expected to affect 
costs. These items fall into Andersen and Newman’s (1973) predisposing, enabling, and illness 
(need) determinants of healthcare utilization, and include demographic, geographical, and 
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clinical variables. The RUGIII/HC case-mix algorithm provides a validated classification system 
for understanding resource utilization in HC. Presence or absence of neurological condition, as 
well as predictors of cost were identified from the clinical component of the CAN-STRIVE data 
set. Cost data were available as part of the data collected on resource use, but instead came from 
linked administrative datasets. 
Cost Measurement  
 
 In the HC sample, average weekly costs were calculated by aggregating service episodes 
up to 13 weeks after the date of a RAI-HC assessment, with services provided in at least three of 
those weeks. Where discharge or a follow-up RAI-HC occurred, the episode length used to 
calculate average weekly costs was determined by those dates. A single set of standard service 
costs that represented median wages from 2007/2008 for each of the various service categories 
were applied to billing/payment records from contracted agencies. Use of median wage rates 
were used since they permit the average weekly cost to represent the volume of services 
provided, rather than the actual expenditures. Depending on the type of service provided, costs 
were applied either hourly, or per visit. However, CCAC case manager time was not included as 
part of these service costs. The wage rates for the various services can be found in Appendix E. 
Informal care costs were also available for the HC sample. These costs were calculated by taking 
the reported hours of support for activities of daily living (ADL) and instrumental activities of 
daily living (IADL) over the 7 day period, and applying an hourly rate in order to valuate 
personal care. This estimation procedure was appropriate for the proposed research project since 
it has been used extensively in case-mix research (Björkgren et al., 2000; Poss et al., 2008). A 
wage rate of $14.09 was applied to the weekly personal care hours, which was half of the 
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standard hourly wage rate of a personal support worker. The total cost of HC was calculated by 
combining the informal care costs with the average weekly costs. 
Exposure Measurement 
 
 Individuals with ADRD, ALS, and MS in the CAN-STRIVE HC sample were identified 
through the Disease Diagnoses section, section J, or the RAI-HC. ADRD (RAI-HC item J1g and 
J1h), and MS (J1k) were available from a pick list, while ALS diagnosis was written in using the 
International Classification of Disease (ICD) 10th Revision codes (J2a to J2d). These conditions 
were considered present if they were coded as either 1, indicating that the condition was present 
but did not require HC treatment or service, or 2, indicating that the condition was either being 
monitored or treated by a HC professional.  
Independent (Predictor) Variables 
 Personal and clinical variables were identified as potential predictor variables based cost 
and clinical literature for ADRD, ALS, and MS. The findings from the literature reviewed can be 
found in the Neurological Conditions, and Review of Existing Literature sections. Any 
symptoms or clinical characteristics associated with ADRD, ALS, or MS, and any variables 
tested as a potential predictor of cost in the existing cost literature were included for analysis for 
all three conditions. All variables that were included in the analyses have been organized based 
on the Andersen and Newman classification of healthcare resource utilization.  
Predisposing Variables: 
 
 Predisposing variables examined here included age and sex. Approximate age at time of 
assessment was estimated based on individuals’ reported date of birth (BB2) and RAI-HC 
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assessment date (A1), and was kept as a continuous variable. Sex (BB1) was reported as a binary 
variable where zero indicated female, and one indicated male. 
Enabling Variables: 
  Enabling variables are factors that permit or hinder individuals to access healthcare 
services. For this project, these included residence in one of the 14 CCACs, and cohabitation 
with a primary or secondary caregiver. Individuals’ CCACs were available in the existing CAN-
STRIVE HC dataset. The CCACs were coded as dummy variables, with the Hamilton Niagara 
Haldimand Brant CCAC as the reference category. Cohabitation with either a primary or 
secondary caregiver was identified using the ‘lives with client’ item in the RAI-HC (G1a and 
G1b). These items were collapsed into a single binary variable so that zero indicated that the 
individual did not live with either a primary or secondary caregiver, and one indicated 
cohabitation with either or both primary and secondary caregivers.  
Need Variables: 
 In total, 39 different need variables were included for analysis. These consisted of 
variables reflecting ADRD, ALS, or MS symptoms and associated impairments (Ropper and 
Samuels, 2009; Compston and Coles, 2002; Kiernan et al., 2011; Krivickas et al., 1997; Ballard 
et al., 2011). These span across a number of categories including mobility, daily function, 
bladder and bowel, swallowing, breathing, speech, cognitive, behavioural, mental, and vision 
impairments, as well as pain, and dizziness. Neurological comorbidities that are common in the 
HC population were also considered. Health related quality of life (HRQOL) was also included 
as one of the variables of interest (McCrone et al., 2008; Grima et al., 2000). Finally, the 
RUGIII/HC case-mix ratios were also included due to its ability to explain resource intensity; 
however, this variable was also included to control for any clinical or personal characteristics not 
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associated with ADRD, ALS, or MS that may affect drive resource use. More detailed 
descriptions of the individual and scale measures can be found as follows.  
Cognitive symptoms 
Cognitive functions such as memory loss and communication can be affected by 
neurological disorder. For ADRD in particular, cognitive performance describes not only the 
progression of the condition, but also may predict the cost of care (Jönsson et al., 2006; 
Andersen et al., 2003). Although less common, cognitive impairment can also affect individuals 
with ALS and MS (Compston and Coles, 2002; Kiernan et al., 2011). As such, cognitive 
performance was included as a potential predictor variable, and was measured using the 
Cognitive Performance Scale (CPS). The CPS was originally created for use in nursing home 
settings and included seven measures of cognitive performance available in the RAI for nursing 
home settings. These items include comatose status, short-term memory, cognitive skills for 
daily decision-making, the ability to be understood by others and ADL self-performance in 
eating (Morris et al., 1994). The items included in the CPS were derived from the Mini-Mental 
State Exam (MMSE), which is a widely used test of cognitive status that has been found to be 
both valid and reliable, and the Test for Severe Impairment, which addresses sensitivity issues in 
the MMSE (Morris et al., 1994). The resulting test for cognitive performance is a hierarchical 
algorithm comprised of seven levels, from intact (scale score 0) to very severe impairment (scale 
score 6) that has been found to be both reliable and valid in both nursing home and HC settings 
(Morris et al., 1994; Landi et al., 2000). The CPS was kept in its original form with seven levels 
in this analysis. 
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Functional and Movement Symptoms 
ADLs describe the ability to perform daily activities required for self-care. The first ADL 
classification was introduced by Katz (1963) to measure function as an indicator of care needs, 
as well as to evaluate the effectiveness of treatment. In this analysis, ADLs were used as 
indicators of self-care function affected by symptoms of ADRD, ALS and MS, such as gait 
ataxia, muscle weakness, spasticity and rigidity. In addition, difficulties performing ADLs have 
been identified in some studies to be associated with cost (Kang et al., 2006; Gustavsson et al., 
2011). ADLs are typically evaluated using a summary measure that determines dependence for 
daily activities such as bathing, eating, dressing and locomotion. The RAI-HC includes ADL 
items on dressing (H2e and H2f in RAI-HC), personal hygiene (H2i), toilet use (H2h), 
locomotion (H2c and H2d), transfer (H2b), bed mobility (H2a), and eating (H2g). These items 
are then scaled from independent (0) to total dependence (4), with the additional option where 
the activity did not occur (8), which is also coded as total dependence (Morris et al., 1999). 
Although these scores can be used to produce summary scales, the hierarchical classification of 
ADLs was chosen for this project. This Self-Performance Hierarchy uses only four of the seven 
ADL items: eating, locomotion, personal hygiene and toilet use. These items were identified 
through factor analysis as the most consistent indicators of early, middle, and late loss of ADL 
self-performance (Morris et al., 1999). The Self-Performance Hierarchy has seven levels 
including independent, supervision, limited, extensive 1, extensive 2, dependent, and total 
dependence (Morris et al., 1999). The scoring criteria can be found in Appendix F. Although the 
Self Performance Hierarchy was originally created for the interRAI nursing home instrument, it 
it is both valid and reliable in HC settings as well (Landi et al., 2000). 
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Other movement and physical function characteristics are also present for ADRD, ALS, 
and MS, and can potentially affect the cost of care. These items include unsteady gait, falls, and 
stair climbing. The item for unsteady gait (K6a) was a binary variable and was considered 
present if coded as one. Stair climbing (H5) was measured as ‘up and down stairs without help,’ 
‘up and down stairs with help,’ and ‘not go up and down stairs,’ and coded as zero, one, and two 
respectively. This variable was kept in its continuous form. Finally, falls were identified using 
the ‘falls frequency’ item (K5). This item was collapsed into a binary variable so that zero 
denoted that no falls had occurred, while a value of one denoted that at least one fall had 
occurred in the previous 90 days.  
Like ADLs, IADLs also measure the self-maintenance abilities of individuals. While 
ADLs are generally physical functions that are more likely to be impaired in the elderly, IADLs 
are functions considered to be typical of normal activities prior to old age, such as shopping, 
using transportation, and managing finances (Lawton and Brody, 1969). Despite the relatively 
young onset for ALS and MS conditions, IADL limitations had not been identified in the review 
of clinical literature. Given some of the symptoms associated with ALS and MS, however, it was 
felt that at least some difficulty with IADLs could be expected in these individuals. IADL self-
function impairments were specifically identified as symptoms of ADRD. As a result, IADL was 
considered a characteristic of interest across all three conditions. IADL function was measured 
using the interRAI IADL capacity scale, which is highly correlated with the original, validated 
Lawton and Brody (1969) scale in the HC setting. Items in the scale include self-performance in 
meal preparation (H1a), housework (H1b), use of the phone (H1e), transportation (H1g), 
shopping (H1f), managing finances (H1c), and taking medications (H1d) (Landi et al., 2000).  
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Breathing, Swallowing, and Expression (Speech) 
 
Dysphagia was measured using the swallowing item (L3). The swallowing item was kept 
in its original form, which had the following levels: normal (0), requires diet modification to 
swallow solid foods (1), requires diet modification to swallow solid foods and liquids (2), 
combined oral and tube feeding (3), and no oral intake (4). In addition, since dysphagia can lead 
to malnutrition and associated weight loss, the severe malnutrition (L1b) and ‘unintended weight 
loss of more than five percent in last 180 days’ (L1a) items were also included as potential 
predictor variables. Verbal expression was measured using the ‘making self understood’ item 
(C2), and was kept as a continuous variable ranging from zero to four, as found in the RAI-HC. 
Zero indicated understood, while a value of four indicated rarely/never understood. Finally, 
dyspnea was also included and was measured using the shortness of breath (K3e), respirator use 
(P2b), other respiratory treatment (P2c), and tracheostomy (P2m) items. All of these items were 
kept in their original form as binary variables. Presence of any of these characteristics was 
identified where items were coded as one, and zero denoted absence of these characteristics.  
Bladder and Bowel Symptoms 
Bladder incontinence (I1a) and bowel incontinence (I3) were considered present if they 
were coded as greater than, or equal to three. Constipation was identified using the binary ‘no 
bowel movement in three days’ item (K3b), and was considered present if coded as one. 
Visual Symptoms 
 Visual impairment was coded as a binary variable. It was considered present if the RAI-
HC vision item (D1) was coded as moderately impaired (2), highly impaired (3), or severely 
impaired (4), or the visual limitation/difficulties item (D2) was coded in one. Although an item 
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was available measuring vision decline, it was not included as part of the visual symptoms item 
because vision decline over time was not a symptom of ADRD, ALS, or MS.  
Pain symptoms 
 
Pain was identified as a common symptom in individuals with MS and ALS. For the 
current project, pain was measured using the interRAI Pain Scale. The interRAI Pain Scale was 
developed using the Visual Analogue Scale (VAS) as the external standard because of its 
efficiency and sensitivity for various levels of pain (Fries et al., 2001). Pain frequency and 
intensity, as found in the interRAI tools, were predictive of VAS scored pain (Fries et al., 2001). 
Initial separation in the pain algorithm was split into the following groups: no pain, less than 
daily pain, and daily pain (Fries et al., 2001). The daily pain category was then further split by 
pain intensity, into daily mild to moderate pain, and horrible or excruciating daily pain (Fries et 
al., 2001). In total, the interRAI Pain Scale is comprised of four levels, and has high concordance 
with the VAS, which is considered the “gold standard” in the measurement of pain (Fries et al., 
2001). The four levels are no pain (0), mild pain that is less than daily (1), moderate pain 
describing daily mild or moderate paint (2), and severe pain describing daily pain that is horrible 
or excruciating (3). Again, although the Pain Scale was originally devised for nursing home 
setting, the large proportion of similar items between the nursing home and HC instruments 
suggests that this scale should effectively identify various levels of pain in HC as well 
(Zyczkowska et al., 2007).  
Behavioral, Mood, and Mental Symptoms 
 
Mood disorders, primarily depression and anxiety, are common for individuals with 
neurological conditions. They can be part of the clinical characteristic of a given neurological 
condition, but can also be caused by diagnosis with the neurological condition. Depression and 
PREDICTORS OF COSTS FOR ADRD, ALS, AND MS  
 
  47 
anxiety associated with ADRD, ALS and MS were considered as potential clinical predictors of 
cost and were measured using the Depression Rating Scale (DRS). The DRS was validated 
against the Hamilton Depression Rating Scale, which is the current standard for psychiatric 
research, as well as the Cornell Scale for Depression in Dementia, which is relevant to the 
nursing home population (Burrows et al., 2000). According to Burrows et al., (2000), the DRS 
items include the following:  
a. Resident made negative statements (E1a) 
b. Persistent anger with self or others (E1b) 
c. Expressions of what appear to be unrealistic fears (E1c) 
d. Repetitive health complaints (E1d) 
e. Repetitive anxious complaints, concerns (E1e) 
f. Sad/pained/worried facial express (E1f) 
g. Recurrent crying/tearfulness (E1g) 
 
For each of these items, corresponding numerical scores were given to indicate that the behavior 
had not exhibited in last three days (0), had been exhibited in one to two of last three days (1), or 
exhibited on each of last three days (2). The DRS is a continuous variable with a range from zero 
to 14. The cutoff for mild to moderate depression is considered three on this scale (Burrows et 
al., 2000). The DRS has been used in a number of studies of HC clients (Dalby et al., 2008; 
Szczerbinska et al., 2011; Maxwell et al., 2008)  
 Other behavioral and mental symptoms not included in the RAI DRS are also common, 
particularly in individuals with ADRD. The following additional characteristics were therefore 
also included for analysis: aggression/hostility, delusions, hallucinations, and reduced social 
interaction. Aggression and/or hostility were categorized into a single binary variable. These 
symptoms were considered to be present if verbally abusive symptoms (E3b) or physically 
abusive symptoms (E3c) were coded as either one or two, or the openly expresses conflict with 
family of friends item (F1b) was coded as one. The delusions (K3f), hallucinations (K3g), and 
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social interaction (F1a) criteria were kept in their original binary form from the RAI-HC, and 
were considered present if they were coded as one. 
Comorbidities 
 Since comorbidities are common for at least some of the neurological conditions, other 
neurological conditions in the HC dataset were included in the analyses. The neurological 
comorbidities tested include ADRD, ALS, cerebral palsy, epilepsy, Huntington’s disease, MS, 
muscular dystrophy, Parkinson’s disease, stroke, spinal cord injury, and traumatic brain injury. 
As with identifying the presence of ADRD, ALS, and MS, the presence of these other conditions 
could be identified from the Disease Diagnoses section of the RAI-HC. Traumatic brain injury 
(J1j) and Parkinson’s disease (J1i) could be found in the pick list, while the remaining conditions 
were written in using ICD 10 codes. These comorbidities were included into the analyses as 
binary variables, with a value of one indicating presence of the comorbidity, and zero indicating 
absence of the comorbidity. As the aim of this project was to identify the effects of 
characteristics of neurological conditions on cost, non-neurological comorbidities were not tested 
in the analyses.  
Health Related Quality of Life 
Although HRQOL did not necessarily pertain to any specific clinical characteristic for 
ADRD, ALS or MS, it was included as a potential predictor of cost for each of the three 
conditions considered in this project. Primarily, HRQOL was included because it is an important 
outcome in health economics research, and therefore has the potential to affect the cost of care. 
HRQOL was measured in this project using the Health Status Index (HSI), which is a 
crosswalked version of the Health Utilities Index Mark Two (HUI2) (Wodchis et al., 2003; 
Wodchis et al., 2007). The HUI2 is a health status classification system that is based on seven 
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attributes and associated preference weights (Wodchis et al., 2003). The HSI is comprised of 33 
items in HC, measuring sensation, mobility, emotion, cognition, self-care and pain (Wodchis et 
al., 2003). Unlike the HUI2, the HSI does not include fertility as a component of HRQOL 
(Wodchis et al., 2003). The scoring for each of the attributes in the HSI reflects the preferences 
of a representative community sample for each health state, and was derived from the HUI2 
(Wodchis et al., 2003). A scoring function is then used to produce a total HSI score from zero to 
one, where one represents perfect health, and zero indicates death (Wodchis et al., 2003). The 
worst possible score is -0.03, and represents health states considered to be worse than death 
(Wodchis et al., 2003). The multiplicative preference scoring function, and the list of RAI-HC 
items included in the HSI scale can be found in Appendix G. Preliminary evidence suggests that 
the HSI has good validity, and can be used to substitute the HUI2 for group-level comparisons 
(Wodchis et al., 2003; Wodchis et al., 2007).   
Case-mix 
The RUGIII/HC was included in order to control for clinical characteristics not 
associated with the condition of interest. In addition, since case-mix systems are designed to 
group individuals into resource homogenous groups, it was also identified as a potential predictor 
of cost for ADRD, ALS, and MS. The RUGIII/HC system classifies clients into seven clinical 
levels: Special Rehabilitation, Extensive Services, Special Care, Clinically Complex, Impaired 
Cognition, Behaviour Problems, and Reduced Physical Functions (Björkgren et al., 2000). 
Inclusion in the Special Rehabilitation category was defined by use of over 120 minutes of 
physical, occupational, or speech therapy per week (Björkgren et al., 2000). Within each 
category, further subgroups were determined based on ADL items, as well as IADL items for the 
Special Rehabilitation, Clinically Complex, Impaired Cognition, Behaviour Problems, and 
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Reduced Physical Functions categories (Björkgren et al., 2000). In total, the RUGIII/HC system 
is comprised of 23 groups. The structure of the RUGIII/HC, as well as the inclusion criteria for 
each of the seven levels can also be seen in Appendix H. Ratio level values were then assigned to 
each of the 23 RUGIII/HC categories. These values were based on the case-mix index (CMI) 
values for combined formal and informal care time, derived from the HC sub-study of the CAN-
STRIVE project (Hirdes et al., 2010). The RUGIII/HC categories and associated case-mix values 
can be found in Appendix I.  
5.5 Statistical Analysis 
 
 Statistical analysis for this study was carried out using Statistical Analysis Software 
(SAS), Version 9.2 (SAS Institute, Cary, NC, USA). Descriptive and sample characteristics were 
calculated using frequency and means procedures. Bivariate regression analyses were performed 
for all independent variables across all three conditions. Multivariate linear regression analyses 
were carried out for each of the three conditions using the hypothesized characteristics. Since the 
analyses were performed on population-level data, and the population sizes were very large in all 
cases, it was expected that the multivariate regression models would be very robust. 
Nevertheless, since cost is typically heavily left skewed, a log-transformed model was also run. 
This log transformation was carried out in order to check the effects that any of the violation of 
assumptions for regression analysis had produced any misleading results.  
Bivariate Analysis 
 Bivariate analyses were carried out between all hypothesized variables for each diagnosis 
group. These included frequency and means procedures used to produce descriptive statistics of 
the HC population, as well as mean costs. Descriptive statistics were also generated for a 
comparison group using the same bivariate analyses. The comparison group was composed of all 
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individuals within the HC sample without ADRD, ALS, and MS, as well as cerebral palsy, 
epilepsy, Huntington’s disease, muscular dystrophy, Parkinson’s disease, spinal cord injury, 
stroke, and traumatic brain injury. Simple linear regressions were also used to test the association 
between each of the hypothesized variables and cost in order to gain an appreciation of the 
independent associations between cost and all hypothesized variables for ADRD, ALS, and MS. 
However, nonsignificance in simple regression was not an excluding criteria for testing in 
multivariate regression analyses. 
Multivariate Regression Analysis 
For both the transformed and untransformed models, full models were initially run that 
included all 41 independent variables. Manual backward elimination was then performed in 
order to remove nonsignificant variables. A number of steps were taken to ensure that only truly 
nonsignificant variables were removed from the model. The cutoff for significance was 
intentionally set at a p-value of 0.10 during the initial removal of nonsignificant variables in 
order to keep as many variables within the model as possible. In addition, all variables that were 
removed during this initial stage were then individually re-added to the model and re-run to test 
for significance in the absence of the other removed variables. Variables that were significant at 
the 0.10 level were then reintroduced into the model simultaneously for further backward 
elimination. At this stage, the significance level was reduced to a maximum p-value of 0.05. All 
variables with p-values greater than 0.05 were then removed, and individually re-entered once 
again. All variables that were significant at the 0.05 level when individually reintroduced were 
again entered to the model simultaneously. These steps were repeated in cases where variables 
became nonsignificant when reintroduced to the model, or where other variables became 
nonsignificant after the reintroduction of the variables. Where more than one model was 
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identified, the explained variance value was used to identify the best model. In addition, possible 
alternative models were also checked using automatic forward selection, backward elimination, 
and stepwise procedures. As a final step, all removed variables were individually reintroduced 
into the model to ensure that as many variables remained in the models as possible. 
Interaction terms between variables thought to be theoretically relevant were also 
included into the analyses after the final model had been identified. These interaction terms 
included age and ADL capacity, age and IADL capacity, age and cohabitation, sex and 
cohabitation, difficulty breathing and respirator, difficulty breathing and respiratory treatment 
other than respirator, and difficulty breathing and tracheostomy.  
Model Diagnostics 
 Model diagnostics were performed by checking the residual plots for both the 
transformed and untransformed final models for each of the three conditions. In addition, 
collinearity was checked using the variance inflation factor (VIF). There is no standard cut point 
to suggest the presence of collinearity; however, VIF between four and ten have traditionally 
been suggested as appropriate cut points (O’Brien, 2007). Even based on the most conservative 
of cut points, there was no evidence to suggest that serious collinearity was present in any of the 
ADRD and ALS models. For the MS models, only the CMI and ADL variables had VIF greater 
than four, at 4.1 and 4.2, respectively. Given that the VIF for these variables remained on the low 
end of previously suggested cut point range, collinearity was not thought to be of concern even 
in the MS models. Based on even the most liberal VIF cut point of ten, however, all interaction 
terms had to be removed from all the models. VIF for the interaction terms as well as ADL, 
IADL, cohabitation, sex, breathing, respirator use, other respiratory treatment, and tracheostomy 
PREDICTORS OF COSTS FOR ADRD, ALS, AND MS  
 
  53 
variables ranged from 23 to 115, indicating very strong collinearity between interaction terms 
and these variables.  
Missing Values 
 Models were checked for observations with missing values, and means procedures with 
the missing option were used to identify the variables with missing variables. These variables 
included ADL, speech, vision, and CMI for MS and ADRD. No missing values were found for 
any of the variables in ALS. Since the sample size for ADRD, and MS were both large and no 
variable had greater than four missing variables, any observations with missing values were 
excluded from multivariate regression analyses. SAS automatically excludes such observations 
from multivariate regression analyses. Therefore no additional steps had to be taken to remove 
these variables.  
Sensitivity Analysis 
 As the CAN-STRIVE dataset includes repeat assessments for at least some individuals 
with ADRD, ALS, and MS, a one-way sensitivity analysis was conducted on all models to assess 
the impact of the repeat assessments in the dataset on the conclusions of the final models. For 
each of the conditions, the final untransformed and transformed models identified were re-run 
using a sample that excluded repeat assessments. Repeat assessments were removed so that only 
the most recent RAI-HC assessments were included into the analyses.
PREDICTORS OF COSTS FOR ADRD, ALS, AND MS  
 
  54 
6.0 RESULTS 
6.1 Sample Characteristics 
 Although 435,141 assessments were available, only 70,061 assessments were identified 
where ADRD, ALS, or MS were present. In total, ADRD was present in 59,310 assessments, 
representing 25,901 individuals; ALS was present in 991 assessments, representing 452 
individuals; and MS was present in 9946 assessments, representing 3309 individuals. Within the 
total sample of individuals included in these analyses, the average age was 79. In comparison, 
the average ages for ADRD, ALS, and MS were 82, 63, and 58, respectively. 
Table 2 shows the distribution of individuals across the predisposing variables. 
Distributions across the three neurological conditions and the comparison group show 
differences in the age and sex of individuals across these four groups. The comparison group was 
defined as individuals within the sample that did not have a diagnosis for ADRD, ALS, and/MS, 
as well as cerebral palsy, epilepsy, Huntington’s disease, muscular dystrophy, Parkinson’s 
disease, spinal cord injury, traumatic brain injury, and/or stroke. Individuals with MS and ALS 
were clustered in the 40 to 79 age groups. Meanwhile, individuals with ADRD and those without 
any of the 11 defined neurological conditions were primarily concentrated in the 60 to 99 age 
groups. Across conditions, a greater proportion of individuals were female; however, the sex 
distribution did vary across the groups. 
Differences in the distribution of individuals across CCACs and the proportion of 
individuals living with caregivers were also evident across the four groups. Overall, the 
distribution of individuals across the CCACs was similar across the ADRD and MS groups, as 
compared to both the comparison group, and the entire HC population (not shown). The 
proportion of individuals with ADRD in WW was higher in comparison to the distribution of 
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individuals with other conditions in the WW CCAC. Individuals with ALS, however, were 
present in higher proportions as compared to the overall HC population in a number of CCACs. 
These CCACs included the MH, CW, Central, and Champlain CCACs. The rates of individuals 
cohabiting with caregivers were also different across the groups. In all cases, individuals with 
ADRD, ALS, and MS were more likely to live with a primary or secondary caregiver than 
individuals without neurological conditions. In particular, an overwhelming proportion of 
individuals with ALS lived with their caregivers. The distribution of these enabling factors can 
be found in Table 3.  
The proportion of individuals experiencing problem symptoms or characteristics 
associated with their conditions were generally higher for ADRD, ALS, and MS as compared to 
individuals without any of the 11 identified neurological conditions listed above. Individuals 
with neurological conditions had greater difficulties with ADLs. Among the three neurological 
conditions considered in this project, the proportion of individuals with extensive ADL 
impairments (ADL score ≥ 3) was highest for those with ALS. A similar pattern was found for 
IADL impairments where again, individuals with ALS were concentrated in the highest 
impairment groups at the highest rates for IADL. In addition, greater proportions of individuals 
with ALS had unsteady gait, malnutrition, weight loss, respiratory treatment, breathing difficulty, 
and a larger proportion had experienced at least one fall in the past 180 days as compared to 
those with ADRD, MS, or without neurological conditions. Individuals with ADRD, ALS, and 
MS were unable to use stairs at higher rates than those without neurological conditions, although 
individuals with MS were most likely to be unable to use stairs. Individuals with MS also 
displayed the highest proportion of pain, dizziness, and constipation. Individuals with ADRD 
were likeliest to have bowel and bladder incontinence, as well as withdrawal from social 
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involvement, hallucinations, delusions, and other neurological comorbidities. The distributions 
of these need factors can be found in Table 4.
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Table 2: Distribution of Predisposing Factors by Condition by Percent (number) 
 
ADRD ALS MS 
Comparison 
Group 
Age      
0-19 0.2 (92) 0.0 (0) 0.1 (9) 0.3 (679) 
20-29 0.0 (22) 0.3 (3) 0.7 (70) 0.8 (2241) 
30-39 0.1 (55) 2.7 (27) 5.8 (576) 1.4 (3908) 
40-49 0.3 (147) 12.4 (123) 19.7 (1959) 3.8 (10,405) 
50-59 1.1 (632) 23.7 (235) 31.0 (3084) 7.5 (20,581) 
60-69 4.6 (2742) 26.8 (265) 24.6 (2448) 11.5 (31,438) 
70-79 25.5 (15,140) 25.2 (249) 13.6 (1356) 23.9 (65,397) 
80-89 53.1 (31,479) 8.7 (86) 4.3 (430) 38.0 (103,880) 
90-99 14.9 (8806) 0.1 (1) 0.2 (16) 12.3 (33,545) 
100-115 0.3 (193) 0.1 (1) 0.0 (0) 0.4 (1071) 
Sex     
Male 36.1 (21,403) 46.2 (458) 24.5 (2433)  28.3 (77,273) 
Female 63.9 (37,915) 53.8 (533) 75.5 (7515) 71.7 (195,929) 
 
Table 3: Distribution of Enabling Factors by Condition by percent (number) 
 
ADRD ALS MS 
Comparison 
Group 
Cohabit     
Yes 66.1 (39,206) 83.4 (826) 70.6 (7018) 48.8 (133,298) 
CCAC     
HNHB CCAC 17.3 (10,281) 14.5 (144) 17.6 (1754)  16.8 (45,867) 
MH CCAC 5.0 (2968) 9.9 (98) 4.1 (406) 4.8 (13,030) 
CW CCAC 2.6 (1555) 4.7 (47) 2.9 (285) 3.0 (8116) 
TC CCAC 5.3 (3126) 4.2 (42) 4.1 (403) 6.2 (16,804) 
CENT CCAC 10.6 (6270) 15.2 (151) 8.0 (792) 10.1 (27,471) 
CE CCAC 11.3 (6676) 7.7 (76) 13.0 (1289) 11.9 (32,478) 
SE CCAC 4.5 (2688) 3.1 (31) 3.7 (363) 3.7 (10,226) 
CHAM CCAC 10.6 (6288) 12.6 (125) 9.2 (911) 7.4 (20,153) 
NSM CCAC 3.5 (2073) 4.0 (40) 3.2 (315) 3.7 (10,202) 
NE CCAC 5.3 (3157) 6.3 (62) 6.0 (598) 6.6 (17,987) 
NW CCAC 2.8 (1679) 2.4 (24) 4.0 (396) 3.2 (8746) 
ESC CCAC 5.6 (3339) 4.2 (42) 6.3 (628) 6.2 (17,027) 
SW CCAC 8.2 (4870) 8.8 (87) 12.2 (1215) 11.6 (31,654) 
WW CCAC 7.3 (4348) 2.2 (22) 6.0 (593) 4.9 (13,441) 
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Table 4: Distribution of Need Variables by Condition by percent (number) 
 
ADRD ALS MS 
Comparison 
Group 
ADL Hierarchy     
0 39.8 (23,577) 27.9 (276) 43.4 (4318) 77.5 (211,672) 
1 19.2 (11,397) 6.8 (67) 6.5 (650) 7.5 (20,547) 
2 18.3 (10,881) 16.5 (163) 10.6 (1053) 8.5 (23,364) 
3 10.8 (6387) 7.7 (76) 17.2 (1715) 3.4 (9312) 
4 5.7 (3383) 14.6 (145) 7.9 (788) 1.7 (4727) 
5 3.6 (2134) 15.1 (150) 8.4 (840) 1.1 (2882) 
6 2.6 (1558) 11.5 (114) 5.9 (583) 0.3 (797) 
IADL Capacity     
0 1.1 (676) 1.1 (11) 1.1 (106) 5.8 (15,908) 
1 2.5 (1459) 2.0 (20) 3.6 (361) 12.6 (34,321) 
2 6.9 (4070) 5.2 (51) 11.5 (1145) 16.9 (46,222) 
3 2.9 (1715) 1.0 (10) 0.4 (39) 0.9 (2512) 
4 11.7 (6938) 14.6 (141) 22.7 (2259) 29.2 (79,750) 
5 34.0 (20,157) 40.1 (397) 49.1 (4884) 29.9 (81,706) 
6 41.0 (24,303) 36.4 (361) 11.6 (1154) 4.7 (12,783) 
Unsteady Gait     
Yes 60.5 (35,860) 71.3 (707) 64.7 (6431) 56.0 (152,884) 
Falls1     
Yes 31.0 (18,384) 40.8 (404) 33.7 (3355) 24.9 (67,999) 
Stair Use     
Without Help 36.7 (21,740) 20.7 (205) 15.2 (1516) 41.0 (111,993) 
With Help 22.2 (13,181) 18.8 (186) 11.1 (1108) 16.3 (44,431) 
Does not use Stairs 41.1 (24,397) 60.6 (600) 73.6 (7324) 42.7 (116,778) 
Difficulty Swallowing     
Normal 89.6 (53,165) 43.7 (433) 83.1 (8269) 94.7 (258,687) 
Diet modifications for solid 
foods 7.1 (4226) 20.4 (202) 11.1 (1105) 3.7 (10,185) 
Diet modifications for solid 
foods and liquids 2.7 (1605) 18.6 (184) 3.5 (351) 0.8 (2294) 
Oral and tube feeding 0.2 (94) 7.2 (71) 0.9 (85) 0.4 (1171) 
No oral intake 0.4 (228) 10.2 (101) 1.4 (138) 0.3 (862) 
Malnutrition     
Yes 0.8 (465) 2.1 (21) 0.8 (78) 1.0 (2585) 
Weight Loss2     
Yes 5.4 (3208) 15.3 (152) 3.3 (329) 6.9 (18,868) 
Respirator Use     
Yes 0.2 (89) 6.5 (64) 0.4 (39) 0.5 (1323) 
Other Respiratory     
                                                        
1 Yes denotes those with at least one fall in the previous 90 days. 
2 Yes denotes unintended weight loss of at least 5% of body weight in previous 120 days. 
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Treatments3 
Yes 2.9 (1689) 12.1 (12) 3.6 (355) 5.9 (16,076) 
Tracheostomy     
Yes 0.0 (22) 2.3 (23) 0.2 (21) 0.3 (840) 
Breathing Difficulty     
Yes 15.5 (9204) 29.0 (287) 10.1 (245) 28.5 (77,786) 
Expression     
Understood 44.5 (26,396) 69.6 (69) 82.7 (8221) 91.1 (248,786) 
Usually understood 25.5 (15,136) 11.6 (115) 11.4 (1137) 6.8 (18,638) 
Often understood 15.4 (9147) 4.4 (44) 3.0 (302) 1.2 (3248) 
Sometimes understood 9.9 (5884) 9.9 (98) 2.0 (198) 0.7 (1813) 
Rarely/never understood 4.6 (2751) 4.4 (44) 0.9 (89) 0.3 (707) 
CPS     
0 2.5 (1456) 61.5 (609) 60.0 (5966) 68.6 (187,531) 
1 7.7 (4573) 24.9 (247) 19.1 (1902) 16.6 (45,281) 
2 47.6 (28,222) 8.4 (83) 16.4 (1631) 12.5 (34,206) 
3 21.8 (12,919) 2.9 (29) 2.3 (228) 1.3 (3545) 
4 3.4 (2042) 0.5 (5) 0.1 (14) 0.2 (479) 
5 13.9 (8292) 0.1 (1) 0.8 (79) 0.6 (1651) 
6 3.1 (1814) 1.7 (17) 1.3 (128) 0.2 (508) 
DRS     
0 58.7 (34,797) 48.9 (485) 64.3 (6397) 66.3 (181,173) 
1 14.5 (8627) 17.4 (172) 11.6 (1156) 12.5 (34,144) 
2 11.0 (6481) 13.0 (129) 9.5 (945) 8.7 (23,778) 
3 5.1 (3015) 6.8 (67) 4.9 (488) 4.3 (11,649) 
4 4.2 (2490) 4.8 (48) 3.4 (341) 3.2 (8808) 
5 2.0 (1177) 2.0 (20) 1.9 (193) 1.5 (4069) 
6 1.9 (1113) 3.4 (34) 1.9 (186) 1.6 (4257) 
7 0.8 (487) 0.7 (7) 0.7 (73) 0.6 (1644) 
8 0.8 (490) 2.0 (20) 0.7 (67) 0.6 (1554) 
9 0.3 (198) 0.4 (4) 0.3 (29) 0.3 (671) 
10 0.4 (246) 0.2 (2) 0.5 (45) 0.3 (673) 
11 0.1 (74) 0.1 (1) 0.2 (17) 0.1 (234) 
12 0.1 (76) 0.0 (0) 0.0 (7) 0.1 (331) 
13 0.0 (20) 0.1 (1) 0.0 (3) 0.0 (78) 
14 0.1 (27) 0.1 (1) 0.0 (1) 0.1 (137) 
Pain Scale     
No pain 52.0 (30,814) 40.9 (405) 34.3 (3409) 25.7 (70,061) 
Mild pain (not daily) 14.8 (8778) 10.4 (103) 11.4 (1132) 12.6 (34,326) 
Mild/moderate pain (daily) 28.6 (16,987) 37.9 (376) 38.4 (3823) 45.3 (123,833) 
Severe pain (daily) 4.6 (2738) 10.8 (107) 15.9 (1584) 16.5 (44,971) 
Constipation     
Yes 0.81 (481) 1.1 (11) 2.5 (245) 1.0 (2700) 
                                                        
3 Other respiratory treatments, excluding respirator use. 
PREDICTORS OF COSTS FOR ADRD, ALS, AND MS  
 
  60 
Bowel Incontinence     
Yes 19.6 (11,602) 6.1 (60) 17.8 (1766) 4.97 
Bladder Incontinence     
Yes 44.4 (26,340) 14.9 (148) 39.3 (3907) 22.0 (60,154) 
Vision4     
Yes 13.8 (8193) 4.8 (48) 13.0 (1292) 11.9 (32,444) 
Dizziness     
Yes 11.7 (6948) 7.7 (77) 13.8 (1374) 16.6 (45,212) 
Aggression     
Yes 18.8 (11,170) 11.1 (110) 13.2 (1309) 10.4 (28,322) 
Social Withdrawal     
Yes 9.2 (5440) 3.4 (34) 2.8 (281) 2.7 (7478) 
Hallucinations     
Yes 6.2 (3690) 0.2 (2) 0.4 (42) 0.7 (1897) 
Delusions     
Yes 4.2 (2463) 0.2 (2) 0.2 (20) 0.4 (1146) 
Comorbidities     
ADRD N/A 1.9 (19) 1.7 (167) 0.0 (0) 
Amyotrophic Lateral Sclerosis 0.0 (19) N/A 0.1 (10) 0.0 (0) 
Cerebral Palsy 0.0 (15) 0.0 (0) 0.2 (19) 0.0 (0) 
Epilepsy 1.3 (756) 0.5 (5) 1.6 (156) 0.0 (0) 
Huntington’s Disease 0.1 (47) 0.0 (0) 0.0 (3) 0.0 (0) 
Multiple Sclerosis 0.3 (167) 1.0 (10) N/A 0.0 (0) 
Muscular Dystrophy 0.0 (8) 0.0 (0) 0.1 (5) 0.0 (0) 
Parkinson’s Disease 6.8 (4048) 1.1 (11) 0.7 (70) 0.0 (0) 
Spinal Cord Injury 0.0 (1) 0.1 (1) 0.1 (8) 0.0 (0) 
Stroke 23.7 (14,068) 6.3 (62) 4.9 (484) 0.0 (0) 
Traumatic Brain Injury 1.4 (829) 0.7 (7) 1.2 (117) 0.0 (0) 
Health Status Index     
-0.03-0.13 3.9 (2317) 2.7 (27) 2.5 (247) 1.7 (4567) 
0.14-0.30 18.7 (11,108) 15.4 (153) 13.6 (1354) 11.6 (31,764) 
0.31-0.47 24.6 (14,614) 29.5 (292) 26.0 (2575) 19.2 (52,307) 
0.48-0.64 26.8 (15,902) 28.1 (278) 35.1 (3496) 33.5 (91,394) 
0.65-0.81 19.8 (11,747) 17.8 (176) 19.9 (1977) 23.1 (63,020) 
0.82-1 6.1 (3630) 6.6 (65) 3.0 (299) 11.0 (30,150) 
 
 
                                                        
4 Yes denotes any visual impairment, limitations, or difficulties. 
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Table 5 displays the distribution of individuals across the 23 RUGIII/HC CMI groups by 
condition. Individuals with ADRD were primarily clustered in the PA2, IA2, IB, CA2, PD, and 
PA1 categories, accounting for roughly 82 percent of the ADRD population. Not surprisingly, 
those with MS were also highly clustered in some case-mix groups due to the inclusion of the 
MS diagnosis criteria in the RUGIII/HC algorithm. These categories included CA1, CA2, SSA, 
and SSB. The clustering of the ALS population was less evident. Nevertheless, these individuals 
were present in higher proportions in the PPD, PA2, PA1, CB, SE1, and RA1 groups. The 
graphical distribution these populations across the RUGIII/HC can be found in Figure 2.
PREDICTORS OF COSTS FOR ADRD, ALS, AND MS  
 
  62 
Table 5: Distribution of Population across RUGIII/HC CMI Groups by percent (number) 
Formal and Informal 
RUGIII/HC Case-Mix 
Groups 
ADRD ALS MS 
Comparison 
Group 
0.485 (PA1) 6.0 (3562) 7.7 (76) 0.0 34.6 (94,517) 
0.593 (BA1) 0.2 (102) 0.0 (0) 0.0 0.1 (393) 
0.609 (CA1) 1.0 (600) 2.6 (20) 23.2 (2310) 11.8 (32,173) 
0.839 (IA1) 0.3 (152) 0.0 (0) 0.0 0.0 (115) 
0.933 (PA2) 33.3 (19,742) 14.5 (144) 0.0 27.7 (75,768) 
0.967 (RA1) 0.4 (223) 7.0 (69) 3.1 (305) 2.4 (6451) 
1.126 (CA2) 8.5 (5050) 4.6 (46) 23.7 (2357) 10.6 (29,082) 
1.281 (BA2) 1.7 (1004) 0.1 (1) 0.0 0.3 (848) 
1.379 (PB) 4.0 (2344) 6.0 (59) 0.0 3.5 (9455) 
1.609 (RA2) 1.6 (937) 2.9 (29) 0.7 (69) 0.8 (2287) 
1.637 (IA2) 17.6 (10,422) 0.7 (7) 0.0 0.9 (2363) 
1.660 (CB) 2.9 (1709) 8.4 (83) 4.9 (485) 2.3 (6384) 
1.718 (BB) 0.5 (275) 0.0 (0) 0.0 0.1 (184) 
1.755 (PC) 0.9 (513) 3.0 (30) 0.0 1.0 (2812) 
1.878 (SSA) 0.4 (205) 1.5 (15) 26.8 (2661) 0.4 (1147) 
2.121 (IB) 10.1 (5993) 0.2 (2) 0.0 0.5 (1273) 
2.417 (PD) 7.0 (4129) 17.9 (177) 0.0 1.5 (3949) 
2.498 (SE1) 0.7 (421) 7.6 (75) 1.9 (187) 0.5 (1298) 
2.586 (CC) 2.1 (1257) 2.5 (25) 0 0.6 (1583) 
2.743 (RB) 0.5 (313) 7.8 (77) 1.5 (153) 0.2 (625) 
2.791 (SSB) 0.6 (345) 3.3 (33) 14.0 (1397) 0.1 (332) 
4.240 (SE2) 0.0 (10) 1.6 (16) 0.2 (23) 0.1 (125) 
5.151 (SE3) 0.0 (0) 0.7 (7) 0.0 (1) 0.0 (36) 
 
   
Figure 2: Distribution of Population across RUGIII/HC CMI Groups 
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Across the three conditions, the average CMI was 1.42, and the average total weekly cost 
was $594.81. These means were close in value to the ADRD population, where the CMI, and 
weekly cost were 1.40, and $593.32, respectively. In contrast, both MS and ALS displayed 
substantially different sample characteristics. For the MS population, CMI and total weekly costs 
1.52 and $574.92. ALS, meanwhile, had a case-mix ratio value of 1.77 and a mean total weekly 
cost of $898.41. In contrast, individuals in the comparison group had a mean CMI of 0.87, and 
an average weekly cost of $337.16. Across the CMI groups too, it appeared that individuals with 
ADRD, ALS, and MS generally had higher mean costs than the comparison groups. Table 6 
shows the mean costs for each condition broken down by CMI.
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Table 6: Mean costs (in dollars) by Formal and Informal RUGIII/HC Case-Mix Groups 
Formal and Informal 
RUGIII/HC Case-Mix 
Groups 
ADRD ALS MS 
Comparison 
Group 
0.485 (PA1) 243.47 292.25 N/A 198.27 
0.593 (BA1) 332.83 N/A N/A 218.29 
0.609 (CA1) 271.17 355.67 247.64 253.10 
0.839 (IA1) 405.16 N/A N/A 282.66 
0.933 (PA2) 412.52 451.96 N/A 352.49 
0.967 (RA1) 440.88 701.97 467.31 386.98 
1.126 (CA2) 539.92 529.77 426.52 436.96 
1.281 (BA2) 562.22 130.54 N/A 430.11 
1.379 (PB) 568.01 752.54 N/A 519.19 
1.609 (RA2) 656.53 834.49 722.29 575.61 
1.637 (IA2) 647.59 814.73 N/A 569.69 
1.660 (CB) 833.27 592.80 592.08 610.98 
1.718 (BB) 698.60 834.14 N/A 604.70 
1.755 (PC) 665.72 1102.55 N/A 669.93 
1.878 (SSA) 869.15 1218.86 719.17 817.19 
2.121 (IB) 814.39 1138.55 N/A 792.45 
2.417 (PD) 1017.16 1454.55 N/A 866.73 
2.498 (SE1) 1070.48 1543.51 1076.54 880.74 
2.586 (CC) 1098.48 1336.76 N/A 989.51 
2.743 (RB) 1082.30 N/A 989.57 1053.43 
2.791 (SSB) 1253.40 1431.36 982.51 1117.96 
4.240 (SE2) 899.33 2309.47 1856.09 1356.81 
5.151 (SE3) N/A 2737.15 686.63 2430.60 
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6.2 Bivariate Regression Models 
 Bivariate linear regression models identified a number of variables that were significantly 
(p ≤ 0.05) and independently associated with cost. For the ADRD group, independent 
associations were seen for all variables, with the exception of pain, difficulty breathing, 
dizziness, MD, SCI, and TBI. Huntington’s disease was borderline significant at 0.056. Similar 
results were found in the log-adjusted model; however, tracheostomy and epilepsy became 
nonsignificant in this model. 
 For individuals with ALS, variables that were independently associated with cost 
included CMI, HSI, age, cohabitation with caregiver, ADL, IADL, falls, help with stairs, does 
not use stairs, trouble swallowing, respirator use, respirator treatment other than respirator, 
tracheostomy, depression, pain, cognitive performance, constipation, trouble with expression, 
vision, aggression, bladder and bowel constipation, and ADRD. In the log-transformed model, 
sex became significant, while malnutrition and vision became nonsignificant. 
For MS, variables significantly associated with cost included the following: CMI, HSI, 
sex, cohabitation with caregiver, ADL, IADL, unsteady gait, falls, help with stair use and does 
not use stairs, difficulty swallowing, weight loss, malnutrition, respiratory treatment other than 
respirator, tracheostomy, pain, cognitive performance, constipation, communication, vision, 
dizziness, bladder and bowel incontinence, social involvement, hallucinations, delusions, ALS, 
ADRD, CP, SCI, TBI, and CCACs. Variables that were significant were similar in the log-
transformed model, but also included age, respirator use, as well as Huntington’s disease, and 
excluded social involvement, delusions, and ALS.  
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6.3 Multivariate Regression Models 
 
The final untransformed multivariate regression model for ADRD can be found in Table 
7. ALS diagnosis and cohabitation with caregiver contributed the greatest increases in cost. 
Respirator use, hallucinations, falls, and CMI also led to substantial increases in costs for 
individuals with ADRD. Only age, the does not use stairs, and the MH and SW CCACs were 
negatively associated with care costs. Results from the sensitivity analyses were displayed 
alongside the results of the final models for all conditions in order to demonstrate the effect of 
the repeat assessments within the CAN-STRIVE dataset in this project. A few items became 
nonsignificant in the sensitivity analysis used to assess the effects of the repeat assessments in 
the dataset on the predictors of costs that were identified. 
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Table 7: Untransformed multivariate regression model for ADRD 
    Sensitivity Analysis 
  Model R2=35.18%  
df=37 
F-value=869.43 
Model P-value=<.0001 
N=59 310 
Model R2=30.34%  
df=37 
F-Value=307.55 
Model P-Value=<.0001 
N=25 900 
 Parameter 
Estimate (s.e) 
P-Value Parameter 
Estimate (s.e.) 
P-Value 
Intercept 13.80 (17.45) 0.43 39.51 (26.33) 0.13 
Predisposing         
Age -1.24 (0.19) <.0001 -1.40 (0.29) <.0001 
Enabling         
MH CCAC -21.25 (8.19) 0.01 -2.34 (12.31) 0.85 
CW CCAC 42.35 (10.68) <.0001 51.84 (15.16) 0.0006 
TC CCAC 60.26 (8.04) <.0001 44.26 (11.94) 0.0002 
CENT CCAC -2.43 (6.35) 0.70 -7.29 (10.22) 0.48 
CE CCAC 17.18 (6.16) 0.01 26.11 (9.83) 0.01 
SE CCAC 31.63 (8.47) 0.00 44.89 (12.81) 0.0005 
CHAM CCAC 13.41 (6.28) 0.03 14.87 (9.61) 0.12 
NSM CCAC 109.70 (9.42) <.0001 78.67 (13.82) <.0001 
NE CCAC 113.17 (7.96) <.0001 107.20 (12.76) <.0001 
NW CCAC 33.66 (10.31) 0.00 11.98 (17.71) 0.50 
ESC CCAC 84.98 (7.8) <.0001 71.61 (12.12) <.0001 
SW CCAC -26.74 (6.82) <.0001 -23.76 (10.77) 0.03 
WW CCAC 2.47 (7.08) 0.73 -2.24 (11.24) 0.84 
Cohabit 291.12 (3.75) <.0001 277.47 (5.75) <.0001 
Need         
Formal and Informal RUGIII/HC 
Case-Mix 
81.33 (5.27) <.0001 85.91 (8.21) <.0001 
ADL Hierarchy 53.07 (1.74) <.0001 47.32 (2.72) <.0001 
IADL Capacity 20.18 (1.46) <.0001 20.49 (2.12) <.0001 
Unsteady Gait 8.10 (3.70) 0.03 15.63 (5.71) 0.01 
Falls 8.22 (3.64) 0.02 8.16 (5.52) 0.14 
Requires Help with Stairs 42.96 (4.67) <.0001 40.44 (7.22) <.0001 
Does not use Stairs -28.08 (4.24) <.0001 -31.68 (6.52) <.0001 
Difficulty Swallowing 51.66 (3.7) <.0001 44.84 (6.17) <.0001 
Weight Loss 38.55 (7.16) <.0001 26.54 (9.79) 0.01 
Respirator Use 99.44 (41.84) 0.02 -8.66 (70.79) 0.90 
DRS 9.51 (0.91) <.0001 8.28 (1.37) <.0001 
Pain Scale 9.82 (1.72) <.0001 6.65 (2.64) 0.01 
CPS 44.59 (1.8) <.0001 42.57 (2.83) <.0001 
Breathing Difficulty 22.15 (4.53) <.0001 21.74 (7.08) 0.002 
Aggression 16.06 (4.83) 0.0005 18.03 (7.78) 0.02 
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Bowel Incontinence 15.23 (4.37) 0.00 16.22 (6.62) 0.01 
Hallucinations 15.17 (4.77) 0.00 12.07 (7.7) 0.12 
Delusions 71.74 (7.08) <.0001 66.76 (10.74) <.0001 
Vision 19.52 (8.49) 0.02 13.05 (12.64) 0.30 
Stroke Comorbidity 17.85 (3.85) <.0001 19.07 (6.16) 0.002 
Parkinson's Disease Comorbidity 36.06 (6.56) <.0001 30.37 (10.86) 0.01 
ALS Comorbidity 602.97 (90.48) <.0001 223.21 (115.55) 0.05 
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Two untransformed models were identified for ALS. These multivariate regression 
models can be found in Table 8 and Table 9. Both models had similar levels of explained 
variance, as well as significant covariates. The only difference between the two models was the 
significance of IADL capacity in the first ALS model, and the significance of unsteady gait in 
the second model. Both unsteady gait and IADL capacity became borderline nonsignificant when 
both variables were kept in the same model with p-value=0.054 and 0.056, respectively. 
In both models, many covariates were associated with large increases in cost. 
Tracheostomy use was the single greatest contributor to cost, although ADRD, bowel 
incontinence, the NSM and NW CCACs, and cohabitation with caregiver were also associated 
with substantial increases in cost. In fact, with the exception of age, none of the covariates were 
negatively and significantly associated with cost. In the sensitivity analysis, respirator use, bowel 
incontinence, age, unsteady gait, difficulty swallowing, tracheostomy, cognitive performance, 
trouble breathing, and ADRD comorbidity all became nonsignificant.  
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Table 8: Untransformed Multivariate Regression Model for ALS 
    Sensitivity Analysis 
  Model R2=55.21%  
df=27 
F-value=42.62 
Model P-value=<.0001 
N=991 
Model R2=48.95%  
df=27 
F-Value=16.10 
Model P-Value=<.0001 
N=482 
 Parameter 
Estimate (s.e.) 
P-Value Parameter 
Estimate 
(s.e.) 
P-Value 
Intercept -18.23 (120.56) 0.88 -18.81 (151.24) 0.90 
Predisposing         
Age -3.17 (1.30) 0.01 -2.96 (1.70) 0.08 
Enabling         
MH CCAC 66.82 (63.50) 0.30 6.91 (81.88) 0.93 
CW CCAC 103.27 (81.25) 0.20 61.20 (105.55) 0.56 
TC CCAC 12.49 (84.54) 0.88 8.51 (100.57) 0.93 
CENT CCAC 138.63 (56.95) 0.02 50.89 (80.53) 0.53 
CE CCAC -32.69 (68.67) 0.63 -99.80 (86.90) 0.25 
SE CCAC -54.01 (97.76) 0.61 -90.19 (122.87) 0.46 
CHAM CCAC 175.82 (59.30) 0.003 119.06 (79.09) 0.13 
NSM CCAC 265.55 (85.88) 0.002 108.63 (131.28) 0.41 
NE CCAC 347.60 (73.37) <.0001 266.39 (107.26) 0.01 
NW CCAC 93.32 (106.21) 0.38 -2.29 (157.68) 0.99 
ESC CCAC 67.68 (85.54) 0.43 50.51 (115.72) 0.66 
SW CCAC -55.78 (66.66) 0.40 -34.74 (91.93) 0.71 
WW CCAC -14.67 (109.31) 0.89 -17.01 (139.40) 0.90 
Cohabit 186.95 (44.77) <.0001 146.56 (60.15) 0.02 
Need         
Formal and Informal RUGIII/HC 
Case-Mix 
96.24 (34.34) 0.01 186.18 (47.79) 0.0001 
ADL Hierarchy 99.49 (13.26) <.0001 54.85 (18.04) 0.003 
IADL Capacity 32.36 (15.75) 0.04 44.81 (18.36) 0.02 
Needs Help with Stairs 121.93 (51.65) 0.02 156.42 (61.83) 0.01 
Does not use Stairs 167.45 (45.89) 0.0003 176.96 (56.31) 0.002 
Difficulty Swallowing 33.02 (13.11) 0.01 27.25 (19.20) 0.16 
Respirator Use 169.21 (77.61) 0.03 201.44 (115.56) 0.08 
Tracheostomy Use 644.08 (132.18) <.0001 277.09 (175.61) 0.12 
CPS 74.37 (17.26) <.0001 11.22 (25.11) 0.66 
Breathing Difficulty 75.55 (35.63) 0.03 68.40 (48.14) 0.16 
Bowel Incontinence 327.91 (70.82) <.0001 156.64 (102.21) 0.13 
ADRD Comorbidity 308.85 (121.36) 0.02 210.89 (144.62) 0.15 
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Table 9: Alternate Untransformed Multivariate Regression Model for ALS 
    Sensitivity Analysis 
  Model R2=55.20%  
df=27 
F-value=43.94 
Model P-value=<.0001 
N=991 
Model R2=48.31%  
df=27 
F-Value=15.72 
Model P-Value=<.0001 
N=482 
 Parameter 
Estimate (s.e.) 
P-Value Parameter 
Estimate 
(s.e.) 
P-Value 
Intercept 22.41 (114.31) 0.20 77.62 (147.16) 0.60 
Predisposing         
Age -3.00 (1.30) 0.02 -2.83 (1.71) 0.10 
Enabling         
MH CCAC 66.54 (63.50) 0.29 6.86 (82.37) 0.93 
CW CCAC 110.97 (81.24) 0.17 56.66 (106.21) 0.59 
TC CCAC 21.53 (84.44) 0.80 8.53 (101.35) 0.93 
CENT CCAC 134.46 (57.05) 0.02 51.50 (81.38) 0.53 
CE CCAC -20.83 (68.50) 0.76 -92.96 (87.39) 0.29 
SE CCAC -38.98 (97.60) 0.69 -76.50 (123.44) 0.54 
CHAM CCAC 185.26 (59.21) 0.002 129.49 (79.45) 0.10 
NSM CCAC 270.78 (85.82) 0.002 103.62 (132.46) 0.43 
NE CCAC 342.15 (73.45) <.0001 265.28 (108.29) 0.01 
NW CCAC 105.13 (105.83) 0.32 3.37 (159.13) 0.98 
ESC CCAC 86.46 (85.58) 0.31 54.61 (116.62) 0.64 
SW CCAC -56.74 (66.70) 0.39 -33.54 (92.97) 0.72 
WW CCAC -2.68 (109.24) 0.98 -8.03 (140.16) 0.95 
Cohabit 194.24 (44.62) <.0001 157.50 (60.31) 0.01 
Need         
Formal and Informal RUGIII/HC 
Case-Mix 
102.32 (34.33) 0.003 195.59 (47.98) <.0001 
ADL Hierarchy 109.32 (12.73) <.0001 66.92 (17.59) 0.0002 
Unsteady Gait 70.51 (35.27) 0.05 37.73 (47.75) 0.43 
Needs Help with Stairs 123.46 (51.56) 0.02 177.75 (62.64) 0.01 
Does not use Stairs 175.92 (45.07) 0.0001 202.73 (55.98) 0.0003 
Difficulty Swallowing 35.31 (13.12) 0.01 32.65 (19.25) 0.08 
Respirator Use 159.40 (77.53) 0.04 188.36 (116.18) 0.11 
Tracheostomy Use 656.43 (132.36) <.0001 270.81 (177.39) 0.13 
CPS 76.81 (17.17) <.0001 12.87 (25.28) 0.61 
Breathing Difficulty 80.57 (35.45) 0.02 84.43 (47.92) 0.08 
Bowel Incontinence 324.92 (70.83) <.0001 154.98 (102.82) 0.13 
ADRD Comorbidity 321.73 (121.43) 0.01 235.96 (145.27) 0.11 
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The untransformed multivariate regression model for MS found 19 variables significantly 
associated with cost. No predisposing characteristics were significantly associated with cost. 
These variables and their corresponding parameter estimates and p-values can be found in Table 
10. Tracheostomy use was associated with the greatest increase in cost. HSI, depression, pain, 
dizziness, and trouble communicating were the only clinical characteristics negatively associated 
with cost. Negative associations were also found for all eight CCACs that had significant levels 
of association with cost. Items that became nonsignificant in the sensitivity analysis included 
pain, unsteady gait, needs help with stairs, weight loss, tracheostomy, and verbal expression. 
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Table 10: Untransformed Multivariate Regression Model for MS 
    Sensitivity Analysis 
  Model R2=46.76%  
df=32 
F-value=272.07 
Model P-value=<.0001 
N=9946 
Model R2=44.40%  
df=32 
F-Value=81.72 
Model P-Value=<.0001 
N=3307 
 Parameter 
Estimate (s.e.) 
P-Value 
Parameter 
Estimate (s.e.) 
P-Value 
Intercept 105.87 (30.35) 0.001 133.42 (53.11) 0.01 
Enabling         
MH CCAC -46.22 (18.46) 0.01 -47.58 (29.7) 0.11 
CW CCAC -2.34 (21.36) 0.91 18.78 (33.06) 0.57 
TC CCAC -43.21 (18.57) 0.02 -40.09 (29.22) 0.17 
CENT CCAC -18.85 (14.39) 0.19 -6.21 (25.37) 0.81 
CE CCAC -13.67 (12.24) 0.26 -8.85 (22.81) 0.70 
SE CCAC 58.48 (19.24) 0.002 80.48 (33.74) 0.02 
CHAM CCAC -5.27 (13.65) 0.70 -35.46 (22.78) 0.12 
NSM CCAC -17.98 (20.45) 0.38 -29.75 (32.62) 0.36 
NE CCAC 30.31 (15.79) 0.05 19.12 (28.39) 0.50 
NW CCAC -61.99 (18.57) 0.001 -69.75 (36.39) 0.06 
ESC CCAC 40.33 (15.54) 0.01 71.42 (27.11) 0.01 
SW CCAC -78.32 (12.5) <.0001 -75.03 (23.25) 0.001 
WW CCAC -10.58 (15.88) 0.51 -25.52 (27.01) 0.34 
Cohabit 247.97 (7.83) <.0001 231.64 (13.72) <.0001 
Need         
Formal and Informal RUGIII/HC 
Case-Mix 
119.21 (9.08) <.0001 98 (16.41) <.0001 
HSI -254.39 (29.13) <.0001 -233.87 (50.16) <.0001 
ADL Hierarchy 47.7 (3.45) <.0001 56.01 (6.15) <.0001 
IADL Capacity 25.32 (3.34) <.0001 24.09 (5.42) <.0001 
Unsteady Gait 21.18 (8.03) 0.01 12.71 (14.28) 0.37 
Needs Help with Stairs 50.4 (13.55) 0.0002 25.5 (21.33) 0.23 
Does not use Stairs 55.2 (10.65) <.0001 43.72 (17.35) 0.01 
Difficulty Swallow 56.03 (5.76) <.0001 55.22 (10.85) <.0001 
Weight Loss 97.56 (18.92) <.0001 40.79 (28.52) 0.15 
Respiratory Treatment other than 
Respirator  
61.64 (18.58) 0.001 90.4 (36.29) 0.01 
Tracheostomy Use 695.41 (75.87) <.0001 171.17 (143.77) 0.23 
DRS -5.36 (1.99) 0.01 -9.82 (3.3) 0.003 
Pain Scale -21.22 (4.12) <.0001 -11.5 (7.12) 0.11 
CPS 17.7 (4.46) <.0001 19.65 (7.99) 0.01 
Difficulty with Expression -20.09 (7.21) 0.01 -6.63 (13.28) 0.62 
Dizziness -27.87 (10.21) 0.01 -33.84 (16.96) 0.05 
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Bowel Incontinence 40.01 (9.67) <.0001 57.37 (17.75) 0.001 
Delusions 166.73 (76.7) 0.03 269.14 (94.12) 0.004 
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The log-transformed model for ADRD produced similar results to the untransformed 
model. However, fewer significant covariates were found in this model. Respirator use, vision 
problems, bowel incontinence, and delusions became nonsignificant. ALS was also 
nonsignificant in this model, but epilepsy became significantly associated with cost for those 
with ADRD. With the absence of ALS in this model, cohabitation with caregiver became the 
single largest contributor to cost. The presence of hallucinations, weight loss, as well as 
reductions in ADL functionality also contributed greatly to cost. In the sensitivity analysis of this 
model, only aggression and epilepsy became nonsignificant. The results of this model and its 
sensitivity analysis can be found in Table 11.  
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Table 11: Log-transformed multivariate regression model for ADRD 
    Sensitivity Analysis 
  Model R2=44.48%  
df=33 
F-value=1461.77 
Model P-value=<.0001 
N=59 310 
Model R2=41.16%  
df=33 
F-Value=548.20 
Model P-Value=<.0001 
N=25 900 
 Parameter 
Estimate (s.e.) 
P-Value 
Parameter 
Estimate (s.e.) 
P-Value 
Intercept 2.078 (0.012) <.0001 2.119 (0.018) <.0001 
Predisposing         
Age -0.001 (0) 0.0001 -0.001 (0) <.0001 
Enabling         
MH CCAC 0.003 (0.006) 0.59 0.018 (0.009) 0.03 
CW CCAC 0.022 (0.007) 0.0026 0.036 (0.010) 0.0006 
TC CCAC 0.044 (0.006) <.0001 0.034 (0.008) <.0001 
CENT CCAC 0.004 (0.004) 0.33 0.003 (0.007) 0.72 
CE CCAC 0.021 (0.004) <.0001 0.029 (0.007) <.0001 
SE CCAC 0.008 (0.006) 0.17 0.023 (0.009) 0.01 
CHAM CCAC 0.004 (0.004) 0.34 0.004 (0.007) 0.60 
NSM CCAC 0.068 (0.007) <.0001 0.061 (0.010) <.0001 
NE CCAC 0.065 (0.006) <.0001 0.068 (0.009) <.0001 
NW CCAC 0.043 (0.007) <.0001 0.025 (0.012) 0.04 
ESC CCAC 0.043 (0.005) <.0001 0.038 (0.008) <.0001 
SW CCAC -0.021 (0.005) <.0001 -0.021 (0.007) 0.0043 
WW CCAC 0.004 (0.005) 0.36 -0.002 (0.008) 0.84 
Cohabit 0.319 (0.003) <.0001 0.309 (0.004) <.0001 
Need         
Formal and Informal RUGIII/HC 
Case-Mix 
0.077 (0.004) <.0001 0.080 (0.006) <.0001 
ADL Hierarchy 0.032 (0.001) <.0001 0.028 (0.002) <.0001 
IADL Capacity 0.024 (0.001) <.0001 0.023 (0.001) <.0001 
Unsteady Gait 0.018 (0.003) <.0001 0.023 (0.004) <.0001 
Falls 0.011 (0.003) <.0001 0.010 (0.004) 0.01 
Needs Help with Stairs 0.030 (0.003) <.0001 0.027 (0.005) <.0001 
Does not use Stairs -0.055 (0.003) <.0001 -0.054 (0.005) <.0001 
Difficulty Swallowing 0.021 (0.003) <.0001 0.018 (0.004) <.0001 
Weight Loss 0.036 (0.005) <.0001 0.036 (0.007) <.0001 
DRS 0.007 (0.001) <.0001 0.007 (0.001) <.0001 
Pain Scale 0.012 (0.001) <.0001 0.009 (0.002) <.0001 
CPS 0.025 (0.001) <.0001 0.022 (0.002) <.0001 
Breathing Difficulty 0.016 (0.003) <.0001 0.015 (0.005) 0.0016 
Aggression 0.011 (0.003) 0.0003 0.006 (0.005) 0.18 
Hallucinations 0.043 (0.005) <.0001 0.037 (0.007) <.0001 
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Stroke Comorbidity 0.020 (0.003) <.0001 0.020 (0.004) <.0001 
Parkinson’s Disease Comorbidity 0.026 (0.005) <.0001 0.026 (0.008) 0.0006 
Epilepsy Comorbidity -0.026 (0.010) 0.01 -0.029 (0.017) 0.09 
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Two potential final models were identified when cost was log-transformed for ALS. Both 
models had very similar levels of explained variance. The results from the first of these models 
can be found in Table 12. As compared with the untransformed model, a number of covariates 
became nonsignificant in this model including ADRD, difficulty breathing, cognitive 
performance, trouble with stairs, difficulty swallowing, respirator use, and age. Central CCAC 
also became nonsignificant in this model. Hallucinations and HSI became significant in the log-
transformed model. Hallucinations were associated with a substantial decrease in cost, as was 
HSI; however, it is important to note that a one-unit increase in HSI represents a change from 
death to perfect health. Cohabitation with a caregiver was associated with the greatest increase in 
cost. All CCACs significant in the model were positively associated with cost. A number of 
variables became nonsignificant in the sensitivity analysis. These variables included respirator 
use and bowel incontinence. Hallucinations also became borderline significant.  
The alternative log-transformed model was relatively similar. Bowel incontinence and 
hallucinations became non-significant in the alternative model, and instead, cognitive 
performance and difficulty with stairs, and needs help with stairs became significant. A 
sensitivity analysis was also performed for this model. Respirator use and cognitive performance 
became nonsignificant in this model. The results of this alternate mode can be found in Table 13.
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Table 12: Log-transformed Multivariate Regression Model for ALS 
    Sensitivity Analysis 
  Model R2=59.06%  
df=22 
F-value=63.48 
Model P-value=<.0001 
N=991 
Model R2=52.39%  
df=22 
F-Value=22.95 
Model P-Value=<.0001 
N=482 
 Parameter 
Estimate (s.e.) 
P-Value 
Parameter 
Estimate (s.e.) 
P-Value 
Intercept 2.190 (0.052) <0.0001 2.178 (0.075)  <0.0001 
Enabling         
MH CCAC 0.014 (0.030) 0.64 -0.035 (0.044) 0.42 
CW CCAC 0.061 (0.038) 0.11 0.009 (0.057) 0.88 
TC CCAC 0.001 (0.040) 0.97 -0.024 (0.054) 0.66 
CENT CCAC 0.043 (0.027) 0.11 0.001 (0.043) 0.98 
CE CCAC -0.028 (0.032) 0.38 -0.042 (0.047) 0.37 
SE CCAC -0.025 (0.046) 0.58 -0.061 (0.065) 0.35 
CHAM CCAC 0.085 (0.028) 0.00 0.045 (0.043) 0.30 
NSM CCAC 0.121 (0.040) 0.00 0.028 (0.070) 0.69 
NE CCAC 0.150 (0.035) <.0001 0.120 (0.058) 0.04 
NW CCAC -0.046 (0.050) 0.35 -0.105 (0.085) 0.22 
ESC CCAC 0.050 (0.040) 0.22 0.039 (0.062) 0.53 
SW CCAC -0.017 (0.031) 0.58 -0.023 (0.049) 0.65 
WW CCAC 0.060 (0.052) 0.25 0.036 (0.075) 0.63 
Cohabit 0.160 (0.021) <0.0001 0.160 (0.032) <0.0001 
Need          
Formal and Informal RUGIII/HC 
Case-Mix 0.089 (0.015) <.0001 0.120 (0.024) <0.0001 
ADL Hierarchy 0.045 (0.006) <.0001 0.031 (0.009) 0.001 
IADL Capacity 0.047 (0.007) <.0001 0.048 (0.010) <.0001 
Unsteady Gait 0.049 (0.017) 0.01 0.056 (0.025) 0.03 
Respirator Use 0.087 (0.032) 0.003 0.063 (0.055) 0.25 
HSI -0.161 (0.43) 0.01 -0.127 (0.063) 0.04 
Bowel Incontinence 0.081 (0.032) 0.04 0.000 (0.053) 1.00 
Hallucinations -0.330 (0.160) 0.04 -0.323 (0.170) 0.06 
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Table 13: Alternate Log-transformed Multivariate Regression Model for ALS 
    Sensitivity Analysis 
  Model R2=59.13%  
df=23 
F-value=60.82 
Model P-value=<.0001 
N=991 
Model R2=52.85%  
df=23 
F-Value=22.32 
Model P-Value=<.0001 
N=482 
 Parameter 
Estimate (s.e.) 
P-Value 
Parameter 
Estimate (s.e.) 
P-Value 
Intercept 2.131 (0.054) <.0001 2.111 (0.08) <.0001 
Enabling         
MH CCAC 0.022 (0.030) 0.46 -0.029 (0.044) 0.51 
CW CCAC 0.072 (0.038) 0.06 0.016 (0.056) 0.78 
TC CCAC 0.006 (0.040) 0.88 -0.019 (0.054) 0.72 
CENT CCAC 0.048 (0.027) 0.07 0.003 (0.043) 0.94 
CE CCAC -0.021 (0.032) 0.52 -0.035 (0.046) 0.45 
SE CCAC -0.023 (0.046) 0.61 -0.059 (0.065) 0.36 
CHAM CCAC 0.090 (0.028) 0.00 0.052 (0.042) 0.22 
NSM CCAC 0.129 (0.040) 0.00 0.045 (0.070) 0.52 
NE CCAC 0.161 (0.035) <.0001 0.134 (0.057) 0.02 
NW CCAC -0.030 (0.050) 0.54 -0.074 (0.085) 0.39 
ESC CCAC 0.056 (0.040) 0.17 0.048 (0.062) 0.44 
SW CCAC -0.013 (0.031) 0.69 -0.011 (0.049) 0.82 
WW CCAC 0.054 (0.052) 0.29 0.038 (0.075) 0.61 
Cohabit 0.163 (0.021) <.0001 0.166 (0.032) <.0001 
Need         
Formal and Informal RUGIII/HC 
Case-Mix 
0.087 (0.015) <.0001 0.119 (0.024) <.0001 
ADL Hierarchy 0.045 (0.006) <.0001 0.028 (0.009) 0.003 
IADL Capacity 0.042 (0.007) <.0001 0.043 (0.010) <.0001 
Unsteady Gait 0.047 (0.017) 0.01 0.045 (0.026) 0.08 
Respirator 0.085 (0.033) 0.01 0.061 (0.055) 0.27 
CPS 0.020 (0.008) 0.01 0.006 (0.013) 0.62 
Needs Help with Stairs 0.057 (0.025) 0.02 0.090 (0.034) 0.01 
Does not use Stairs 0.053 (0.022) 0.02 0.074 (0.031) 0.02 
HSI -0.103 (0.047) 0.03 -0.068 (0.069) 0.32 
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The log-transformed model for MS can be found in Table 14. Very similar covariates 
were found in this model as compared to the untransformed model, with the exception of other 
respiratory treatments, tracheostomy use, and delusions, which became nonsignificant, and 
bowel incontinence and breathing difficulties became significant in the log-transformed model. 
Cohabitation with caregiver was associated with the greatest increase in cost. Increasing CMI 
and decreasing HSI were also associated with substantial increases in cost. Many of the CCACs 
became nonsignificant in the log-transformed model, including MH, CW, TC, Central, CE, and 
Champlain CCACs. The SW, and NE CCACs became significant in this model. In the sensitivity 
analysis for this model, a number of variables became nonsignificant, including unsteady gait, 
falls, pain, and trouble breathing. 
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Table 14: Log-transformed Multivariate Regression Model for MS 
    Sensitivity Analysis 
  Model R2=52.92%  
df=30 
F-value=371.45 
Model P-value=<.0001 
N=9946 
Model R2=49.47%  
df=30 
F-Value=106.91 
Model P-Value=<.0001 
N=3307 
 Parameter 
Estimate 
(s.e) 
P-Value 
Parameter 
Estimate 
(s.e.) 
P-Value 
Intercept 2.079 (0.023) <.0001 2.109 (0.041) <.0001 
Enabling         
MH CCAC -0.021 (0.014) 0.13 -0.01 (0.023) 0.67 
CW CCAC 0.015 (0.016) 0.34 0.045 (0.026) 0.08 
TC CCAC -0.022 (0.014) 0.12 -0.022 (0.023) 0.34 
CENT CCAC -0.007 (0.011) 0.54 -0.001 (0.02) 0.95 
CE CCAC -0.004 (0.009) 0.69 0.011 (0.018) 0.53 
SE CCAC 0.057 (0.015) <.0001 0.059 (0.026) 0.02 
CHAM CCAC -0.003 (0.01) 0.77 -0.016 (0.018) 0.36 
NSM CCAC -0.011 (0.015) 0.47 -0.021 (0.025) 0.41 
NE CCAC 0.039 (0.012) 0.001 0.024 (0.022) 0.28 
NW CCAC -0.066 (0.014) <.0001 -0.086 (0.028) 0.002 
ESC CCAC 0.003 (0.012) 0.77 0.039 (0.021) 0.06 
SW CCAC -0.049 (0.009) <.0001 -0.039 (0.018) 0.03 
WW CCAC -0.015 (0.012) 0.21 -0.003 (0.021) 0.89 
Cohabit 0.286 (0.006) <.0001 0.277 (0.011) <.0001 
Need         
Formal and Informal RUGIII/HC 
Case-Mix 
0.107 (0.007) <.0001 0.088 (0.013) <.0001 
HSI -0.218 (0.022) <.0001 -0.214 (0.038) <.0001 
ADL Hierarchy 0.029 (0.003) <.0001 0.034 (0.005) <.0001 
IADL Capacity 0.039 (0.003) <.0001 0.04 (0.004) <.0001 
Unsteady Gait 0.017 (0.006) 0.01 0.015 (0.011) 0.17 
Falls 0.016 (0.006) 0.005 0.016 (0.01) 0.12 
Needs Help with Stairs 0.099 (0.01) <.0001 0.066 (0.017) <.0001 
Does not use Stairs 0.078 (0.008) <.0001 0.051 (0.013) 0.0001 
Difficulty Swallowing 0.013 (0.004) 0.002 0.02 (0.008) 0.01 
Weight Loss 0.055 (0.014) 0.0001 0.043 (0.022) 0.05 
DRS -0.003 (0.002) 0.03 -0.005 (0.003) 0.04 
Pain Scale -0.009 (0.003) 0.003 -0.006 (0.005) 0.27 
Breathing Difficulty -0.023 (0.009) 0.01 -0.028 (0.015) 0.07 
Difficulty with Expression -0.019 (0.004) <.0001 -0.023 (0.008) 0.01 
Bladder Incontinence 0.022 (0.005) <.0001 0.021 (0.01) 0.03 
Bowel Incontinence 0.027 (0.007) 0.0003 0.037 (0.014) 0.01 
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A summary table for all models showing the effects of the independent variables on cost 
can be found in Table 15. 
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Table 15: Summary Table of the Effects of Independent Variables 
  Untransformed Log-Transformed 
  ADRD ALS 1 ALS 2 MS ADRD ALS 1 ALS 2 MS 
Predisposing         
Age --- -- - NS --- NS NS NS 
Sex NS NS NS NS NS NS NS NS 
Enabling         
MH CCAC -- NS NS - NS NS NS NS 
CW CCAC +++ NS NS NS ++ NS NS NS 
TC CCAC +++ NS NS - +++ NS NS NS 
CENT CCAC NS + + NS NS NS NS NS 
CE CCAC ++ NS NS NS +++ NS NS NS 
SE CCAC ++ NS NS ++ NS NS NS +++ 
CHAM CCAC + ++ ++ NS NS ++ ++ NS 
NSM CCAC +++ ++ ++ NS +++ ++ ++ NS 
NE CCAC +++ +++ +++ NS +++ +++ +++ ++ 
NW CCAC ++ NS NS -- +++ NS NS --- 
ESC CCAC +++ NS NS ++ +++ NS NS NS 
SW CCAC --- NS NS --- --- NS NS --- 
WW CCAC NS NS NS NS NS NS NS NS 
Cohabit +++ +++ +++ +++ +++ +++ +++ +++ 
Need         
Formal and 
Informal 
RUGIII/HC Case-
Mix 
+++ ++ ++ +++ +++ +++ +++ +++ 
HSI NS NS NS --- NS -- - --- 
ADL Hierarchy +++ +++ +++ +++ +++ +++ +++ +++ 
IADL Capacity +++ +  +++ +++ +++ +++ +++ 
Unsteady Gait + NS + ++ +++ ++ ++ ++ 
Falls + NS  NS +++ NS  ++ 
Help with Stairs +++ + + ++ +++ NS + +++ 
Does not use 
Stairs 
--- ++ +++ +++ --- NS + +++ 
Diff. Swallowing +++ + + +++ +++ NS NS ++ 
Malnutrition NS NS NS NS  NS NS  
Weight Loss +++ NS NS +++ +++ NS NS +++ 
DRS +++ NS NS -- +++ NS NS - 
Pain Scale +++ NS NS --- +++ NS NS -- 
CPS +++ +++ +++ +++ +++ NS ++ NS 
Respirator Use + + + NS NS ++ ++ NS 
PREDICTORS OF COSTS FOR ADRD, ALS, AND MS  
 
  86 
Respiratory 
Treatment Other 
than Respirator 
Use 
NS NS NS ++ NS NS NS NS 
Tracheostomy 
Use 
NS +++ + +++ NS NS NS NS 
Breathing Diff. +++ + + NS +++ NS NS -- 
Bladder 
Incontinence 
NS NS NS NS NS NS NS +++ 
Bowel 
Incontinence 
++ +++ +++ +++ NS + NS ++ 
Social 
Withdrawal 
NS NS NS NS NS NS NS NS 
Diff. with 
Expression 
NS NS NS -- NS NS NS --- 
Aggression ++ NS NS NS ++ NS NS NS 
Hallucination +++ NS NS NS +++ - NS NS 
Delusions + NS NS + NS NS NS NS 
Dizziness NS NS NS -- NS NS NS NS 
Vision ++ NS NS NS NS NS NS NS 
ADRD N/A + + NS N/A NS NS NS 
ALS +++ N/A N/A NS NS N/A N/A NS 
CP NS NS NS NS NS NS NS NS 
MD NS NS NS NS NS NS NS NS 
SCI NS NS NS NS NS NS NS NS 
TBI NS NS NS NS NS NS NS NS 
MS NS NS NS N/A NS NS NS N/A 
Huntington's 
Disease 
NS NS NS NS NS NS NS NS 
Stroke +++ NS NS NS +++ NS NS NS 
Parkinson's 
Disease 
+++ NS NS NS +++ NS NS NS 
Epilepsy NS NS NS NS -- NS NS NS 
 
 
+++ positive association with p-value ≤.0001 
++ positive association with p-value ≤.01 
+ positive association with p-value ≤.05 
--- negative association with p-value ≤.0001 
-- negative association with p-value ≤.01 
- negative association with p-value ≤.05 
NS not significant at 0.05 level 
N/A not applicable to the model
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Table 16 shows the explained variances for each of the multivariate regression models. In 
addition, the explained variance for the RUGIII/HC case-mix, predisposing variables, enabling 
variables, and all other need variables can be found for each of the three neurological conditions 
included in this project. Overall, ALS had the highest explained variances, regardless of 
variables, or whether the dependent variable had been log-transformed. The models looking only 
at the effect of the predisposing variables on cost had the lowest explained variance scores, while 
the final models identified in this project had the highest of explained variances. The models 
with CMI had high explained variance, independent of other variables; however, the enabling 
and other need variables tested within the models also contributed to the explained variance in 
the final model. In fact, these other variables, independent of CMI and CCAC variables, had 
explained variances that were very close to those found in the final models. Finally, the log-
transformed models consistently showed higher levels of explained variance.  
Table 17 shows the incremental effect of the addition of the other variables on the 
explained variance. Even with the presence of the RUGIII/HC case-mix variable, the other need 
variables and the enabling variables resulted in substantial increases in the levels of explained 
variances across all conditions and models.
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Table 16: Explained Variances (R2) by Model and Condition 
 ADRD ALS 1 ALS 2 MS 
Untransformed Models     
Final Model 35.2% 55.2% 55.2% 46.8% 
Predisposing Variables 0.0% 0.0% 0.0% 0.0% 
Enabling Variables 17.9% 14.1% 14.1% 16.2% 
Need Variables     
    Formal and Informal       
    RUGIII/HC Case-Mix 
20.8% 39.2% 39.2% 33.4% 
    All other Need Variables 27.1% 50.9% 50.9% 39.0% 
Log-Transformed Models     
Final Model 44.9% 59.1% 59.1% 52.9% 
Predisposing Variables 0.0% 0.0% 0.0% 0.0% 
Enabling Variables 30.5% 20.0% 20.0% 25.9% 
Need Variables     
    Formal and Informal  
    RUGIII/HC Case-Mix 
21.0% 43.1% 43.1% 33.7% 
    All other Need Variables 29.2% 51.8% 51.7% 38.6% 
 
 
Table 17: Incremental Effect of Independent Variables on Explained Variances by Model 
and Condition 
 
 ADRD ALS 1 ALS 2 MS 
Untransformed Models     
Formal and Informal 
RUGIII/HC Case-Mix 
20.8% 39.2% 39.2% 33.4% 
All other Need Variables +6.8% +12.1% +12.1% +6.8% 
Predisposing Variables +0.3% +0.4% +0.3% 0.0% 
Enabling Variables +7.2% +3.3% +3.3% +6.1% 
Log-Transformed Models     
Formal and Informal 
RUGIII/HC Case-Mix 
20.7% 43.2% 43.1% 33.7% 
All other Need Variables +9.2% +11.1% +11.0% +7.7% 
Predisposing Variables +0.4% 0.0% 0.0% 0.0% 
Enabling Variables +14.4% +4.9% +5.1% +11.8% 
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7.0 DISCUSSION 
 Overall, the results from this project demonstrate substantial costs associated with 
ADRD, ALS, and MS. While previous studies were only able to assess the relationship between 
cost and the three conditions using broad measures of severity, this project was able to identify a 
number of specific clinical characteristics that affect severity and clinical complexity for 
individuals with ADRD, ALS, and MS.  In addition, this project is the first Canadian study to 
identify the HC service costs for individuals with ADRD, ALS, and MS.   
7.1 Descriptive Characteristics 
Distribution of Populations Across Characteristics 
 The distributions of HC service users with each of the three conditions across the 
predisposing, enabling, and need factors support previous findings that persons with ADRD, 
ALS, and MS are more clinically complex than individuals without these conditions across the 
clinical items included in this study. The distributions across age groups for each of the 
conditions appeared to be reflective of the typical ages of onset and duration for each of the 
conditions, as are the sex distributions. It was interesting to see that a slightly greater proportion 
of HC users with ALS were female, since males typically have a higher incidence of disease 
(Kiernan et al., 2011); however, the difference in proportions was not large. The average age for 
the ALS population found here was also slightly older than expected, since the average age of 
onset for ALS is 56, and progression occurs rapidly (Kinsley and Siddique, 2012). It is likely that 
both these observations can be explained by the higher propensity of women and older 
individuals to use HC services.  
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It was also interesting to see that while the distribution of individuals across the CCACs 
were similar for ADRD, MS, and the non-neurological comparison group, the population of HC 
users with ALS seemed to be distributed differently across the 14 CCACs. The larger proportion 
of individuals in the more urbanized MH, CW, Central, and Champlain CCACs as compared to 
the general CCAC population may reflect the greater availability of resources for individuals 
with ALS in these regions of Ontario. These resources include specialized ALS clinics, 
neurologists, and ongoing ALS clinical trials (ALS Society of Ontario, n.d). Although 
specialized clinics are also available for those with ADRD and MS, these clinics can be found in 
a greater number of regions across Ontario (Alzheimer Society of Ontario, n.d.; MS Society of 
Canada, n.d).  
Finally, it was unsurprising to see the high proportion of individuals with ADRD, ALS, 
and MS residing with their caregiver(s). In particular, the clinical complexity and high levels of 
functional limitations observed in these individuals would necessitate the availability of a 
cohabiting caregiver in order for these individuals to remain in the community (Aronson et al., 
1996). Despite the clinical complexity associated with these conditions, however, some 
individuals were able to remain in their homes without either a primary or secondary caregiver. 
One explanation is that these individuals were still at the early stages of their conditions and did 
not yet require the help of a live-in caregiver. The absence of a cohabiting primary or secondary 
caregiver does not preclude the regular presence of an informal caregiver, but the volume of 
support available may be diminished.    
The proportions of individuals with ADRD, ALS, and MS affected by the characteristics 
tested in this study had not previously been reported. The findings here did seem to correspond 
with the clinical progression and characteristics for each of the three conditions described in the 
PREDICTORS OF COSTS FOR ADRD, ALS, AND MS  
 
  91 
literature previously (Gustavsson et al., 2011; McCrone et al., 2008; Grima et al., 2000; Kang et 
al., 2006; López-Bastida et al., 2009; Reese et al., 2011; Leicht et al., 2011; Jönsson et al., 2006; 
Rojas et al., 2011). At least across the clinical characteristics considered in this project, these 
conditions are likely more complex than non-neurological conditions. The higher concentrations 
of individuals with ADRD, ALS, and MS in higher ADL and IADL levels suggest substantial 
disability for these individuals. This finding corresponds with existing literature on the 
neurological conditions, which has identified neurological conditions as one of the leading 
causes of disability in Canada and worldwide (CIHI, 2007; WHO, 2006).  
For those with ADRD, the concentration of individuals in the two to three ranges on the 
CPS is indicative of early-stage ADRD. Although the proportion of individuals with aggression, 
delusions, hallucinations, bladder incontinence, and bowel incontinence were invariably the 
highest for those with ADRD across the three neurological conditions and the comparison group, 
the presence of these problem characteristics was low, relative to the proportion of individuals 
with these characteristics across all individuals with ADRD (Bassiony et al., 2000; Skelly and 
Flint, 1995; Lyketsos et al., 2002). Since these characteristics are generally associated with 
moderate to severe stages of dementia (Tyas and Gutmanis, 2008; Gauthier, 2002), the lower 
rates of aggression, delusions, hallucinations and incontinence in this HC population are likely 
due to the higher proportion of individuals with early-stage dementia in the HC population. This 
finding resembles the care setting patterns for those with ADRD found in prior studies (Yaffe et 
al., 2002; Tyas and Gutmanis, 2008).  
For those with ALS, a greater proportion of individuals reported having problem 
characteristics than those with ADRD or MS. Further, those with ALS also reported greater 
severity for many of these characteristics. Unlike those with ADRD, the ALS population in this 
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study displayed similar rates of problem characteristics including cognitive performance to the 
overall ALS population (Ringholz et al., 2005). While this observation is reflective of the clinical 
complexity and severity associated with ALS, it is also likely reflective of the pattern of care 
corresponding to the progression for each of the three conditions. Individuals with ADRD and 
MS may be more likely to be admitted to nursing home (Stolp-Smith et al., 1998; Aronson et al., 
1996; Krivickas et al., 1997; Tyas and Gutmanis, 2008), while comparatively few individuals 
with ALS end up in nursing home settings (Kehyayan et al., submitted). Beyond the scope of 
these diagnostic groups, the clinical variation across the ADRD, ALS, and MS HC populations 
demonstrate that even though persons with these conditions are often defined by their diagnoses, 
clinical characteristics are much more descriptive of individuals with these conditions.   
Mean Costs and Resource Use 
 No prior estimates of HC costs for individuals with ADRD, ALS, and MS in HC could be 
found. Therefore, comparisons to prior estimates could not be made. In studies looking beyond 
the scope of HC care costs, annual costs appeared to be greatest for MS, followed by ADRD, 
then ALS (López-Bastida et al., 2009; Andersen et al., 2011; McCrone et al., 2008). The 
discrepancy between the findings of this project and prior findings can likely be explained by the 
inclusion of indirect costs in prior studies. In particular, MS is known to have substantial effects 
on productivity loss due to its young age of onset (Grima et al., 2008). Further, very few studies 
have focused on costs related to ALS. As a result, it is difficult to gauge the reliability of the cost 
estimates provided by López-Bastida et al. (2009). It is also important to note that comparisons 
of cost across the three neurological conditions cannot accurately be made due to the differing 
methodologies used in prior studies. Interestingly, although the mean costs of care and mean 
CMI values were similar in both the initial analyses and sensitivity analyses for ADRD and MS, 
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the mean cost of care and mean CMI value were substantially lower for ALS in the sensitivity 
analysis. This finding suggests that repeat assessments were likely to have led to an 
oversampling of individuals with higher resource use. Overall, the mean cost trends identified in 
this project are likely to be reflective of HC care costs, but these trends are unlikely to be 
representative of total cost of illness patterns. It is clear from the mean dollar and CMI values, 
however, that HC costs and service utilization are higher for individuals with ADRD, ALS, and 
MS than for those without any neurological conditions. Further, it is evident that the levels of 
resource utilization for individuals with each of the three conditions are different.  
7.2 Regression Models 
 The multivariate regression models in this project identified a number of variables 
associated with cost of care in HC beyond the characteristics identified in previous studies. 
Predictors of costs identified in both models were assumed to be valid even though the normality 
assumptions had been violated in the untransformed models. The multivariate models were 
expected to be quite robust so that these violations were not expected to seriously affect the 
validity of the findings in those models. In addition, the higher number of covariates and the 
lower explained variances in the untransformed models as compared to the log-transformed 
models suggests that the normality violations would merely cause a weakening of effects. 
Therefore, unless unsupported by the literature review, the findings in both the untransformed 
and transformed models were thought to be valid. Detailed discussions of findings for each of the 
different conditions follow. 
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Predisposing Factors 
Alzheimer’s Disease and Related Dementias 
 
 Age was the only predisposing characteristic that was significantly associated with cost. 
Interestingly, age was predictive of lower HC costs. The significance and direction of this 
association was surprising since age of onset is not known to affect the severity of ADRD, which 
typically drives costs (Huff et al., 1987). One possible explanation for this finding may be the 
greater proportion of individuals with frontotemporal lobe dementia in younger populations 
(Jeffries and Agrawal, 2009). Unlike Alzheimer’s disease, which is the most common form of 
dementia in elderly populations, early symptoms of frontotemporal lobe dementia are associated 
with greater behavioral changes and speech impairments (Jeffries and Agrawal, 2009). Although 
speech impairments are not known to increase care costs (Fries et al., 2001), behavioral 
difficulties can be associated with increased costs. It is possible that the progression of 
frontotemporal lobe dementia may result in greater costs during the early stages of the condition. 
Given that the present results show decreased resource use with age after controlling for need 
and enabling factors, an alternative explanation may be ageism within the HC setting, whereby 
older individuals are systematically provided with fewer resources. Although ageism in HC is 
also possible, the ability to conclusively determine ageism is beyond the scope of this project. A 
final possibility may be that more caregiver support is more accessible for younger persons with 
ADRD in HC, and so younger individuals with higher levels of severity are able to remain within 
their homes for longer periods of time. Regardless of the explanation, it is clear that more 
attention should be paid to ensuring that the needs of older individuals with ADRD in HC are 
met.  
PREDICTORS OF COSTS FOR ADRD, ALS, AND MS  
 
  95 
Amyotrophic Lateral Sclerosis 
 Only age was significantly associated with lower costs for individuals with ALS in HC, 
and was predictive of lower care costs. Age had previously been identified as significant 
predictor of costs in previous studies. Although age of onset is not known to affect the severity or 
progression of ALS, it is possible that younger individuals with ALS may be associated with 
greater costs due to the increased likelihood of frontal temporal dementia at earlier ages (Kiernan 
et al., 2011). It may also be possible that the significance of age is reflective of ageism in the 
distribution of HC services. Like ADRD, however, the ability to ascertain ageism is beyond the 
scope of this project. Since age was only significant in the untransformed model, it is possible 
that the significance of this variable is the result of violations to the normality assumption in 
multivariate regression models.  
Multiple Sclerosis 
 
 Neither predisposing factor was significantly associated with cost for individuals with 
MS. Although previous findings have suggested that age and sex are likely to affect productivity 
losses associated with MS, the cost measurement in this study looks exclusively at care costs. As 
a result, the nonsignificance of both variables was expected since age and sex are not known to 
affect the severity or progression of the condition.  
Enabling Factors 
 
 Both enabling variables tested in this project were associated with costs across all 
conditions and models. Like previous studies, cohabitation with a caregiver resulted in 
substantial increases in care costs (Moore et al., 2001). Cohabitation with a caregiver was likely 
predictive of increased care costs because of the availability of a caregiver for greater durations 
of time. In cases where cohabitation with the caregiver was the result of ADRD, ALS, or MS 
PREDICTORS OF COSTS FOR ADRD, ALS, AND MS  
 
  96 
diagnosis, cohabitation may also indicate greater disease severity, which is associated with 
increased care costs (Jönsson et al., 2006; Andersen et al., 2003; Rojas et al., 2011; Leicht et al., 
2011; Gustavsson et al., 2011; López-Bastida et al., 2009; McCrone et al., 2008; Reese et al., 
2011).  
 The significance of some CCACs in predicting care costs for ADRD, ALS, and MS was 
also expected. Compared with the HNHB CCAC, the NE CCAC, in particular, was associated 
with the greatest increase in cost, followed by the NSM CCAC for both ADRD and ALS. 
Interestingly, both these CCACs encompass northern and primarily rural regions of Ontario, 
where access to alternative medical services may be difficult. As a result, it is possible that the 
ADRD and ALS care costs in these regions are higher because of the absence or limited 
accessibility of other care services in these regions. In the NE CCAC region, in particular, 
limited nursing homes and the clustering of these homes in the more urban regions of this CCAC 
may necessitate HC services for those living outside the proximity of these homes (NSM LHIN, 
2013; NE LHIN, 2013). In contrast, CCACs were predictive of lower care costs for those with 
MS. The greatest reduction in care costs relative to the HNHB CCAC was seen in the NW 
CCAC. Since all CCACs significantly associated with cost were negatively associated, it is 
possible that the HNHB CCAC had the highest regional costs for MS care. Finally, the variations 
in costs across at least some of the CCACs are very likely the result of regional variations in care 
costs and practice patterns that are common across health conditions and jurisdictions.  
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Illness Factors 
 Although illness factors were consistently the most important in predicting care costs 
across ADRD, ALS, and MS, the results of the multivariate models demonstrate that clinical 
characteristics have a far greater effect on HC costs. In particular, ADL function, IADL function, 
cognitive performance, unsteady gait, and the RUGIII/HC CMI were most consistent in their 
ability to strongly predict costs.  
Cognitive Performance 
 Cognitive performance was predictive of increased costs across the conditions. Level of 
cognitive impairment had been identified as a predictor of costs for ADRD in previous studies 
(Gustavsson et al., 2011; Jönsson et al., 2006; Rojas et al., 2011). Cognitive impairment in 
persons with ALS and MS most likely also indicate dementia (Compston and Coles, 2002; 
Mitchell and Borasio, 2007). The increase in costs for each unit increase in CPS appeared to vary 
across the conditions; however, CPS was predictive of the highest increase in costs for ALS, and 
lowest for MS. The differences in costs associated with CPS appeared to reflect the different 
types of dementia that are common in ADRD and ALS. Since individuals with ALS that develop 
dementia tend to develop frontotemporal lobe dementia, it was unsurprising that cognitive 
performance was associated with the greater increases in care costs than those with ADRD. 
According to Rojas et al. (2011), frontotemporal lobe dementia is costlier than Alzheimer’s 
disease, which is the primary form of dementia afflicting those with an ADRD diagnosis 
(Geldmacher and Whitehouse, 1996). No specific type of dementia had been associated with 
dementia found in individuals with MS, but the low rates of dementia for these individuals may 
explain the small increases in costs associated with CPS. 
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Functional- and Movement-Related Characteristics 
 
 ADL functionality was positively associated with costs across all conditions and models. 
The association between ADLs and cost had been identified in studies on ADRD (Kang et al., 
2006; Reese et al., 2011; Andersen et al., 2001), but had not been established for MS or ALS. 
Across conditions, however, impaired ADL functions are likely to increase care costs because of 
the extensive assistance required by individuals to complete these activities. In particular, the 
daily aspect of these activities, including eating, locomotion, personal hygiene and/or toilet use 
explains the significance of ADL functionality in predicting HC care costs across conditions. The 
costs associated with these activities are most likely driven by assistance provided to individuals 
with these conditions by PSWs, and family members providing informal care. 
While a single-unit increase in ADL score resulted in similar increases in care costs for 
ADRD and MS, the increase in care costs associated with ALS were about two times as high as 
the increases for ADRD and MS. This finding is likely representative of the much higher 
proportion of individuals with ALS in the highest ADL levels, as compared to those with ADRD 
and MS, since the cost of care is likely to increase exponentially across the ADL levels. This 
finding demonstrates that even a minimal increase in ADL limitation for those with ALS is 
associated with much greater care costs in HC. Nevertheless, the presence of any ADL 
impairment for those with any of the three neurological conditions considered in this project 
represents substantial increases in weekly care costs.  
IADL functionality was also positively associated with HC costs across all three 
conditions and models. The increases in care costs were similar across the three conditions and 
were consistently smaller than the increases in care costs associated with ADL impairments. As 
with ADL functionality, IADL impairments require extensive daily assistance. IADL limitations 
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are also therefore likely to increase care costs because of the large amount of personal support 
and informal caregiving required to perform these activities for individuals with ADRD, ALS, 
and MS. Although a single-unit increase in IADL level appeared to result in small increases in 
costs for all three conditions, the high concentration of these individuals in the highest IADL 
levels suggests that assistance with IADL tasks contributed enormously to the high costs of these 
conditions.  
Unsteady gait was significantly and positively associated with HC costs for all three 
conditions. Falls were also significantly and positively associated with costs in some of the 
ADRD and MS models. Since muscle weakness and rigidity are part of the clinical course for all 
three conditions, the association between these characteristics and cost was unsurprising. Again, 
it was interesting to see that both unsteady gait and falls resulted in relatively similar increases in 
cares costs for ADRD and MS, while unsteady gait resulted in increased care costs that were 
more than three times higher for ALS. Unlike ADRD and MS, muscle weakness and rigidity 
affect a large proportion of individuals with ALS during early stages (Kiernan et al., 2011). The 
rapid progression of ALS also probably means that regardless of onset, limb muscle weakness 
and rigidity affects most individuals with ALS quite severely over a short period of time 
(Kiernan et al., 2011). In addition, while individuals with ADRD and MS tend to enter nursing 
homes when their conditions become complex, individuals with ALS are more likely to remain 
in their homes. As a result, the higher costs associated with unsteady gait in individuals with 
ALS are likely a reflection of the severity of limb muscle rigidity and weakness in these 
individuals, as well as the likelihood for these individuals to remain in HC throughout the 
progression of the condition. Management of unsteady gait would therefore require much more 
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extensive assistance by a combination of HC professionals, PSWs, and family members for 
individuals with ALS in HC.  
Finally, needing help with stairs was also associated with increased care costs across all 
conditions. The costs associated with the need for assistance with stairs was highest for those 
with ALS, and lowest for those with ADRD. Since stair use is an indication of muscle weakness 
and rigidity, and these signs are common and progress most rapidly in those with ALS (Kiernan 
et al., 2011), this finding is likely reflective of the rapid and severe functional decline found in 
those with ALS. As assistance with stairs is also likely to require care provided by PSWs, 
informal caregivers, PTs, and OTs, it is unsurprising to find that assistance of stairs is associated 
with increased care costs across all three conditions. Interestingly, those with MS and ALS that 
did not use stairs were also associated with increased care costs while individuals with ADRD 
that did not use stairs were associated with decreased care costs. Unlike individuals with ALS 
and MS, those with ADRD are likely to develop motor rigidity and coordination problems in 
much later stages. As a result, it is possible that the decreased costs associated with those with 
ADRD not using stairs reflect transition of many of these individuals to long-term care facilities, 
while those with ALS and MS continue to require substantial HC resources. 
Breathing, Swallowing, and Expression (Speech) 
 Shortness of breath was predictive of costs in at least one model across the three 
conditions. For ADRD and ALS, breathing difficulties were associated with increased care costs, 
while it was associated with reduced care costs for those MS. Care costs associated with 
respiratory difficulties were much higher for individuals with ALS, while associated costs for 
those with ADRD were comparatively low. This finding may be explained by the fact that 
respiratory difficulties are generally more severe for individuals with ALS. While respiratory 
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challenges tend to occur during sleep for individuals with ADRD (Pond et al., 1990), it is a 
continuous symptom for individuals with ALS (Mitchell and Borasio, 2007). In addition, death is 
caused by pneumonia with related shortness of breath in the majority of individuals with ALS.  
As a result, substantial anxiety and pain is caused by this characteristic in those with ALS 
(Kiernan et al., 2011). It is likely that distress over respiratory difficulties results in greater levels 
of service use for these individuals since they are likelier to seek treatment for this symptom.  
In contrast, the lower costs associated with respiratory difficulties for ADRD are likely to 
reflect the differences in the progression for this condition. Since dyspnea is associated with late 
progression for ADRD, it is likely that these individuals are transitioned into institutionalized 
settings before respiratory difficulties become associated with substantial increases in cost. For 
MS, trouble breathing rarely becomes severe as the disease progresses (Gosselink et al., 1999); 
as a result, HC services are unlikely to be sought by these individuals for this problem. Further, 
individuals with MS may choose to do less, and therefore require less PSW or informal caregiver 
assistance, while they are experiencing respiratory challenges. Nevertheless, the small decrease 
in costs associated with respiratory difficulties may require further investigation to ensure that 
adequate care is being provided for those with MS experiencing shortness of breath.  
 At least one form of respiratory treatment was predictive of increased costs for all three 
conditions. Non-respirator treatments were associated with the lowest increases in care costs, 
while tracheostomy was associated with the largest increase in care costs. Respirator use was 
also predictive of substantial increases in costs for those with ADRD and ALS, but was two 
times higher for those with ALS. The overall significance of the association between respiratory 
therapies and HC costs has been identified in previous studies (Sevick et al., 1996). The high 
costs of these therapies are typically driven by the need for increased monitoring by nurses, 
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PSWs, as well as informal caregivers within the HC setting (Sevick et al., 1996). In addition, 
Rowland and Schneider (2001) have found that mechanical ventilators cause significant burden 
to the families of those with ALS. It is possible that the larger increases in costs associated with 
respiratory treatments for those with ALS are also reflective of the pattern of institutionalization 
for individuals with ADRD and MS requiring respiratory therapy (Buchanan et al., 2002). Since 
individuals with ALS are much likelier to remain in their homes even when permanent respirator 
use is required, it is unsurprising that respirators are associated with the greatest increase in cares 
costs for individuals with ALS.  
 Dysphagia was predictive of increased costs for ADRD, ALS, and MS. Associated 
weight loss was also significantly associated with increased costs for those with ADRD and MS, 
although malnutrition was not significant in any of the conditions. Since treatment for dysphagia 
is addressed by modifications to diet and feeding, increased costs may be caused by the need for 
dietitians to assist in planning dietary modifications, as well as assistance from PSWs and family 
caregivers to assist and supervise in feeding. Speech therapy is also used as part of dysphagia 
therapy (Compston and Coles, 2002), and it is likely that the majority of HC costs are associated 
with use of speech language pathology services. However, specific service costs were not 
identified in this project, so the contribution of speech language pathology, dietitian and PSW 
services to HC costs for individuals with these conditions could not be determined.  
 Finally, difficulty with expression was predictive of reduced care costs for individuals 
with MS. As Fries et al. (2001) discussed, the negative association between resource use and 
verbal expression difficulties may be caused by the under-treatment of symptoms without 
physical cues. The negative association between pain and cost observed in those with MS 
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seemed to correspond with the assertion by Fries et al. (2001) that difficulties with 
communication can result in reduced pain management. 
However, it was interesting that verbal expression was not significantly predictive of 
costs for individuals with ADRD, or ALS. It is possible that ADRD and ALS are associated with 
fewer symptoms with nonphysical cues and so difficulties with expression were not predictive of 
costs for these conditions. Detection of nonphysical cues may also be better for individuals with 
ADRD and ALS. Regardless of the mechanism causing this finding, more attention should be 
paid to ensure the needs of individuals with MS and difficulties with communication are 
adequately addressed.  
Bladder and Bowel Incontinence 
 Bowel incontinence was associated with care costs for all three conditions. Although 
bowel incontinence was predictive of higher costs for all conditions, the costs associated with 
bowel incontinence were very substantially higher in those with ALS. No previous studies had 
identified bowel incontinence as a significant predictor of cost for these conditions, but the 
problem is known to be associated with substantial care costs (Miner, 2004). Though many of 
the costs for bowel incontinence are related to treatments and therapies that are beyond the cost 
measurements included in this project, the day-to-day management bowel incontinence is known 
to result in substantial costs as well (Miner, 2004). The much higher cost of bowel incontinence 
for those with ALS is likely to reflect the increased likelihood for individuals with ADRD and 
MS to enter nursing homes since bowel incontinence is known to be one of the primary 
predictors of nursing home admission from home care across most conditions (Miner, 2004; 
Tsuji et al., 1995; O’Donnell et al., 1992). For individuals with ADRD and MS with bowel 
incontinence, it is most likely that they are admitted to nursing home before the symptom 
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becomes associated with large care costs. Interestingly, incontinence is not a clinical 
characteristic associated with ALS since involuntary bladder and bowel muscles are not 
generally affected (Williams and Windebank, 1991). One possible explanation may be that 
bowel incontinence found in these individuals is the result of concomitant dementia. The 
concomitant dementia would also explain why bowel incontinence contributes so much more 
cost in these individuals with ALS, although CPS and ADRD comorbidity are already part of the 
ALS multivariate regression models.  
 Bladder incontinence was a significant predictor of increased care costs for MS only. 
Since bladder incontinence in those with MS is generally caused by a combination of failure to 
empty the bladder, and failure to store urine, treatment generally requires drug therapy and self-
catheterization where necessary (Compston and Coles, 2002). Increased costs surrounding 
bladder incontinence for these individuals are likely to be caused by increased costs associated 
with the management of medications, and assistance with catheter use by nurses, PSWs, and 
family members. Bladder incontinence is also a symptom of ADRD, but was not significantly 
associated with cost in this project. Since urinary incontinence can sometimes lead to early 
nursing home admissions (Thom et al., 1997), it may again be possible that individuals with 
ADRD developing urinary incontinence were transitioned to nursing homes before the problem 
became demanded substantial increases in costs. Indeed, individuals with ADRD are more likely 
to transition to nursing home than those with MS. 
Visual Symptoms 
 Vision was only predictive of cost for individuals with ADRD, but did not contribute 
greatly to the cost of care for these individuals. The significance of vision in predicting ADRD 
cost was likely caused by cognitive disturbances that are the result of visual misperceptions and 
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poor vision in these individuals (Geldmacher and Whitehouse, 1996). Since these vision 
problems are already likely to exacerbate cognitive impairment, which was already present in all 
models, it was unsurprising that these symptoms led only to a small increase in care costs.  
 Visual symptoms also affect individuals with MS; however, the vision variable was 
nonsignificant across MS models. Vision impairments caused by MS typically involve temporary 
blindness, unilateral optic neuritis, diplopia, or flashes of light (Noseworthy et al., 2000). Since 
the measurement of vision in the RAI-HC only measures vision status in the previous three days, 
these temporary visual impairments may be undetected. In addition, since these visual symptoms 
are generally temporary, it is unlikely that they result in long-term increases in care costs. 
Finally, HC professionals are unlikely to be able to address the types of vision problems 
experienced by individuals with MS, so changes in care use would not be significant. 
Pain 
 Pain was significantly associated with cost for ADRD and MS. A one-unit increase on 
the RAI pain scale was responsible for small increases in costs. Pain was not expected to 
contribute substantial care costs to the treatment of individuals with ADRD since pain treatment 
generally consists of drug therapy (Scherder et al., 2009). The small increase in costs could 
reflect an increased need for help with housework, since pain may limit the performance of some 
of these tasks. It is possible that the increases in costs associated with pain were small since the 
ADL and IADL scales already captured the majority of these needs. Finally, increased costs 
associated with pain for these individuals were likely limited since higher levels of cognitive 
impairment are known to reduce reports of pain and pain severity, and therefore limit treatment 
for the pain.  
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 In contrast, pain was predictive of reduced costs in individuals with MS. This finding was 
alarming since pain in individuals with MS can be treated, but typically requires some 
combination of physical therapy and pharmacological treatment (Noseworthy et al., 2000). As 
discussed earlier, it is possible that pain may be unreported because of difficulties with verbal 
expression, and so treatment and assistance is not provided. Pain may also cause withdrawal 
resulting in reduced demands for both formal and informal care. Regardless of the mechanism, 
the pattern of decreased costs and pain was consistent in the bivariate analysis, across the MS 
models, and in the sensitivity analysis for the untransformed model, suggesting that this finding 
was unlikely to be the result of a statistical error. This finding is alarming, however, and may 
reflect an under-treatment of pain symptoms for individuals with MS in HC. 
 It was surprising to see that pain was not significantly associated with cost for individuals 
with ALS. Pain in ALS can generally be addressed by a combination of drug and physical 
therapy for musculoskeletal pain and pain from joint stiffness (Mitchell and Borasio, 2007). Pain 
caused by skin pressure can also be addressed through care provided by nurses (Mitchell and 
Borasio, 2007). One explanation is that pain may not be significant because it is incorporated in 
the HSI index, which was significant in the log-transformed models for those with ALS. 
Addition of the pain scale could have over-explained the significance of the association between 
pain and care costs. Nevertheless, pain for individuals with ALS in HC may not be adequately 
addressed, and further investigation is required in future studies.  
Behavioral, Mood, and Mental Symptoms 
 Depression was significantly predictive of small changes in HC costs for ADRD and MS. 
ADRD was positively associated with costs, while MS was negatively associated with costs. 
Depression is part of the clinical course for ADRD and MS (Geldmacher and Whitehouse, 1996; 
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Sadovnick et al., 1996). Since depression can present through social withdrawal, reductions in 
care costs for those with MS may not be surprising. Combined with reduced capacity to verbally 
express needs and fatigue, individuals with depression may make fewer demands on HC 
professionals, PSWs, and informal caregivers. Since verbal expression was not predictive of care 
costs for those with ADRD, and fatigue is not generally associated with ADRD, it is possible that 
these individuals were more likely to continue expressing some care needs. Although depression 
is common in individuals with ALS following initial diagnosis, full-fledged depression rarely 
develops (Mitchell and Borasio, 2007). As a result, it was unsurprising that depression was not 
predictive of care costs in those with ALS. 
 Delusions were significantly associated with increased care costs for individuals with 
ADRD and MS. The increase in care costs caused by delusions was almost ten times higher for 
those with MS than those with ADRD. Delusions can cause individuals to act dangerously or 
violently, so costs for delusions in those with ADRD and MS are likely driven by supervision 
provided by family caregivers. Delusions for individuals with ADRD tend to result in 
interpersonal conflicts related to accusations of theft and marital infidelity, as well as perceived 
persecution by caregivers (Geldmacher and Whitehouse, 1996; Hwang et al., 1999). Costs for 
those with ADRD may also be lower since aggression is also significantly predictive of costs in 
the model for these individuals. Therefore, some of the costs caused by delusions may also be 
predicted by costs associated with aggressive behaviours. The delusions present in individuals 
with MS have not been typified; however, psychosis for those with MS is generally associated 
with late-stage disease, an increased number of lesions, and dementia (Feinstein et al., 1992). As 
a result, the substantial increase in cost associated with delusions for those with MS is likely 
driven by the disease severity.  
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 Psychosis through hallucinations was also predictive of care costs for ADRD and ALS. 
Hallucinations were associated with substantial increases in costs for those with ADRD, while 
they were associated with substantial decreases in care costs for those with ALS. As with 
delusions, increased care costs for those with ADRD may be incurred through supervisory needs, 
as well as coping and comforting of individuals with hallucinations. It was interesting to see that 
hallucinations contributed far greater costs than delusions for these individuals.  
In contrast, hallucinations are not generally part of the clinical profile of individuals with 
ALS, but can be caused by associated frontotemporal lobe dementia (Kiernan et al., 2011). Since 
hallucinations for individuals with ALS may begin experiencing these symptoms during the 
terminal phase, it is possible that the reduced care costs may reflect the reduction of service use 
during this time (Kiernan et al., 2011). Instead, ALS is generally treated through respiratory 
therapies, and drug therapies for restlessness and anxiety during the terminal phase (Mitchell and 
Borasio, 2007). Further, although the terminal phase is associated with multidisciplinary care, the 
costs of these services and therapies may be beyond the measurements of cost in this project. As 
a result, it may appear that hallucinations are predictive of significantly lower care costs for 
individuals with ALS when it in fact reflects disease progression and its corresponding care. 
Comorbidities 
 Neurological comorbidities were only predictive of costs for individuals with ADRD and 
ALS. For individuals with ALS, ADRD was significantly associated with very substantial 
increases in care costs. The large increase in care costs was unsurprising since ADRD diagnosis 
for these individuals causes increasing clinical complexity. 
 For individuals with ADRD, ALS, stroke, and Parkinson’s disease were all associated 
with increased care costs. This finding corresponded with neurological conditions that typically 
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have dementia comorbidities. The direction of the association was also expected since clinical 
complexity is known to increase care costs. ALS comorbidity increased care costs considerably, 
and corresponded with the high costs associated with ALS identified in this project. 
Interestingly, epilepsy diagnosis was associated with lower care costs. 
Health Status Index 
 Increases in the HSI were associated with very substantial reductions in HC costs for 
individuals with ALS and MS. This finding corresponded with previous findings that improved 
HRQOL was predictive of lower care costs for ALS and MS (López-Bastida et al., 2008; Grima 
et al., 2000).  
RUGIII/HC Case Mix Index 
 The CMI variable was significantly predictive of increased care costs for all conditions, 
and had the highest level of explained variance of any individual item tested in this project. It 
was unsurprising that the CMI variable was significantly predictive of costs for individuals with 
ADRD since this population was older, and similar to the population in which the RUGIII/HC 
was initially derived. Although the RUGIII/HC had demonstrated reasonable reliability and 
validity, this CMI had not been designed specifically for use in populations with neurological 
conditions. Therefore, it was interesting to see that the RUGIII/HC CMI was also significant in 
predicting care costs for individuals with ALS and MS. In addition, individuals with ALS and 
MS were much younger than the average ages of those with ADRD, and in the general HC 
population. It is probable that the RUGIII/HC CMI was significantly predictive of costs for ALS 
and MS because of the suitability of many RUGIII/HC algorithm items for individuals with these 
two conditions. In particular, the inclusion of a number of characteristics that are common to the 
neurological conditions within the RUGIII/HC likely contributed to the effectiveness of this CMI 
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on these groups. These characteristics include tracheostomy and respirator use, respiratory 
therapy, cognitive performance, ADL function, and IADL function. In addition, a number of 
specific items within the CPS, ADL, and IADL scales were relevant to ADRD, ALS, and MS, 
and also likely contributed to the effectiveness of the RUGIII/HC for individuals with these 
conditions. These items included the ability to be understood by others, cognitive skills for daily 
decision-making, the ability to manage personal finances, and locomotion.  
 Across all conditions, CMI consistently had the greatest level of explained variance in the 
bivariate analyses. CMI had less predictive power compared to the explained variances found for 
the remaining variables within the models, excluding CCACs. This finding suggests that some 
additions to the RUGIII/HC algorithm may increase the predictive power of this case-mix 
system, at least for the neurological population. Clinical characteristics identified in the models 
that were not already included in the RUGIII/HC algorithm included the following: stair use, 
unsteady gait, falls, difficulty with speech, difficulty with breathing, difficulty with speech, 
bladder incontinence, bowel incontinence, pain, depression, delusions, ALS, Parkinson’s disease, 
epilepsy and stroke diagnosis, and visual problems. A number of these items were predictive of 
cost across all three conditions. Addition of even some of these items to the RUGIII/HC 
algorithm is likely to improve the predictive abilities of the case-mix system for individuals with 
neurological conditions, although it is expected that it would also improve the performance of 
this CMI in the general HC population.  
7.3 Andersen and Newman Framework 
 The findings from this project both support and expand on the findings from previous 
studies identifying predictors of costs for ADRD, ALS, and MS. Grounded in Andersen and 
Newman’s framework for healthcare service utilization, this project found that the enabling and 
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illness factors were consistently predictive of cost in a HC setting. In particular, a couple of 
clinical characteristics were significant across all conditions and models, including sensitivity 
analyses, suggesting that these characteristics are highly predictive of resource utilization for 
individuals with ADRD, ALS, and MS in the HC setting. These characteristics included CMI, 
and ADL functionality. Other characteristics were also consistently found across conditions, 
though not necessarily across all models. These characteristics included cognitive impairment, 
IADL capacity, unsteady gait, assistance with stairs and no stair use, difficulty swallowing, 
respiratory challenges, and bowel incontinence. As a result, it is likely that beyond neurological 
diagnoses, these specific characteristics have high relative importance for predicting resource 
utilization for individuals with these conditions in HC. Similarly, cohabitation was significantly 
predictive of higher costs across models for all three conditions; therefore, cohabitation with a 
caregiver is also very likely to have high relative importance for predicting HC resource use for 
these individuals. At least one CCAC was also consistently significant across all conditions and 
models; however, the directions of the associations and the significance of specific CCACs 
varied across the models. As a result, geographic location is likely to have medium relative 
importance, contingent on the specific CCAC. 
Interestingly, although Andersen and Newman identified predisposing characteristics to 
have medium relative importance in predicting healthcare utilization, this assertion was not 
supported by the findings in this project for the HC setting. Only age was significant within the 
ADRD and ALS models, and became nonsignificant in the log-transformed models for ALS. In 
addition, the direction of the association for age did not support Andersen and Newman’s (1973) 
argument that older age can lead to increased healthcare seeking behavior. As a result, 
predisposing variables were of low relative importance in predicting healthcare utilization in this 
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project. Overall, the high relative importance of the illness factors found in this project, along 
with the medium relative importance of the enabling factors, and low relative importance of the 
demographic predisposing factors for individuals with ADRD, ALS, and MS in HC were 
consistent with the conclusions of a previous study on the Andersen and Newman framework in 
a HC setting (Kempen and Suurmeijer, 1991).  
7.4 Limitations 
 Although the results from this project expand on previous findings, a few limitations 
should be noted. The relationship between a number of symptoms related to ADRD, ALS, and 
MS and cost could not be studied because these symptoms were not available in the RAI-HC 
tool. These symptoms included fatigue, emotional lability, sexual dysfunction, agitation, and 
drooling. However, the absence of these symptoms from the analyses in this project is not 
expected to be of great concern since these symptoms are unlikely to drive HC service costs 
substantially.  
Another limitation in this project had to do with the diagnosis measurement. In particular, 
the analyses in this project did not differentiate between the various subtypes of ADRD, ALS, 
and MS. Since the progression and severity for each of these conditions differ based on subtype, 
differentiation between these subtypes may have identified other predictors of costs. Similarly, 
no measure of time since onset of disease was available. Although time since onset is associated 
with severity for ADRD, ALS, and MS, it nevertheless would have been interesting to see the 
relationship between time since onset, and HC care costs.   
 Finally, though this analysis provides accurate estimates of costs based on HC service 
utilization, the measurement of cost in this project was somewhat limited. Though the purpose of 
this project was to identify predictors of HC service costs, the predictors identified in this project 
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may not be reflective of the predictors of combined direct and indirect costs. Further, even 
though this project identified the majority of direct costs including formal and informal care, this 
project did not differentiate between the care types, or the formal service types. Within the 
formal costs as well, the measure of cost in this project excluded drug costs, which are likely to 
be particularly substantial for ALS and MS. Case manager time was not included in these 
analyses. Since case managers play substantial roles in the formal care provision for individuals 
in HC, the inclusion of costs associated with case manager time would have provided more 
reliable estimates of HC care costs for each of the conditions. While it is unlikely that the 
absence of case manager time would have altered the predictor variables in the model, inclusion 
of case manager time would have also provided a more accurate portrait of predictors of HC care 
costs for those with ADRD, ALS, and/or MS. Assuming that case manager time is proportionate 
to HC service utilization, the absence of case manager costs is unlikely to be of concern.   
7.5 Strengths 
 The primary strength of this project was the data from the CAN-STRIVE HC study. As 
detailed earlier, these data include RAI-HC assessments for the entire Ontario HC population 
between 2005 and 2008. Clinical data are expected to be accurate since trained healthcare 
professionals perform RAI-HC assessments. In addition, incentives were put in place to ensure 
that data collected in the RAI-HC reflected the actual needs of individuals in HC. Accurate cost 
data were also available from this dataset. Resource utilization data were obtained from 
administrative records, and mean wage rates from across the province for each these services 
were applied.  
 Similarly, the use of the case-mix approach to estimating cost was also an important 
strength in this project. The review of cost literature suggested that this is the first project to use 
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a case-mix approach to estimating and predicting care costs for individuals with ADRD, ALS, or 
MS. The use of the case-mix approach allowed service use and cost to be understood in the 
context of resource need. In addition, the RUGIII/HC categorization provided a ratio-level 
estimate of resource use, so that the costs associated with ADRD, ALS, and MS can be 
understood in comparison to other neurological conditions, as well as to the general HC 
population. The use of the same methodology across the cost estimate and prediction procedures 
also ensure that the findings from this project can be compared across conditions. 
 Another strength of the project was the identification of a number of specific clinical 
characteristics and their relationships to cost. Although prior studies had explored the effect of 
severity on cost, these previous findings had only been able to measure severity through ADL 
impairment ratings, Expanded Disability Status Scale, or cognitive impairment scales. The 
results from this project allow severity to be measured much more comprehensively through the 
availability of specific clinical characteristics. At this time, it does not appear that any other 
study has been able to identify such detailed clinical predictors of cost for ADRD, ALS, or MS.  
 A final strength of this project is the generalizability of these findings. Since the findings 
from this project were based on the entire population of HC service users with ADRD, ALS, and 
MS between April 2005 and June 2008, the predictors of costs identified for these conditions are 
very likely to be generalizable towards other HC jurisdictions in Canada. In addition, some of the 
clinical predictors of costs identified this project are likely to be generalizable across at least 
some of the neurological conditions. The specific clinical characteristics that were predictive of 
cost across ADRD, ALS, and MS, including stair use, difficulty swallowing, respiratory 
challenges, and incontinence, are common across a number of other neurological conditions, and 
are likely to be significant predictors of costs for these conditions as well. These conditions 
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include cerebral palsy, with symptoms such as limb function impairment and bladder 
incontinence (Koman et al., 2004); Huntington’s disease and muscular dystrophy, which are 
associated with movement impairment and swallowing symptoms (Walker, 2007; Emery, 2002); 
and finally Parkinson’s disease, where urinary incontinence and difficulty swallowing are also 
common symptoms (Lees et al., 2009). However, since each of these conditions are associated 
with a number of other symptoms occurring at different stages in the disease progression, further 
research on these conditions is still required to identify predictors of costs for other neurological 
conditions. Further, the amount of cost that is contributed by these characteristics cannot be 
estimated based on the findings from this project.  
7.6 Implications 
 The findings from this project correspond with the aims of the Innovations in Data, 
Evidence and Applications for Persons with Neurological Conditions (ideasPNC). The purpose 
of ideasPNC was the first major study linking interRAI data to the neurological conditions in 
order to better understand the needs of persons with neurological conditions across the 
continuum of care. In this particular project, a number of predictors of HC service needs 
associated with ADRD, ALS, and MS in a HC setting were identified. Some of these predictors 
included ADL functionality and cognitive performance, which had been identified in other 
studies, and are predictive of HC use in the general population as well. Other characteristics, 
such as difficulty with stairs, swallowing, and breathing, had not previously been identified as 
predictors of costs for these conditions.  
The identification of these clinical and personal characteristics are expected to contribute 
to care planning for individuals with these conditions. At the policy level, these findings can help 
ensure that adequate resources are available to provide HC services for these individuals. 
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Ensuring the availability of HC services for individuals with ADRD, ALS, and MS involves the 
ability to predict care needs, as well as resources required to address these needs. The findings 
from this project provide the necessary data to ensure adequate funding and service provision for 
these individuals to remain in the community for as long as possible. In particular, the main 
finding from this project is that clinical complexity found in individuals with ADRD, ALS, and 
MS invariably result in increases in costs. As individuals with these conditions increasingly 
choose to remain in their homes for longer periods of time, the HC costs can be expected to 
increase, reflecting the increasingly complex characteristics of service users. Increased funding 
for the Ontario HC program will be required should the proportion of HC service users with 
neurological conditions increase, as has been predicted. 
Another implication of this project is the applicability of the RUGIII/HC algorithm for 
the neurological populations. Overall, the RUGIII/HC demonstrated reasonable effectiveness in 
its ability to predict resource utilization levels for individuals with ADRD, ALS, and MS. Mean 
costs for individuals with these conditions were higher than the mean costs for individuals 
without neurological conditions within the same RUGIII/HC group. This finding does indicate 
that variability between the predicted and observed levels of resource utilization is higher for 
individuals with these neurological conditions. As a result, future versions of the RUGIII/HC 
should consider the inclusion of additional characteristics predictive of cost for these individuals. 
The need for revisions or adaptations of the RUGIII/HC for the neurological populations will be 
especially important given the expected rise in prevalence for neurological conditions. Beyond 
the neurological populations, the focus on this population is also likely to improve the 
RUGIII/HC for the general population. Many individuals with and without these conditions 
prefer to remain in their homes for as long as possible and so an increase in HC service users can 
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be expected. Improved ability to predict the levels of resource utilization will therefore be crucial 
to the success of HC service provision in Ontario. 
Finally, the findings from this project provide further support that illness factors in the 
Andersen and Newman model are the most important predictors of healthcare service use in HC 
settings. These findings also suggests that the factors driving healthcare service use is at least 
somewhat different in HC than in other care settings. In addition, it is important to note that the 
relative importance of predisposing and enabling factors were similar between HC service users 
with neurological conditions, and the general HC population. This finding implies that although 
revisions to the framework proposed by Andersen and Newman (1973) are required in the HC 
setting, no specific revisions are required to describe individuals with neurological conditions.  
7.7 Future Directions 
The findings from this project are expected to improve the understanding of mechanisms 
driving care costs for ADRD, ALS, and MS. Future studies of cost for these conditions should 
consider addressing the weaknesses identified in this project. Indeed, while the findings from this 
project provide a broad understanding of the clinical mechanisms driving costs for the 
neurological conditions, more specific analysis would help to identify predictors of cost for 
specific HC services. Future HC cost research would also benefit from the addition of case 
manager time and drug expenditures into the cost measurement. The inclusion of these costs 
would provide a more complete estimate of direct costs associated with these conditions. Finally, 
since some predictors of costs were nonsignificant when repeat assessments were removed, 
future research should also determine whether clinical predictors of costs are different in 
populations with repeat assessments removed.  
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Beyond the three neurological conditions discussed in this project, the relationship 
between cost and the neurological conditions is still not well understood across other 
neurological conditions and other non-acute care settings. Future research estimating and 
identifying predictors of costs should continue to apply high-quality cost and clinical data to 
other neurological conditions. In particular, this project has demonstrated the excellent research 
capabilities for data collected using the interRAI instruments. Future cost studies for other 
neurological conditions care settings should therefore consider the use of data collected through 
interRAI instruments. These other care settings may include nursing home, palliative care, as 
well as mental health facilities. Other conditions with adequate sample sizes across these care 
settings include cerebral palsy, epilepsy, Huntington’s disease, muscular dystrophy, Parkinson’s 
disease, stroke, spinal cord injury, and traumatic brain injury.  
7.8 Conclusions 
 Overall, individuals with ADRD, ALS, and MS displayed greater clinical complexity and 
higher care costs. The mean costs of care for ADRD, ALS, and MS were higher than for 
individuals without neurological conditions in HC. This finding was demonstrated by the mean 
costs of care, as well as through the mean CMI values found for each of the three conditions. In 
addition, these conditions displayed greater proportions of severity or presence of problem 
characteristics.  
Characteristics predictive of costs across the three neurological conditions were fairly 
consistent. These characteristics included CMI, cohabitation with caregiver, ADL, IADL, 
unsteady gait, difficulty with stair use, respiratory challenges, difficulty swallowing, impaired 
cognitive performance, and incontinence. In almost all cases, these characteristics were 
predictive of higher costs. Many of these characteristics had previously been associated with the 
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three neurological conditions, but had not been identified as predictors of costs. Nevertheless, 
these results were consistent with prior findings that disease severity was predictive of increased 
care costs.  
Taken together, these findings suggest that individuals in HC with ADRD, ALS, and MS 
have greater clinical complexity than individuals without neurological conditions. It is these 
clinical complexities that result in higher care costs for individuals with these conditions. 
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Appendix A: CCAC/LHIN Map 
 
 
 
(Source: Community Care Access Centres, n.d.) 
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14. North West 
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Appendix B: MEDLINE PubMed Search Strategy 
 
The purpose of this literature review was to examine existing cost literature for the neurological 
conditions that specifically studied predictors of cost. As little research has been conducted 
looking at predictors of cost for the neurological conditions exist, a very general search statement 
was used in order to capture as many articles as possible. 
 
Search Statement: 
 
("multiple sclerosis"[MeSH Terms] OR "dementia"[MeSH Terms] OR "alzheimer 
disease"[MeSH Terms] OR "amyotrophic lateral sclerosis"[MeSH Terms]) AND 
("economics"[Subheading] OR "economics"[All Fields] OR "cost"[All Fields] OR "costs and 
cost analysis"[MeSH Terms]) 
 
Exclusion and Inclusion Criteria: 
 
Results from the search statement were further filtered to exclude non-English articles, non-
human studies, and articles without an available abstract and full text. Articles on the predictors 
of cost had to be manually selected. During manual selection, only original research articles that 
explicitly stated determining predictors or drivers of cost were included.  
 
Results: 
 
A total of 3590 articles were found using the search statement above. After applying exclusion 
criteria, 2192 articles remained. Through manual selection, only ten articles were found that fit 
the inclusion criteria. 
  
 
Appendix C: Summary of Existing Cost Literature 
Author 
Condition 
Region 
Purpose Design Sample Analysis Findings 
Reese et al., 
2011b 
 
Alzheimer’s 
Disease (AD) 
 
Germany 
Report service use 
and costs for 
patients with AD, 
and to explore 
influence of 
sociodemographic 
and illness-related 
determinants in 
ambulatory setting. 
Cross 
Sectional 
N=395 
outpatient memory 
clinic, office based 
neurologists, general 
practitioner clinics, 
mental disorder clinic 
t-tests, chi-square tests, and Mann-
Whitney U-tests used to test 
differences in demographic 
characteristics. 
Multivariate analyses used to create 
model of independent predictors of 
higher costs including age, gender, 
and ADL.  
Model explained only 7-43% of 
variability in costs. 
Direct medical care costs and LTC 
costs related differently to patient’s 
clinical characteristics. 
Leicht et al., 
2011 
 
Dementia 
 
Germany 
Estimate net costs 
of dementia by 
degree of severity. 
Include detailed 
assessment of costs 
of care. 
Cross 
Sectional 
N=348 
Sample from German 
Study on Ageing and 
Dementia in Primary 
Care Subjects 
 
Differences in proportions tested 
using Chi-square test or Fisher’s 
exact test.  
Group differences tested with t-
tests. 
Across disease stages, nursing care 
accounted for 75% of total costs. Half 
of these nursing costs resulted from 
informal care. 
Gustavsson et 
al., 2011 
 
Alzheimer’s 
Disease (AD) 
 
Spain, Sweden, 
UK, US 
Identify measures 
of disease severity 
that are most 
important 
predictors of 
societal costs of 
care. 
Cross 
Sectional 
N=2444 
1222 and their 
caregivers in 
community or 
residential settings. 
Descriptive means and standard 
deviations. 
Multivariate model used to identify 
important drivers of costs of care. 
ADL ability most important predictor 
of cost of care for community 
dwelling patients. 
Predictors of costs were the same 
across countries. 
Rojas et al., 
2011 
 
Dementia 
 
Argentina 
Compare costs 
between various 
subtypes of 
dementia. 
Case-Control 
Direct 
N=79 
Patients diagnosed 
with dementia 
presenting to hospital 
between 2002 and 
2008 
Means and standard deviation for 
descriptive data.  
Differences among dementia 
subtypes estimated using ANOVA. 
Different types of dementia have 
different costs. 
McCrone et 
al., 2008 
 
Multiple 
Sclerosis (MS) 
 
Investigate links 
between service 
use, costs, QOL, 
and disability. 
Cross 
Sectional 
N=1942 
members of the MS 
Society of Great 
Britain and Northern 
Ireland 
Spearman’s correlations given 
between costs and other continuous 
variables in addition to Pearson’s 
correlations. 
Regression models using least 
squares method used to identify 
Age, being divorced/separated, MS 
type, and years with MS were all 
significantly associated with higher 
service costs (p=<0.05). 
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United 
Kingdon 
patient characteristics that were 
significantly associated with cost. 
Andersen et 
al., 2003 
 
Dementia 
 
Denmark 
Use longitudinal 
data to examine 
changes in 
healthcare costs 
with disease 
progression. 
Prospective 
cohort study 
N=3346 
Community sample 
randomly drawn from 
Danish Population 
Register living in 
Odense 
Multivariate linear regression used 
to analyze impact of disease 
progression on healthcare costs. 
 
Change in costs over time increased 
with disease progression, particularly 
in the severe stage of dementia.  
Functional abilities also important 
factor for exampling changes in costs. 
Grima et al., 
2000 
 
Multiple 
Sclerosis (MS) 
 
Canada 
Quantify cost of 
MS and examine 
the influence of 
disability on patient 
utility and 
healthcare costs. 
Cross 
Sectional 
N=42 
Patients recruited 
during regularly 
scheduled visits to 
MS clinics either at 
the Montreal 
Neurological 
Institute, or the 
London Health 
Sciences Centre. 
Patient costs were calculated for 
each category. No methods for 
statistical analysis were provided. 
Strong positive relationship observed 
between EDSS and remission 
healthcare costs.  
Jönsson et al., 
2006 
 
Alzheimer’s 
Disease (AD) 
 
Sweden, 
Denmark, 
Norway, 
Finland 
Estimate the costs 
of formal and 
informal care and 
identify 
determinants of 
care costs. 
Prospective 
cohort study 
N=272 
Recruited from 
memory clinics. 
Non-parametric rank analogue of 
ANOVA used to test for differences 
in costs of care between patients in 
different MMSE states. 
Dementia costs related to dementia 
severity, as well as presence of 
behavioral disturbances. 
Kang et al., 
2006 
 
Dementia 
 
Korea 
Analyze healthcare 
expenditures and 
cost per dementia 
patient. 
Cross 
Sectional 
N=609 
Randomly selected 
patients from 
nationwide claim 
database of the 
Korean National 
Health Insurance 
Corporation 
Descriptive means for direct and 
indirect costs calculated. Testing 
comparisons were performed on the 
three levels of severity. 
Limitations on ADL significantly 
affects service use (p=<0.05). 
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Appendix D: University of Waterloo Office of Research Ethics, Ethics Clearance 
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Appendix E: Standardized Service Wage Rates in Ontario Home Care (2007-8) 
 
Service Cost (per visit or hourly) 
Nursing Visit $55.56 
Nursing Hourly $47.31 
Personal Care Hourly $28.18 
Physical Therapy Visit $100.02 
Occupational Therapy Visit $111.60 
Speech Language Pathology Visit $101.31 
Social Work Visit $140.85 
Nutrition/Dietetic Visit $112.22 
Respite Hourly $31.36 
 
(Source: Hirdes et al., 2010) 
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Appendix F: Scoring Rules for the RAI ADL Self-Performance Hierarchy 
 
(Source: Morris et al., 1999)
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Appendix G: HSI Multiplicative Function and Mapping 
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(Source: Wodchis et al., 2000)
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Appendix H: RUGIII/HC Grouping Criteria 
 
(Source: Poss et al., 2008)
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Appendix I: RUGIII/HC Case-Mix Index Values 
 
RUGIII/HC Groups CMI Values 
RB 2.743 
RA2 1.609 
RA1 0.967 
SE3 5.151 
SE2 4.240 
SE1 2.498 
SSB 2.791 
SSA 1.878 
CC 2.586 
CB 1.660 
CA2 1.126 
CA1 0.609 
IB 2.121 
IA2 1.637 
IA1 0.839 
BB 1.718 
BA2 1.281 
BA1 0.593 
PD 2.417 
PC 1.755 
PB 1.379 
PA2 0.933 
PA1 0.485 
 
(Source: Hirdes et al., 2010) 
